0001171843-15-006138.txt : 20151110 0001171843-15-006138.hdr.sgml : 20151110 20151109112310 ACCESSION NUMBER: 0001171843-15-006138 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20150930 FILED AS OF DATE: 20151109 DATE AS OF CHANGE: 20151109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Capstone Therapeutics Corp. CENTRAL INDEX KEY: 0000887151 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 860585310 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-21214 FILM NUMBER: 151214628 BUSINESS ADDRESS: STREET 1: 1275 WEST WASHINGTON STREET STREET 2: SUITE 101 CITY: TEMPE STATE: AZ ZIP: 85281 BUSINESS PHONE: 6022865520 MAIL ADDRESS: STREET 1: 1275 WEST WASHINGTON STREET STREET 2: SUITE 101 CITY: TEMPE STATE: AZ ZIP: 85281 FORMER COMPANY: FORMER CONFORMED NAME: ORTHOLOGIC CORP DATE OF NAME CHANGE: 19940211 10-Q 1 gff10q_110915.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 10-Q

 

(Mark One)

 

[X]QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended  September 30, 2015

 

or

 

[    ]TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _______________________________        to ____________________

 

Commission File Number: 0-21214

 

CAPSTONE THERAPEUTICS CORP.
(Exact name of registrant as specified in its charter)

 

Delaware 86-0585310   
(State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.)

 

1275 W. Washington Street, Suite 104, Tempe, Arizona 85281
(Address of principal executive offices) (Zip Code)

 

(602) 286-5520

(Registrant's telephone number, including area code)

 

 

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. [X] Yes [_] No

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

 [X] Yes [_] No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. Large accelerated filer Accelerated filer ___
Non-accelerated filer ___ (do not check if a smaller reporting company) Smaller reporting company _X__

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). [_] Yes [X] No

 

APPLICABLE ONLY TO CORPORATE ISSUERS:

 

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

 

40,885,411 shares of common stock outstanding as of October 31, 2015

 

1
 

CAPSTONE THERAPEUTICS CORP.

 

INDEX

 

  Page No.
 

Forward Looking Statements

3

     
Part I Financial Information  
     
 

Item 1. Financial Statements (Unaudited)

  
     

Condensed Consolidated Balance Sheets as of September 30, 2015 and December 31, 2014

4

     
 

Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2015 and 2014

5

     
 

Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2015 and 2014

6

     
Notes to Condensed Consolidated Financial Statements

7

     
 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 13
     

Item 4. Controls and Procedures

17

     

Part II

Other Information

  
     

Item 1. Legal Proceedings

17

     
  Item 6. Exhibits 17
   

 

EXHIBIT 31.1

EXHIBIT 31.2

EXHIBIT 32

EXHIBIT 101

 

2
 

Forward Looking Statements

 
We may from time to time make written or oral forward-looking statements, including statements contained in our filings with the Securities and Exchange Commission and our reports to stockholders. The safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 protects companies from liability for their forward looking statements if they comply with the requirements of that Act. This Quarterly Report on Form 10-Q should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2014, and contains forward-looking statements made pursuant to that safe harbor. These forward-looking statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could materially affect actual results, levels of activity, performance or achievements. Factors that may cause actual results to differ materially from current expectations, which we describe in more detail in our Form 10-K for the year ended December 31, 2014, and our Form S-1 filed with the Securities and Exchange Commission on June 26, 2015, as amended, include, but are not limited to:

 

·Failure to obtain additional funds to continue operations;

·the impact of the terms or conditions of agreements associated with funds obtained to fund operations;

·the impact of our actions to preserve cash including implementation of a virtual operating model;

·unfavorable results of product candidate development efforts, including through our joint venture;
·unfavorable results of pre-clinical or clinical testing, including through our joint venture;
·delays in obtaining, or failure to obtain FDA approvals;
·increased regulation by the FDA and other agencies;
·the introduction of competitive products;
·impairment of license, patent or other proprietary rights;
·the impact of present and future joint venture, collaborative or partnering agreements or the lack thereof;
·failure to successfully implement our drug development strategy for AEM-28 and its analogs; and
·failure to obtain additional funds required to complete clinical trials and supporting research and production efforts necessary to obtain FDA, or comparable foreign agency, approval for product candidates or secure development agreements with pharmaceutical manufacturers.

 

If one or more of these or other risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect, actual results may vary significantly from what we projected. The forward-looking statements in this Quarterly Report on Form 10-Q reflect our current views with respect to future events and are subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, business strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

 

3
 

PART I – Financial Information

Item 1. Financial Statements

 

CAPSTONE THERAPEUTICS CORP.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

 

   September 30,  December 31,
   2015  2014
   (unaudited)   
ASSETS          
Current assets          
Cash and cash equivalents  $637   $2,164 
Other current assets   360    555 
Total current assets   997    2,719 
           
Patent license rights, net   549    666 
Furniture and equipment, net   -    - 
Total assets  $1,546   $3,385 
           
LIABILITIES AND EQUITY          
Current liabilities          
Accounts payable  $132   $124 
Other accrued liabilities   56    158 
Total current liabilities   188    282 
           
Equity          
Capstone Therapeutics Corp. Stockholders' Equity          
Common Stock  $.0005 par value; 150,000,000 shares authorized;   20    20 
40,885,411 shares in 2015 and 2014 issued and outstanding          
Additional paid-in capital   189,426    189,268 
Accumulated deficit   (188,088)   (186,185)
Total Capstone Therapeutics Corp. stockholders' equity   1,358    3,103 
Noncontrolling interest   -    - 
Total equity   1,358    3,103 
           
Total liabilities and equity  $1,546   $3,385 

 

See notes to unaudited condensed consolidated financial statements

 

4
 

CAPSTONE THERAPEUTICS Corp.

CONDENSED CONSOLIDATED Statements of Operations

(in thousands, except per share data)

(Unaudited)

 

   Three months ended September 30,  Nine months ended September 30,
   2015  2014  2015  2014
OPERATING EXPENSES                    
General and administrative  $241   $373   $1,265   $1,047 
Research and development   175    865    808    2,667 
Total operating expenses   416    1,238    2,073    3,714 
                     
Interest and other expenses (income), net   19    (4)   28    (67)
Loss from operations before taxes   435    1,234    2,101    3,647 
Income tax benefit   -    -    (198)   - 
NET LOSS   435    1,234    1,903    3,647 
Less: Net Loss attributable to the noncontrolling                    
interest   -    -    -    - 
Net Loss attributable to Capstone                    
Therapeutics Corp. stockholders  $435   $1,234   $1,903   $3,647 
Per Share Information:                    
Net loss, basic and diluted, attributable to                    
Capstone Therapeutic Corp. stockholders  $0.01   $0.03   $0.05   $0.09 
Basic and diluted shares outstanding   40,885    40,885    40,885    40,885 

 

See notes to unaudited condensed consolidated financial statements

 

5
 

CAPSTONE THERAPEUTICS Corp.

CONDENSED CONSOLIDATED Statements of CASH FLOWS

(in thousands)

(Unaudited)

 

   Nine months ended
   September 30,
   2015  2014
OPERATING ACTIVITIES          
Net loss  $(1,903)  $(3,647)
Non cash items:          
Depreciation and amortization   117    121 
Non-cash stock compensation   158    52 
Change in other operating items:          
Other current assets   195    (44)
Accounts payable   8    137 
Other accrued liabilities   (102)   234 
Cash flows used in operating activities   (1,527)   (3,147)
INVESTING ACTIVITIES          
Cash flows provided by investing activities   -    - 
FINANCING ACTIVITIES   -      
Cash flows provided by financing activities        - 
           
NET DECREASE IN CASH AND CASH EQUIVALENTS   (1,527)   (3,147)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD   2,164    6,258 
CASH AND CASH EQUIVALENTS, END OF PERIOD  $637   $3,111 

 

See notes to unaudited condensed consolidated financial statements

 

6
 

CAPSTONE THERAPEUTICS CORP.

 

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2015

 

Note A. OVERVIEW OF BUSINESS

 

Description of the Business

 

Capstone Therapeutics Corp. (the “Company”, “we”, “our” or “us”) is a biotechnology company committed to developing a pipeline of novel peptides and other molecules aimed at helping patients with under-served medical conditions. Previously, we were focused on the development and commercialization of two product platforms: AZX100 and Chrysalin (TP508). Since March 2012, we no longer have any interest in or rights to Chrysalin. In 2012 we wound down internal operations, ceased clinical development of AZX100 in dermal scarring, formerly our principal drug candidate, and moved to a more virtual operating model. In 2014, we terminated the License Agreement for AZX100 intellectual property and returned all interest in and rights to the AZX100 intellectual property to the Licensor (AzTE).

 

On August 3, 2012, we entered into a joint venture, LipimetiX Development, LLC, (now LipimetiX Development, Inc.), (the “JV”), to develop Apo E mimetic peptide molecule AEM-28 and its analogs. The JV has a development plan to pursue regulatory approval of AEM-28, or an analog, as treatment for Homozygous Familial Hypercholesterolemia (granted Orphan Drug Designation by FDA in 2012), Acute Hypertriglyceridemic Pancreatitis, and other hyperlipidemic indications. The initial development plan extended through Phase 1a and 1b/2a clinical trials and was completed in the fourth quarter of 2014.

 

The JV received allowance from regulatory authorities in Australia permitting the JV to proceed with the planned clinical trials. The Phase 1a clinical trial commenced in Australia in April 2014 and the Phase 1b/2a clinical trial commenced in Australia in June 2014. The clinical trials for AEM-28 were randomized, double-blinded, placebo-controlled studies to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of six escalating single doses (Phase 1a in healthy patients with elevated cholesterol) and multiple ascending doses of the three highest doses from Phase 1a (Phase 1b/2a in patients with hypercholesterolemia and healthy volunteers with elevated cholesterol and high Body Mass Index). The Phase 1a clinical trial consisted of 36 patients and the Phase 1b/2a consisted of 15 patients. Both clinical trials were completed in 2014 and the Medical Safety Committee, reviewing all safety-related aspects of the clinical trials, observed a generally acceptable safety profile. As first-in-man studies, the primary endpoint was safety; yet efficacy measurements analyzing pharmacodynamics yielded statistical significance in the pooled dataset favoring AEM-28 versus placebo in multiple lipid biomarker endpoints.

 

Concurrent with the clinical development activities with AEM-28, the JV has performed pre-clinical studies that have identified an analog of AEM-28, referred to as AEM-28-14, and a new phospholipid formulation, that has the potential of equivalent efficacy, higher human dose toleration and an extended composition of matter patent life (application filed with the U.S. Patent and Trademark Office in 2015). The JV’s current intent is to prioritize the development of AEM-28-14.

 

The JV and the Company are exploring fundraising, partnering or licensing, to obtain additional funding to continue development activities of AEM-28 and its analogs, including AEM-28-14, and operations.

 

The JV and the Company do not have sufficient funding at this time to continue additional material development activities of AEM-28 and its analogs, including AEM-28-14. The JV may conduct future clinical trials in Australia, the USA, and other regulatory jurisdictions if regulatory approvals, additional funding, and other conditions permit.

 

7
 

The Company, funding permitting, intends to continue limiting its internal operations to a virtual operating model while monitoring and participating in the management of JV’s AEM-28 and analogs development activities and maintaining the required level of corporate governance and reporting required to comply with Securities and Exchange Commission rules and regulations.

 

Description of Current Peptide Drug Candidates.

 

Chimeric Apo E Mimetic Peptide Molecule – AEM-28 and its analogs

 

Apolipoprotein E is a 299 amino acid protein that plays an important role in lipoprotein metabolism. AEM-28 is a 28 amino acid mimetic of Apo E and AEM-28 and its analogs, including AEM-28-14 is a 28 amino acid mimetic of Apo E (with an aminohexanoic acid group and a phospholipid), and both contain a domain that anchors into a lipoprotein surface while also providing the Apo E receptor binding domain, which allows clearance through the heparan sulfate proteoglycan (HSPG) receptors (Syndecan-1) in the liver. AEM-28 and its analogs, including AEM-28-14, as Apo E mimetics, have the potential to restore the ability of these atherogenic lipoproteins to be cleared from the plasma, completing the reverse cholesterol transport pathway, and thereby reducing cardiovascular risk. This is an important mechanism of action for AEM-28 and its analogs, including AEM-28-14. For patients that lack LDL receptors (Homozygous Familial Hypercholesterolemia-HoFH), have acute pancreatitis, or have hypercholesterolemia, AEM-28 and its analogs may provide a therapeutic solution. Our joint venture has an Exclusive License Agreement with the University of Alabama at Birmingham Research Foundation for AEM-28 and certain of its analogs.

 

Company History

 

Prior to November 26, 2003, we developed, manufactured and marketed proprietary, technologically advanced orthopedic products designed to promote the healing of musculoskeletal bone and tissue, with particular emphasis on fracture healing and spine repair. Our product lines, which included bone growth stimulation and fracture fixation devices, are referred to as our “Bone Device Business.” In November 2003, we sold our Bone Device Business.

 

In August 2004, we purchased substantially all of the assets and intellectual property of Chrysalis Biotechnology, Inc., including its exclusive worldwide license for Chrysalin, a peptide, for all medical indications. Subsequently, our efforts were focused on research and development of Chrysalin with the goal of commercializing our products in fresh fracture healing. (In March 2012, we returned all rights to the Chrysalin intellectual property and no longer have any interest in, or rights to Chrysalin.)

 

In February 2006, we purchased certain assets and assumed certain liabilities of AzERx, Inc. Under the terms of the transaction, we acquired an exclusive license for the core intellectual property relating to AZX100, an anti-fibrotic peptide. In 2014, we terminated the License Agreement with AzTE (Licensor) for the core intellectual property relating to AZX100 and returned all interest in and rights to the AZX100 intellectual property to the Licensor.

 

On August 3, 2012, we entered into a joint venture (see Note B below), to develop Chimeric Apo E mimetic peptide molecule AEM-28 and its analogs.

 

Our development activities represent a single operating segment as they shared the same product development path and utilized the same Company resources. As a result, we determined that it is appropriate to reflect our operations as one reportable segment.

 

8
 

OrthoLogic Corp. commenced doing business under the trade name of Capstone Therapeutics on October 1, 2008, and we formally changed our name from OrthoLogic Corp. to Capstone Therapeutics Corp. on May 21, 2010.

 

In these notes, references to “we”, “our”, “us”, the “Company”, “Capstone Therapeutics”, “Capstone”, and “OrthoLogic” refer to Capstone Therapeutics Corp. References to our joint venture or “JV”, refer to LipimetiX Development, Inc. (formerly LipimetiX Development, LLC).

 

Financial Statement Presentation and Management’s Plan

 

The accompanying financials statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.

 

The report from our Independent Registered Public Accounting Firm on our consolidated financial statements for the year ended December 31, 2014 included in our Annual Report on Form 10-K expressed substantial doubt about the Company’s ability to continue as a going concern.

 

Management has determined that the Company will require additional capital above its current cash and working capital balances to further develop AEM-28 and its analogs or continue operations. Accordingly, the Company has reduced its development activities. The Company’s corporate strategy is to raise funds by possibly engaging in a strategic/merger transaction, or conducting a private or public offering of debt or equity securities for capital. These financial statements do not include any adjustments that might result from the outcome of the uncertainty of the Company successfully implementing its corporate strategy.

 

In the opinion of management, the unaudited condensed interim financial statements include all adjustments necessary for the fair presentation of our financial position, results of operations, and cash flows, and all adjustments were of a normal recurring nature. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the complete fiscal year. The financial statements include the consolidated results of Capstone Therapeutics Corp. and our 60% owned subsidiary, LipimetiX Development, Inc. Intercompany transactions have been eliminated.

 

Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to Securities and Exchange Commission rules and regulations, although we believe that the disclosures herein are adequate to make the information presented not misleading. These unaudited condensed financial statements should be read in conjunction with the financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2014. Information presented as of December 31, 2014 is derived from audited financial statements.

 

Use of Estimates

 

The preparation of financial statements in accordance with accounting principles generally accepted in the United States requires that management make a number of assumptions and estimates that affect the reported amounts of assets, liabilities, and expenses in our financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management’s assumptions regarding current events and actions that may impact us in the future, actual results may differ from these estimates and assumptions.

 

9
 

Legal and Other Contingencies

 

The Company is subject to legal proceedings and claims that arise in the ordinary course of business. The Company records a liability when it is probable that a loss has been incurred and the amount is reasonably estimable. There is significant judgment required in both the probability determination and as to whether an exposure can be reasonably estimated. In the opinion of management, there was not at least a reasonable possibility the Company may have incurred a material loss with respect to loss contingencies.

 

Joint Venture Accounting

 

The Company entered into a joint venture in which it has contributed $6,000,000, and the noncontrolling interests have contributed certain patent license rights. Neither the Company nor the noncontrolling interests have an obligation to contribute additional funds to the joint venture or to assume any joint venture liabilities or to provide a guarantee of either joint venture performance or any joint venture liability. The financial position and results of operations of the joint venture are presented on a consolidated basis with the financial position and results of operations of the Company. Intercompany transactions have been eliminated. Joint venture losses were recorded on the basis of common ownership equity interests (60% Company / 40% noncontrolling interests) until common ownership equity was reduced to $0. Subsequent joint venture losses are being allocated to the preferred ownership equity (100% Company). Subsequent to March 31, 2013, all joint venture losses are being allocated to the Company. The Company has a revolving loan agreement with the joint venture to advance the joint venture funds for operations in an amount not to exceed a net (net of expected tax credits or other funds obtained) of $700,000, with the net amount due December 31, 2015. Losses incurred by the joint venture in excess of the capital accounts of the joint venture will be allocated to the Company to the extent of net outstanding advances.

 

Cash and Cash Equivalents

 

At September 30, 2015, cash and cash equivalents included money market accounts.

 

Recent Accounting Pronouncements

 

In August 2014, the Financial Accounting Standards Board issued Accounting Standard Update (“ASU”) No. 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40)(“Update”): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, providing a requirement under U.S. GAAP for an entity’s management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date the financial statements are issued; and if those conditions exist, to disclose that fact, the conditions and the potential effects on the entity’s ability to meet its obligations. The Update will be effective for an annual period ending after December 15, 2016, with early application permitted. We have not elected early application. However, if additional funds are not obtained to continue the development of AEM-28 or its analogs, or operations, it will impair our ability to continue as a going concern. If we do not continue as a going concern, the Company may incur additional losses, up to, and possibly exceeding our net joint venture investment and revolving loan balance.

 

Note B.JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS

 

On August 3, 2012, we entered into a Contribution Agreement with LipimetiX, LLC to form a joint venture, LipimetiX Development, LLC (“JV”), to develop Apo E mimetic molecules, including AEM-28 and its analogs. In June 2015, the JV converted from a limited liability company to a corporation, LipimetiX Development, Inc. The Company contributed $6 million, which included $1 million for 600,000 voting common ownership units (now common stock), representing 60% ownership in the JV, and $5 million for 5,000,000 non-voting preferred ownership units (now preferred stock), which have preferential distribution rights.

 

10
 

LipimetiX, LLC contributed all intellectual property rights for Apo E mimetic molecules it owned and assigned its Exclusive License Agreement between The University of Alabama at Birmingham Research Foundation (“UABRF”) and LipimetiX, LLC, for the UABRF intellectual property related to Apo E mimetic molecules AEM-28 and its analogs to the JV, in return for 400,000 voting common ownership units (now common stock) representing 40% ownership in JV, and $378,000 in cash (for certain initial patent-related costs and legal expenses).

 

LipimetiX, LLC was formed by the principals of Benu BioPharma, Inc. (“Benu”) and UABRF to commercialize UABRF’s intellectual property related to Apo E mimetic molecules, including AEM-28 and analogs. Benu is composed of Dennis I. Goldberg, Ph.D., Phillip M. Friden, Ph.D. and Eric M. Morrel, Ph.D. The Exclusive License Agreement, as amended, calls for payment of patent filing, maintenance and other related patent fees, as well as a royalty of 3% on Net Sales of Licensed Products during the Term of the Agreement. The Agreement terminates upon the expiration of all Valid Patent Claims within the Licensed Patents, which are currently estimated to expire between 2019 and 2035. The Agreement, as amended, also calls for annual maintenance payments of $25,000, various milestone payments of $50,000 to $500,000 and minimum royalty payments of $500,000 to $1,000,000 per year commencing on January 1 of the first calendar year following the year in which the First Commercial Sale occurs. UABRF will also be paid 5% of Non Royalty Income received.

 

Concurrent with entering into the Contribution Agreement and the First Amendment and Consent to Assignment of Exclusive License Agreement between LipimetiX, LLC, UABRF and the Company, the Company and LipimetiX, LLC entered into a Limited Liability Company Agreement for JV which established a Joint Development Committee (“JDC”) to manage JV development activities. Upon conversion by the JV from a limited liability company to a corporation, the parties entered into a Stockholders Agreement for the JV, and the JDC was replaced by a Board of Directors (JV Board). The JV Board is composed of three members appointed by the non-Company ownership group and two members appointed by the Company. Non-development JV decisions, including the issuance of new equity, incurrence of debt, entry into strategic transactions, licenses or development agreements, sales of assets and liquidation, and approval of annual budgets, will be decided by a majority vote of the common stockholders.

 

The JV, on August 3, 2012, entered into a Management Agreement with Benu to manage JV development activities for a monthly fee of approximately $63,000 during the twenty-seven month development period, and an Accounting Services Agreement with the Company to manage JV accounting and administrative functions. The current accounting services fee is $1,000 a month. Commencing in November 2014, and ending in March 2015, Benu received a reduced monthly management fee in the amount of $35,000. Subsequent to March 2015, no management fee has been paid to Benu for their services.

 

The joint venture formation was as follows ($000’s):

 

Patent license rights  $1,045 
Noncontrolling interests   (667)
Cash paid at formation  $378 

 

Patent license rights were recorded at their estimated fair value and are being amortized on a straight-line basis over the key patent life of eighty months.

 

11
 

The financial position and results of operations of the joint venture are presented on a consolidated basis with the financial position and results of operations of the Company. Intercompany transactions have been eliminated. The joint venture agreement requires profits and losses to be allocated on the basis of common ownership equity interests (60% Company / 40% noncontrolling interests). However, for the Company’s consolidated financial statement, joint venture losses were recorded on the basis of common ownership equity interests (60% Company / 40% noncontrolling interests) until common ownership equity was reduced to $0. Subsequent joint venture losses have been allocated to the preferred ownership equity (100% Company). Subsequent to March 31, 2013, all joint venture losses have been allocated to the Company. The Company has a revolving loan agreement with the joint venture to advance the joint venture funds for operations in an amount not to exceed a net (net of expected tax credits or other funds obtained) of $700,000, with the net amount due December 31, 2015. Losses incurred by the joint venture in excess of the capital accounts of the joint venture will be allocated to the Company to the extent of net outstanding advances. At September 30, 2015, outstanding advances on the revolving loan agreement totaled $759,000.

 

The joint venture incurred net operating expenses, prior to the elimination of intercompany transactions, of $503,000 in the nine month period ended September 30, 2015 and $6,738,000 for the period from August 3, 2012 (inception) to September 30, 2015, of which $503,000 and $6,071,000, respectively, have been recorded by the Company. The joint venture operating expenses are included in research and development expenses in the condensed consolidated statements of operations.

 

Neither the Company nor the noncontrolling interests have an obligation to contribute additional funds to the joint venture or to assume any joint venture liabilities or to provide a guarantee of either joint venture performance or any joint venture liability. Losses allocated to the noncontrolling interests represent an additional potential loss for the Company as the noncontrolling interests are not obligated to contribute assets to the joint venture to the extent they have a negative capital account, and depending on the ultimate outcome of the joint venture, the Company could potentially absorb all losses associated with the joint venture. From formation of the joint venture, August 3, 2012, through September 30, 2015, losses totaling $667,000 have been allocated to the noncontrolling interests. If the joint venture or Company is unable to obtain additional funding, the ability of the joint venture to continue development of AEM-28 and its analogs, including AEM-28-14, would be impaired as would the joint venture’s ability to continue operations. If the joint venture does not continue as a going concern, at September 30, 2015 the Company would incur an additional loss of $667,000 for the joint venture losses allocated to the noncontrolling interests.

 

Note C. FUNDRAISING ACTIVITIES

 

As disclosed above, management has determined that the Company will require additional capital above its current cash and working capital balances to further develop AEM-28 and its analogs and to continue operations.  Accordingly, the Company has reduced its development activities.  The Company’s corporate strategy is to raise funds by possibly engaging in a strategic/merger transaction, or conducting a private or public offering of debt or equity securities for capital.    In connection with these efforts, we filed a Registration Statement on Form S-1 with the Securities and Exchange Commission on June 26, 2015, as amended, in connection with our contemplated public offering of shares of our Common Stock. The Registration Statement is not effective as of September 30, 2015.

 

As of September 30, 2015, we have deferred recognition of approximately $148,000 of direct costs, primarily legal costs and filing fees, related to fundraising activities in connection with our contemplated public offering of shares of our Common Stock. These costs are to be offset against the equity raised upon completion of the offering.  The deferred costs are included in other current assets in the Condensed Consolidated Balance Sheet at September 30, 2015.

 

12
 

Note D. Australian Refundable Research & Development Credit

 

In March 2014, LipimetiX Development LLC, (see Note B) formed a wholly-owned Australian subsidiary, Lipimetix Australia Pty Ltd, to conduct Phase 1a and Phase1b/2a clinical trials in Australia. Currently Australian tax regulations provide for a refundable research and development tax credit equal to 45% of qualified expenditures. Subsequent to the end of its Australian tax years, Lipimetix Australia Pty, Ltd intends to submit claims for a refundable research and development tax credit. The transitional Australian tax periods/years granted for Lipimetix Australia Pty, Ltd end on June 30, 2014, December 31, 2014 and thereafter December 31 of each succeeding year. For the tax year ended June 30, 2014, Lipimetix Australia Pty, Ltd received a refundable research and development tax credit of AUD$227,000. At December 31, 2014 a AUD$242,000 development tax credit was recorded by Lipimetix Australia Pty, Ltd, and at September 30, 2015, AUD$202,000 has been accrued, as it is more likely than not that the recorded refundable research and development tax credit will be approved and received. At September 30, 2015, and December 31, 2014, AUD$202,000 (US$142,000), and AUD$242,000 (US$196,000), respectively, have been accrued and are included in other current assets in our condensed consolidated balance sheets.

 

Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

The following is management’s discussion of significant events in the three month period ended September 30, 2015 and factors that affected our interim financial condition and results of operations. This should be read in conjunction with our “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors” included in our Annual Report on Form 10-K for the year ended December 31, 2014 and our Form S-1 filed with the Securities and Exchange Commission on June 26, 2015, as amended.

 

Overview of the Business

 

Capstone Therapeutics Corp. is a biotechnology company committed to developing a pipeline of novel peptides and other molecules aimed at helping patients with under-served medical conditions. Previously, we were focused on the development and commercialization of two product platforms: AZX100 and Chrysalin (TP508). Since March 2012, we no longer have any interest in or rights to Chrysalin. In 2012 we wound down internal operations, ceased clinical development of AZX100 in dermal scarring, formerly our principal drug candidate, and moved to a more virtual operating model. In 2014, we terminated the License Agreement for AZX100 intellectual property and returned all interest in and rights to the AZX100 intellectual property to the Licensor (AzTE).

 

On August 3, 2012, we entered into a joint venture, LipimetiX Development, LLC, (now LipimetiX Development, Inc.) (the “JV”) to develop Apo E mimetic peptide molecule AEM-28 and its analogs. The JV has a development plan to pursue regulatory approval of AEM-28, or an analog, as treatment for Homozygous Familial Hypercholesterolemia (granted Orphan Drug Designation by FDA in 2012), Acute Hypertriglyceridemic Pancreatitis, and other hyperlipidemic indications. The initial development plan extended through Phase 1a and 1b/2a clinical trials and was completed in the fourth quarter of 2014. The clinical trials have a safety primary endpoint and an efficacy endpoint targeting reduction of cholesterol and triglycerides.

 

13
 

The JV received allowance from regulatory authorities in Australia permitting the JV to proceed with the planned clinical trials. The Phase 1a clinical trial commenced in Australia in April 2014 and the Phase 1b/2a clinical trial commenced in Australia in June 2014. The clinical trials for AEM-28 are randomized, double-blinded, placebo-controlled studies to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of six escalating single doses (Phase 1a in healthy patients with elevated cholesterol) and multiple ascending doses of the three highest doses from Phase 1a (Phase 1b/2a in patients with Hypercholesterolemia and normal healthy volunteers with elevated cholesterol and high Body Mass Index). The Phase 1a clinical trial consisted of 36 patients and the Phase 1b/2a consisted of 15 patients. Both clinical trials were completed in 2014 and the Medical Safety Committee, reviewing all safety-related aspects of the clinical trials, observed a generally acceptable safety profile. As first-in-man studies, the primary endpoint was safety; yet efficacy measurements analyzing pharmacodynamics yielded statistical significance in the pooled dataset favoring AEM-28 versus placebo in multiple lipid biomarker endpoints.

 

Concurrent with the clinical development activities of AEM-28, the JV has performed pre-clinical studies that have identified an analog of AEM-28, referred to as AEM-28-14, and a new phospholipid formulation, that has the potential of equivalent efficacy, higher human dose toleration and an extended patent life (application filed in 2015). The JV’s current intent is to prioritize the development of AEM-28-14.

 

The JV and Company are exploring fundraising, partnering or licensing to obtain additional funding to continue development activities of AEM-28 and its analogs, including AEM-28-14, and operations.

 

The JV and the Company do not have sufficient funding at this time to continue additional material development activities of AEM-28 and its analogs, including AEM-28-14. The JV may conduct future clinical trials in Australia, the USA, and other regulatory jurisdictions if regulatory approvals, additional funding, and other conditions permit. The JV may also fund research or studies to investigate AEM-28-14 for treatment of acute coronary syndrome and other indications.

 

The Company, funding permitting, intends to limit its internal operations to a virtual operating model while continuing monitoring and participating in the management of JV’s AEM-28 and analogs development activities and maintaining the required level of corporate governance and reporting required to comply with Securities and Exchange Commission rules and regulations.

 

Description of Our Peptide Drug Candidate.

 

Chimeric Apo E Mimetic Peptide Molecule – AEM-28 and its analogs

 

Apolipoprotein E is a 299 amino acid protein that plays an important role in lipoprotein metabolism. AEM-28 is a 28 amino acid mimetic of Apo E and AEM-28-14 (an analog of AEM-28) is a 28 amino acid mimetic of Apo E (with an aminohexanoic acid group and a phospholipid) and both contain a domain that anchors into a lipoprotein surface while also providing the Apo E receptor binding domain, which allows clearance through the heparan sulfate proteoglycan (HSPG) receptors (Syndecan-1) in the liver. AEM-28 and AEM-28-14, as Apo E mimetics, have the potential to restore the ability of these atherogenic lipoproteins to be cleared from the plasma, completing the reverse cholesterol transport pathway, and thereby reducing cardiovascular risk. This is an important mechanism of action for AEM-28 and AEM-28-14. For patients that lack LDL receptors (Homozygous Familial Hypercholesterolemia-HoFH), have acute pancreatitis, or have hypercholesterolemia, AEM-28 or AEM-28-14 may provide a therapeutic solution. Our joint venture has an Exclusive License Agreement with the University of Alabama at Birmingham Research Foundation for AEM-28 and certain of its analogs.

 

Critical Accounting Policies

 

Our critical accounting policies are those that affect, or could affect our financial statements materially and involve a significant level of judgment by management. The accounting policies and related risks described in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 16, 2015, for the year ended December 31, 2014 are those that depend most heavily on these judgments and estimates. As of September 30, 2015, there have been no material changes to any of the critical accounting policies contained in our Annual Report for the year ended December 31, 2014.

 

14
 

Results of Operations Comparing Three-Month Period Ended September 30, 2015 to the Corresponding Period in 2014.

 

General and Administrative (“G&A”) Expenses: G&A expenses related to our ongoing operations were $241,000 in the third quarter of 2015 compared to $373,000 in the third quarter of 2014. Administration expenses decreased primarily due to the deferral of approximately $148,000 (see Note C) of direct fundraising costs (primarily legal costs and filing fees).

 

Research and Development Expenses: Research and development expenses were $175,000 for the third quarter of 2015 compared to $865,000 for the third quarter of 2014. Our research and development expenses varied in the third quarter of 2015 compared to the same period in 2014 primarily due to the inclusion and fluctuation of operating expenses of the JV, which totaled (net of intercompany transactions) $152,000 for the three months ended September 30, 2015, and $790,000 for the three months ended September 30, 2104. As discussed above, we have significantly reduced our development activities of AEM-28 and its analogs, including AEM-28-14, as we attempt to obtain additional funding.

 

Net Loss attributable to Capstone Therapeutics stockholders: We incurred a net loss in the third quarter of 2015 of $0.4 million compared to a net loss of $1.2 million in the third quarter of 2014. Net loss is affected by the items discussed above in General and Administrative Expenses, and the inclusion of the operating expenses of JV, which totaled (net of intercompany transactions) $152,000 for the three months ended September 30, 2015 and $790,000 for the three months ended September 30, 2014. As discussed above, we have significantly reduced our development activities of AEM-28 and its analogs, including AEM-28-14, as we attempt to obtain additional funding.

 

Results of Operations Comparing Nine-Month Period Ended September 30, 2015 to the Corresponding Period in 2014.

 

General and Administrative (“G&A”) Expenses: G&A expenses related to our ongoing operations were $1,265,000 in 2015 compared to $1,047,000 in 2014. Administration expenses increased primarily due to costs related to the qui tam litigation (settled for a one-time payment of $50,000 in the second quarter of 2015) and investor relations activities. We expect that we may have elevated general and administrative costs, compared to 2014 levels, while we continue fund raising activities.

 

Research and Development Expenses: Research and development expenses were $808,000 for 2015 compared to $2,667,000 for 2014. Our research and development expenses varied in the first nine months of 2015 compared to the same period in 2014 primarily due to the inclusion and fluctuation of operating expenses of the JV, which totaled (net of intercompany transactions) $499,000 for the nine months ended September 30, 2015, and $2,195,000 for the nine months ended September 30, 2104. As discussed above, we have significantly reduced our development activities of AEM-28 and its analogs, including AEM-28-14, as we attempt to obtain additional funding.

 

Interest and Other Expenses (Income), Net: Interest and Other Expenses (Income), Net, decreased from $67,000 of Income in 2014 to $28,000 of Expense in 2015 due to the receipt of $60,000 in 2014 from the conversion of an insurance company, in which we were a policyholder, from mutual to private ownership, while in 2015 the Company incurred a foreign exchange loss of $33,000 related to our joint venture’s Australian activities.

 

15
 

Income Tax Benefit: Income tax benefit in 2015 consisted of a refundable Australian research and development tax credit, as described in Note D to the financial statements included in this Quarterly Report on Form 10-Q, related to our joint venture’s Australian clinical trial activities.

 

Net Loss attributable to Capstone Therapeutics stockholders: We incurred a net loss in the first nine months of 2015 of $1.9 million compared to a net loss of $3.6 million in the first nine months of 2014. Net loss is affected by the items discussed above and the inclusion of the operating expenses of JV, which totaled (net of intercompany transactions) $499,000 for the nine months ended September 30, 2015 and $2,195,000 for the nine months ended September 30, 2014. As discussed above, we have significantly reduced our development activities of AEM-28 and its analogs, including AEM-28-14, as we attempt to obtain additional funding.

 

Liquidity and Capital Resources

 

With the sale of our Bone Device Business in November 2003, we sold all of our revenue producing operations. Since that time, we have primarily relied on our cash and investments to finance all our operations, the focus of which has been research and development of our product candidates.

 

On August 3, 2012, we entered into a joint venture, to develop Apo E mimetic peptide molecule AEM-28 and its analogs. We contributed $6.0 million and through September 30, 2015 we have loaned an additional $759,000 to the JV. At September 30, 2015, we had cash and cash equivalents of $637,000.

 

We intend to continue limiting our internal operations to a virtual operating model in 2015, however, without additional funding, we will not continue development of AEM-28 and its analogs, including AEM-28-14, past completion of the limited projects currently under way. We are exploring strategic options for both the Company and our joint venture. Lack of additional funding within the next 12 months, would impair our ability to continue our current operations and our ability to continue as a going concern.

 

Funding permitting, our planned operations in 2015 consist of continuing monitoring and participating in the management of the JV’s AEM-28 and its analogs, including AEM-28-14, development activities, and maintaining the required level of corporate governance and reporting required to comply with Securities and Exchange Commission rules and regulations.

 

Our future research and development and other expenses will vary significantly from prior periods and depend on the Company’s decisions on future JV operations and obtaining additional funding.

 

We will require additional funds if we chose to extend the development of AEM-28 and its analogs past the initial Phase 1a and Phase1b/2a clinical trials or to continue operations. We cannot currently predict the amount of funds that will be required if we chose to extend the development activities of AEM-28 and its analogs and to continue operations. In any event, to complete the clinical trials and supporting research and production efforts necessary to obtain FDA or comparable foreign agencies’ approval for product candidates would require us to obtain additional capital. New sources of funds, including raising capital through the sales of our debt or equity securities, joint venture or other forms of joint development arrangements, sales of development rights, or licensing agreements, may not be available or may only be available on terms that would have a material adverse impact on our existing stockholders’ interests.

 

16

 

Item 4. Controls and Procedures

 

Disclosure Controls and Procedures

 

Our management, with the participation of our principal executive officer and principal financial and accounting officer, has reviewed and evaluated our disclosure controls and procedures (as defined in the Securities Exchange Act Rule 13a-15(e)) as of the end of the period covered by this Form 10-Q. Based on that evaluation, our management, including our principal executive officer and principal financial and accounting officer, has concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Form 10-Q in ensuring that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and is accumulated and communicated to management, including our principal executive officer and principal financial and accounting officer, as appropriate, to allow timely decisions regarding required disclosure.

 

Internal Control Over Financial Reporting

 

There were no changes in our internal control over financial reporting during the fiscal quarter to which this report relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Part II – Other Information

 

Item 1. Legal Proceedings

 

None

 

Item 6. Exhibits

 

See the Exhibit Index following this report.

 

17

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

CAPSTONE THERAPEUTICS CORP.

(Registrant)

 

 

Signature Title Date
     

/s/ John M. Holliman, III

John M. Holliman, III

 

Chairman and Chief Executive Officer

(Principal Executive Officer)

 

 November 9, 2015

/s/ Les M. Taeger

Les M. Taeger

Senior Vice President and Chief

Financial Officer

(Principal Financial and Accounting Officer)

 November 9, 2015
     

 

 

 

 

 

18

 

Capstone Therapeutics Corp.

(the “Company”)

Exhibit Index to Quarterly Report on Form 10-Q

For the Quarterly Period Ended September 30, 2015

 

No. Description Incorporated by Reference To: Filed Herewith
31.1

Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a), as amended.

 

   X
31.2

Certification of Principal Financial and Accounting Officer Pursuant to Securities Exchange Act Rule 13a-14(a), as amended.

 

   X
32

Certification of Principal Executive Officer and Principal Financial and Accounting Officer Pursuant to 18 U.S.C. Section 1350.*

 

    
101

The following financial information from our Quarterly Report on Form 10-Q for the third quarter of fiscal year 2015, filed with the SEC on November 9, 2015 formatted in Extensible Business Reporting Language (XBRL): (i) the Condensed Consolidated Balance Sheets as of September 30, 2015 and December 31, 2014, (ii) the Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2015 and 2014, (iii) the Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2015 and 2014, and (iv) Notes to Unaudited Condensed Consolidated Financial Statements.

 

* Furnished herewith

 

   X

 EX-31.1 2 exh_311.htm EXHIBIT 31.1

Exhibit 31.1

 

CERTIFICATION

 

I, John M. Holliman, III certify that:

 

1.I have reviewed this quarterly report on Form 10-Q of Capstone Therapeutics Corp.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 9, 2015

 

By: /s/ John M. Holliman, III

John M. Holliman, III
Chairman and Chief Executive Officer

(Principal Executive Officer)

 EX-31.2 3 exh_312.htm EXHIBIT 31.2

Exhibit 31.2

 

CERTIFICATION

 

I, Les M. Taeger, certify that:

 

1.I have reviewed this quarterly report on Form 10-Q of Capstone Therapeutics Corp.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 9, 2015

 

By: /s/ Les M. Taeger 

Les M. Taeger
Senior Vice President and Chief Financial Officer 

(Principal Financial and Accounting Officer)

 

 EX-32 4 exh_32.htm EXHIBIT 32

Exhibit 32

 

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Capstone Therapeutics Corp. (the “Company”) on Form 10-Q for the period ended September 30, 2015 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of John M. Holliman, III, Executive Chairman and Principal Executive Officer of the Company, and Les M. Taeger, Senior Vice President and Chief Financial Officer, and Principal Financial and Accounting Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

 

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 9, 2015

 

/s/ John M. Holliman, III

John M. Holliman, III 

Chairman and Chief Executive Officer 

(Principal Executive Officer)

 

/s/ Les M. Taeger 

Les M. Taeger 

Senior Vice President and Chief Financial Officer 

(Principal Financial and Accounting Officer)

 

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Capstone Therapeutics Corp. and will be retained by Capstone Therapeutics Corp. and furnished to the Securities and Exchange Commission or its staff upon request.

 EX-101.INS 5 caps-20150930.xml XBRL INSTANCE FILE 0000887151 2014-01-01 2014-09-30 0000887151 2015-01-01 2015-09-30 0000887151 2014-07-01 2014-09-30 0000887151 2015-07-01 2015-09-30 0000887151 2012-08-01 2012-08-03 0000887151 2012-08-03 0000887151 2012-08-04 2015-09-30 0000887151 2015-09-30 0000887151 2014-12-31 0000887151 2013-12-31 0000887151 2014-09-30 0000887151 us-gaap:CommonStockMember 2015-09-30 0000887151 us-gaap:PreferredStockMember 2015-09-30 0000887151 us-gaap:RevolvingCreditFacilityMember 2015-09-30 0000887151 caps:VotingCommonOwnershipUnitsMember 2012-08-03 0000887151 caps:NonVotingPreferredOwnershipUnitsMember 2012-08-03 0000887151 caps:ExclusiveLicenseAgreementMember 2012-08-01 2012-08-03 0000887151 caps:ExclusiveLicenseAgreementMember us-gaap:MinimumMember 2012-08-01 2012-08-03 0000887151 caps:ExclusiveLicenseAgreementMember us-gaap:MaximumMember 2012-08-01 2012-08-03 0000887151 caps:LipimetixMember 2015-01-01 2015-09-30 0000887151 caps:LipimetixAustraliaPtyLtdMember 2015-01-01 2015-09-30 0000887151 caps:LipimetixAustraliaPtyLtdMember 2014-01-01 2014-06-30 0000887151 caps:LipimetixAustraliaPtyLtdMember 2014-01-01 2014-12-31 0000887151 caps:LipimetixAustraliaPtyLtdMember 2015-09-30 0000887151 caps:LipimetixAustraliaPtyLtdMember 2014-12-31 0000887151 caps:LipimetixMember 2015-09-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares iso4217:AUD xbrli:pure 637000 2164000 360000 555000 997000 2719000 549000 666000 0 0 1546000 3385000 132000 124000 56000 158000 188000 282000 20000 20000 189426000 189268000 -188088000 -186185000 1358000 3103000 0 0 1358000 3103000 1546000 3385000 241000 373000 175000 865000 416000 1238000 -19000 4000 -435000 -1234000 0 0 -435000 -1234000 0 0 0.01 0.03 40885000 40885000 -435000 -1234000 1265000 1047000 808000 2667000 2073000 3714000 -28000 67000 -2101000 -3647000 -198000 0 -1903000 -3647000 0 0 0.05 0.09 40885000 40885000 -1903000 -3647000 117000 121000 158000 52000 8000 137000 -1527000 -3147000 0 0 0 -1527000 -3147000 6258000 3111000 -195000 44000 -102000 234000 6000000 0.6 0.4 0 1 700000 6000000 600000 0.6 5000000 400000 0.4 0.03 0.05 1000000 5000000 25000 50000 500000 500000 1000000 63000 1000 35000 503000 6738000 503000 6071000 759000 667000 378000 0.45 227000 242000 202000 10-Q false 2015-09-30 2015 Q3 Capstone Therapeutics Corp. 0000887151 --12-31 Smaller Reporting Company CAPS 0 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="center"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in"> <b><font style="FONT-SIZE: 10pt">Note A. OVERVIEW OF BUSINESS</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 2.25pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Description of the Business</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Capstone Therapeutics Corp. (the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;our&#8221; or &#8220;us&#8221;) is a biotechnology company committed to developing a pipeline of novel peptides and other molecules aimed at helping patients with under-served medical conditions. Previously, we were focused on the development and commercialization of two product platforms: AZX100 and Chrysalin (TP508). Since March 2012, we no longer have any interest in or rights to Chrysalin. In 2012 we wound down internal operations, ceased clinical development of AZX100 in dermal scarring, formerly our principal drug candidate, and moved to a more virtual operating model. In 2014, we terminated the License Agreement for AZX100 intellectual property and returned all interest in and rights to the AZX100 intellectual property to the Licensor (AzTE).</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">On August 3, 2012, we entered into a joint venture, LipimetiX Development, LLC, (now LipimetiX Development, Inc.), (the &#8220;JV&#8221;), to develop Apo E mimetic peptide molecule AEM-28 and its analogs. The JV has a development plan to pursue regulatory approval of AEM-28, or an analog, as treatment for Homozygous Familial Hypercholesterolemia (granted Orphan Drug Designation by FDA in 2012), Acute Hypertriglyceridemic Pancreatitis, and other hyperlipidemic indications. The initial development plan extended through Phase 1a and 1b/2a clinical trials and was completed in the fourth quarter of 2014.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The JV received allowance from regulatory authorities in Australia permitting the JV to proceed with the planned clinical trials. The Phase 1a clinical trial commenced in Australia in April 2014 and the Phase 1b/2a clinical trial commenced in Australia in June 2014. The clinical trials for AEM-28 were randomized, double-blinded, placebo-controlled studies to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of six escalating single doses (Phase 1a in healthy patients with elevated cholesterol) and multiple ascending doses of the three highest doses from Phase 1a (Phase 1b/2a in patients with hypercholesterolemia and healthy volunteers with elevated cholesterol and high Body Mass Index). The Phase 1a clinical trial consisted of 36 patients and the Phase 1b/2a consisted of 15 patients. Both clinical trials were completed in 2014 and the Medical Safety Committee, reviewing all safety-related aspects of the clinical trials, observed a generally acceptable safety profile. As first-in-man studies, the primary endpoint was safety; yet efficacy measurements analyzing pharmacodynamics yielded statistical significance in the pooled dataset favoring AEM-28 versus placebo in multiple lipid biomarker endpoints.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Concurrent with the clinical development activities with AEM-28, the JV has performed pre-clinical studies that have identified an analog of AEM-28, referred to as AEM-28-14, and a new phospholipid formulation, that has the potential of equivalent efficacy, higher human dose toleration and an extended composition of matter patent life (application filed with the U.S. Patent and Trademark Office in 2015). The JV&#8217;s current intent is to prioritize the development of AEM-28-14.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The JV and the Company are exploring fundraising, partnering or licensing, to obtain additional funding to continue development activities of AEM-28 and its analogs, including AEM-28-14, and operations.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The JV and the Company do not have sufficient funding at this time to continue additional material development activities of AEM-28 and its analogs, including AEM-28-14. The JV may conduct future clinical trials in Australia, the USA, and other regulatory jurisdictions if regulatory approvals, additional funding, and other conditions permit.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company, funding permitting, intends to continue limiting its internal operations to a virtual operating model while monitoring and participating in the management of JV&#8217;s AEM-28 and analogs development activities and maintaining the required level of corporate governance and reporting required to comply with Securities and Exchange Commission rules and regulations.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">Description of Current Peptide Drug Candidates.</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <u><font style="FONT-SIZE: 10pt">Chimeric Apo E Mimetic Peptide Molecule &#150; AEM-28 and its analogs</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Apolipoprotein E is a 299 amino acid protein that plays an important role in lipoprotein metabolism. AEM-28 is a 28 amino acid mimetic of Apo E and AEM-28 and its analogs, including AEM-28-14 is a 28 amino acid mimetic of Apo E (with an aminohexanoic acid group and a phospholipid), and both contain a domain that anchors into a lipoprotein surface while also providing the Apo E receptor binding domain, which allows clearance through the heparan sulfate proteoglycan (HSPG) receptors (Syndecan-1) in the liver. AEM-28 and its analogs, including AEM-28-14, as Apo E mimetics, have the potential to restore the ability of these atherogenic lipoproteins to be cleared from the plasma, completing the reverse cholesterol transport pathway, and thereby reducing cardiovascular risk. This is an important mechanism of action for AEM-28 and its analogs, including AEM-28-14. For patients that lack LDL receptors (Homozygous Familial Hypercholesterolemia-HoFH), have acute pancreatitis, or have hypercholesterolemia, AEM-28 and its analogs may provide a therapeutic solution. Our joint venture has an Exclusive License Agreement with the University of Alabama at Birmingham Research Foundation for AEM-28 and certain of its analogs.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Company History</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Prior to November 26, 2003, we developed, manufactured and marketed proprietary, technologically advanced orthopedic products designed to promote the healing of musculoskeletal bone and tissue, with particular emphasis on fracture healing and spine repair. Our product lines, which included bone growth stimulation and fracture fixation devices, are referred to as our &#8220;Bone Device Business.&#8221; In November 2003, we sold our Bone Device Business.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In August 2004, we purchased substantially all of the assets and intellectual property of Chrysalis Biotechnology, Inc., including its exclusive worldwide license for Chrysalin, a peptide, for all medical indications. Subsequently, our efforts were focused on research and development of Chrysalin with the goal of commercializing our products in fresh fracture healing. (In March 2012, we returned all rights to the Chrysalin intellectual property and no longer have any interest in, or rights to Chrysalin.)</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In February 2006, we purchased certain assets and assumed certain liabilities of AzERx, Inc. Under the terms of the transaction, we acquired an exclusive license for the core intellectual property relating to AZX100, an anti-fibrotic peptide. In 2014, we terminated the License Agreement with AzTE (Licensor) for the core intellectual property relating to AZX100 and returned all interest in and rights to the AZX100 intellectual property to the Licensor.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">On August 3, 2012, we entered into a joint venture (see Note B below), to develop Chimeric Apo E mimetic peptide molecule AEM-28 and its analogs.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Our development activities represent a single operating segment as they shared the same product development path and utilized the same Company resources. As a result, we determined that it is appropriate to reflect our operations as one reportable segment.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">OrthoLogic Corp. commenced doing business under the trade name of Capstone Therapeutics on October 1, 2008, and we formally changed our name from OrthoLogic Corp. to Capstone Therapeutics Corp. on May 21, 2010.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In these notes, references to &#8220;we&#8221;, &#8220;our&#8221;, &#8220;us&#8221;, the &#8220;Company&#8221;, &#8220;Capstone Therapeutics&#8221;, &#8220;Capstone&#8221;, and &#8220;OrthoLogic&#8221; refer to Capstone Therapeutics Corp. References to our joint venture or &#8220;JV&#8221;, refer to LipimetiX Development, Inc. (formerly LipimetiX Development, LLC).</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Financial Statement Presentation and Management&#8217;s Plan</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The accompanying financials statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The report from our Independent Registered Public Accounting Firm on our consolidated financial statements for the year ended December 31, 2014 included in our Annual Report on Form 10-K expressed substantial doubt about the Company&#8217;s ability to continue as a going concern.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Management has determined that the Company will require additional capital above its current cash and working capital balances to further develop AEM-28 and its analogs or continue operations. Accordingly, the Company has reduced its development activities. The Company&#8217;s corporate strategy is to raise funds by possibly engaging in a strategic/merger transaction, or conducting a private or public offering of debt or equity securities for capital. These financial statements do not include any adjustments that might result from the outcome of the uncertainty of the Company successfully implementing its corporate strategy.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In the opinion of management, the unaudited condensed interim financial statements include all adjustments necessary for the fair presentation of our financial position, results of operations, and cash flows, and all adjustments were of a normal recurring nature. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the complete fiscal year. The financial statements include the consolidated results of Capstone Therapeutics Corp. and our <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 60</font>% owned subsidiary, LipimetiX Development, Inc. Intercompany transactions have been eliminated.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to Securities and Exchange Commission rules and regulations, although we believe that the disclosures herein are adequate to make the information presented not misleading. These unaudited condensed financial statements should be read in conjunction with the financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2014. Information presented as of December 31, 2014 is derived from audited financial statements.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Use of Estimates</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The preparation of financial statements in accordance with accounting principles generally accepted in the United States requires that management make a number of assumptions and estimates that affect the reported amounts of assets, liabilities, and expenses in our financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management&#8217;s assumptions regarding current events and actions that may impact us in the future, actual results may differ from these estimates and assumptions.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Legal and Other Contingencies</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company is subject to legal proceedings and claims that arise in the ordinary course of business. The Company records a liability when it is probable that a loss has been incurred and the amount is reasonably estimable. There is significant judgment required in both the probability determination and as to whether an exposure can be reasonably estimated. In the opinion of management, there was not at least a reasonable possibility the Company may have incurred a material loss with respect to loss contingencies.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Joint Venture Accounting</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company entered into a joint venture in which it has contributed $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6,000,000</font>, and the noncontrolling interests have contributed certain patent license rights. Neither the Company nor the noncontrolling interests have an obligation to contribute additional funds to the joint venture or to assume any joint venture liabilities or to provide a guarantee of either joint venture performance or any joint venture liability. The financial position and results of operations of the joint venture are presented on a consolidated basis with the financial position and results of operations of the Company. Intercompany transactions have been eliminated. Joint venture losses were recorded on the basis of common ownership equity interests (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">60</font>% Company / <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 40</font>% noncontrolling interests) until common ownership equity was reduced to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font>. Subsequent joint venture losses are being allocated to the preferred ownership equity (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">100</font>% Company). Subsequent to March 31, 2013, all joint venture losses are being allocated to the Company. The Company has a revolving loan agreement with the joint venture to advance the joint venture funds for operations in an amount not to exceed a net (net of expected tax credits or other funds obtained) of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">700,000</font>, with the net amount due December 31, 2015. Losses incurred by the joint venture in excess of the capital accounts of the joint venture will be allocated to the Company to the extent of net outstanding advances.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 33.75pt; MARGIN: 0in 0in 0pt 2.25pt"> <b><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Cash and Cash Equivalents</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">At September 30, 2015, cash and cash equivalents included money market accounts.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Recent Accounting Pronouncements</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;In August 2014, the Financial Accounting Standards Board issued Accounting Standard Update (&#8220;ASU&#8221;) No.&#160;2014-15, <i>Presentation of Financial Statements &#150; Going Concern (Subtopic 205-40)(&#8220;Update&#8221;): Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern, providing a requirement under U.S. GAAP for an entity&#8217;s management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date the financial statements are issued; and if those conditions exist, to disclose that fact, the conditions and the potential effects on the entity&#8217;s ability to meet its obligations. The Update will be effective for an annual period ending after December 15, 2016, with early application permitted</i>. We have not elected early application. However, if additional funds are not obtained to continue the development of AEM-28 or its analogs, or operations, it will impair our ability to continue as a going concern. If we do not continue as a going concern, the Company may incur additional losses, up to, and possibly exceeding our net joint venture investment and revolving loan balance.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 0.0005 0.0005 150000000 150000000 40885411 40885411 40885411 40885411 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 2.25pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"> <b><font style="FONT-SIZE: 10pt">Description of the Business</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Capstone Therapeutics Corp. (the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;our&#8221; or &#8220;us&#8221;) is a biotechnology company committed to developing a pipeline of novel peptides and other molecules aimed at helping patients with under-served medical conditions. Previously, we were focused on the development and commercialization of two product platforms: AZX100 and Chrysalin (TP508). Since March 2012, we no longer have any interest in or rights to Chrysalin. In 2012 we wound down internal operations, ceased clinical development of AZX100 in dermal scarring, formerly our principal drug candidate, and moved to a more virtual operating model. In 2014, we terminated the License Agreement for AZX100 intellectual property and returned all interest in and rights to the AZX100 intellectual property to the Licensor (AzTE).</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">On August 3, 2012, we entered into a joint venture, LipimetiX Development, LLC, (now LipimetiX Development, Inc.), (the &#8220;JV&#8221;), to develop Apo E mimetic peptide molecule AEM-28 and its analogs. The JV has a development plan to pursue regulatory approval of AEM-28, or an analog, as treatment for Homozygous Familial Hypercholesterolemia (granted Orphan Drug Designation by FDA in 2012), Acute Hypertriglyceridemic Pancreatitis, and other hyperlipidemic indications. The initial development plan extended through Phase 1a and 1b/2a clinical trials and was completed in the fourth quarter of 2014.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The JV received allowance from regulatory authorities in Australia permitting the JV to proceed with the planned clinical trials. The Phase 1a clinical trial commenced in Australia in April 2014 and the Phase 1b/2a clinical trial commenced in Australia in June 2014. The clinical trials for AEM-28 were randomized, double-blinded, placebo-controlled studies to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of six escalating single doses (Phase 1a in healthy patients with elevated cholesterol) and multiple ascending doses of the three highest doses from Phase 1a (Phase 1b/2a in patients with hypercholesterolemia and healthy volunteers with elevated cholesterol and high Body Mass Index). The Phase 1a clinical trial consisted of 36 patients and the Phase 1b/2a consisted of 15 patients. Both clinical trials were completed in 2014 and the Medical Safety Committee, reviewing all safety-related aspects of the clinical trials, observed a generally acceptable safety profile. As first-in-man studies, the primary endpoint was safety; yet efficacy measurements analyzing pharmacodynamics yielded statistical significance in the pooled dataset favoring AEM-28 versus placebo in multiple lipid biomarker endpoints.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Concurrent with the clinical development activities with AEM-28, the JV has performed pre-clinical studies that have identified an analog of AEM-28, referred to as AEM-28-14, and a new phospholipid formulation, that has the potential of equivalent efficacy, higher human dose toleration and an extended composition of matter patent life (application filed with the U.S. Patent and Trademark Office in 2015). The JV&#8217;s current intent is to prioritize the development of AEM-28-14.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The JV and the Company are exploring fundraising, partnering or licensing, to obtain additional funding to continue development activities of AEM-28 and its analogs, including AEM-28-14, and operations.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The JV and the Company do not have sufficient funding at this time to continue additional material development activities of AEM-28 and its analogs, including AEM-28-14. The JV may conduct future clinical trials in Australia, the USA, and other regulatory jurisdictions if regulatory approvals, additional funding, and other conditions permit.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company, funding permitting, intends to continue limiting its internal operations to a virtual operating model while monitoring and participating in the management of JV&#8217;s AEM-28 and analogs development activities and maintaining the required level of corporate governance and reporting required to comply with Securities and Exchange Commission rules and regulations.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">Description of Current Peptide Drug Candidates.</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <u><font style="FONT-SIZE: 10pt">Chimeric Apo E Mimetic Peptide Molecule &#150; AEM-28 and its analogs</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Apolipoprotein E is a 299 amino acid protein that plays an important role in lipoprotein metabolism. AEM-28 is a 28 amino acid mimetic of Apo E and AEM-28 and its analogs, including AEM-28-14 is a 28 amino acid mimetic of Apo E (with an aminohexanoic acid group and a phospholipid), and both contain a domain that anchors into a lipoprotein surface while also providing the Apo E receptor binding domain, which allows clearance through the heparan sulfate proteoglycan (HSPG) receptors (Syndecan-1) in the liver. AEM-28 and its analogs, including AEM-28-14, as Apo E mimetics, have the potential to restore the ability of these atherogenic lipoproteins to be cleared from the plasma, completing the reverse cholesterol transport pathway, and thereby reducing cardiovascular risk. This is an important mechanism of action for AEM-28 and its analogs, including AEM-28-14. For patients that lack LDL receptors (Homozygous Familial Hypercholesterolemia-HoFH), have acute pancreatitis, or have hypercholesterolemia, AEM-28 and its analogs may provide a therapeutic solution. Our joint venture has an Exclusive License Agreement with the University of Alabama at Birmingham Research Foundation for AEM-28 and certain of its analogs.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"> <b><font style="FONT-SIZE: 10pt">Company History</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Prior to November 26, 2003, we developed, manufactured and marketed proprietary, technologically advanced orthopedic products designed to promote the healing of musculoskeletal bone and tissue, with particular emphasis on fracture healing and spine repair. Our product lines, which included bone growth stimulation and fracture fixation devices, are referred to as our &#8220;Bone Device Business.&#8221; In November 2003, we sold our Bone Device Business.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In August 2004, we purchased substantially all of the assets and intellectual property of Chrysalis Biotechnology, Inc., including its exclusive worldwide license for Chrysalin, a peptide, for all medical indications. Subsequently, our efforts were focused on research and development of Chrysalin with the goal of commercializing our products in fresh fracture healing. (In March 2012, we returned all rights to the Chrysalin intellectual property and no longer have any interest in, or rights to Chrysalin.)</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In February 2006, we purchased certain assets and assumed certain liabilities of AzERx, Inc. Under the terms of the transaction, we acquired an exclusive license for the core intellectual property relating to AZX100, an anti-fibrotic peptide. In 2014, we terminated the License Agreement with AzTE (Licensor) for the core intellectual property relating to AZX100 and returned all interest in and rights to the AZX100 intellectual property to the Licensor.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">On August 3, 2012, we entered into a joint venture (see Note B below), to develop Chimeric Apo E mimetic peptide molecule AEM-28 and its analogs.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Our development activities represent a single operating segment as they shared the same product development path and utilized the same Company resources. As a result, we determined that it is appropriate to reflect our operations as one reportable segment.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">OrthoLogic Corp. commenced doing business under the trade name of Capstone Therapeutics on October 1, 2008, and we formally changed our name from OrthoLogic Corp. to Capstone Therapeutics Corp. on May 21, 2010.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In these notes, references to &#8220;we&#8221;, &#8220;our&#8221;, &#8220;us&#8221;, the &#8220;Company&#8221;, &#8220;Capstone Therapeutics&#8221;, &#8220;Capstone&#8221;, and &#8220;OrthoLogic&#8221; refer to Capstone Therapeutics Corp. References to our joint venture or &#8220;JV&#8221;, refer to LipimetiX Development, Inc. (formerly LipimetiX Development, LLC).</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"> <b><font style="FONT-SIZE: 10pt">Financial Statement Presentation and Management&#8217;s Plan</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The accompanying financials statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The report from our Independent Registered Public Accounting Firm on our consolidated financial statements for the year ended December 31, 2014 included in our Annual Report on Form 10-K expressed substantial doubt about the Company&#8217;s ability to continue as a going concern.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Management has determined that the Company will require additional capital above its current cash and working capital balances to further develop AEM-28 and its analogs or continue operations. Accordingly, the Company has reduced its development activities. The Company&#8217;s corporate strategy is to raise funds by possibly engaging in a strategic/merger transaction, or conducting a private or public offering of debt or equity securities for capital. These financial statements do not include any adjustments that might result from the outcome of the uncertainty of the Company successfully implementing its corporate strategy.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In the opinion of management, the unaudited condensed interim financial statements include all adjustments necessary for the fair presentation of our financial position, results of operations, and cash flows, and all adjustments were of a normal recurring nature. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the complete fiscal year. The financial statements include the consolidated results of Capstone Therapeutics Corp. and our <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 60</font>% owned subsidiary, LipimetiX Development, Inc. Intercompany transactions have been eliminated.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to Securities and Exchange Commission rules and regulations, although we believe that the disclosures herein are adequate to make the information presented not misleading. These unaudited condensed financial statements should be read in conjunction with the financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2014. Information presented as of December 31, 2014 is derived from audited financial statements.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"> <b><font style="FONT-SIZE: 10pt">Use of Estimates</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The preparation of financial statements in accordance with accounting principles generally accepted in the United States requires that management make a number of assumptions and estimates that affect the reported amounts of assets, liabilities, and expenses in our financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management&#8217;s assumptions regarding current events and actions that may impact us in the future, actual results may differ from these estimates and assumptions.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"> <b><font style="FONT-SIZE: 10pt">Legal and Other Contingencies</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company is subject to legal proceedings and claims that arise in the ordinary course of business. The Company records a liability when it is probable that a loss has been incurred and the amount is reasonably estimable. There is significant judgment required in both the probability determination and as to whether an exposure can be reasonably estimated. In the opinion of management, there was not at least a reasonable possibility the Company may have incurred a material loss with respect to loss contingencies.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"> <b><font style="FONT-SIZE: 10pt">Joint Venture Accounting</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company entered into a joint venture in which it has contributed $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6,000,000</font>, and the noncontrolling interests have contributed certain patent license rights. Neither the Company nor the noncontrolling interests have an obligation to contribute additional funds to the joint venture or to assume any joint venture liabilities or to provide a guarantee of either joint venture performance or any joint venture liability. The financial position and results of operations of the joint venture are presented on a consolidated basis with the financial position and results of operations of the Company. Intercompany transactions have been eliminated. Joint venture losses were recorded on the basis of common ownership equity interests (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">60</font>% Company / <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 40</font>% noncontrolling interests) until common ownership equity was reduced to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font>. Subsequent joint venture losses are being allocated to the preferred ownership equity (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">100</font>% Company). Subsequent to March 31, 2013, all joint venture losses are being allocated to the Company. The Company has a revolving loan agreement with the joint venture to advance the joint venture funds for operations in an amount not to exceed a net (net of expected tax credits or other funds obtained) of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">700,000</font>, with the net amount due December 31, 2015. Losses incurred by the joint venture in excess of the capital accounts of the joint venture will be allocated to the Company to the extent of net outstanding advances.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 2.25pt; TEXT-INDENT: 33.75pt"> <b><font style="FONT-SIZE: 10pt">Cash and Cash Equivalents</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">At September 30, 2015, cash and cash equivalents included money market accounts.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"> <b><font style="FONT-SIZE: 10pt">Recent Accounting Pronouncements</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;In August 2014, the Financial Accounting Standards Board issued Accounting Standard Update (&#8220;ASU&#8221;) No.&#160;2014-15, <i>Presentation of Financial Statements &#150; Going Concern (Subtopic 205-40)(&#8220;Update&#8221;): Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern, providing a requirement under U.S. GAAP for an entity&#8217;s management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date the financial statements are issued; and if those conditions exist, to disclose that fact, the conditions and the potential effects on the entity&#8217;s ability to meet its obligations. The Update will be effective for an annual period ending after December 15, 2016, with early application permitted</i>. We have not elected early application. However, if additional funds are not obtained to continue the development of AEM-28 or its analogs, or operations, it will impair our ability to continue as a going concern. If we do not continue as a going concern, the Company may incur additional losses, up to, and possibly exceeding our net joint venture investment and revolving loan balance.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"><strong><font style="FONT-SIZE: 10pt">Note B. JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt">On August 3, 2012, we entered into a Contribution Agreement with LipimetiX, LLC to form a joint venture, LipimetiX Development, LLC (&#8220;JV&#8221;), to develop Apo E mimetic molecules, including AEM-28 and its analogs. In June 2015, the JV converted from a limited liability company to a corporation, LipimetiX Development, Inc. The Company contributed $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6</font> million, which included $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1</font> million for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">600,000</font> voting common ownership units (now common stock), representing <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">60</font>% ownership in the JV, and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5</font> million for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,000,000</font> non-voting preferred ownership units (now preferred stock), which have preferential distribution rights.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt">LipimetiX, LLC contributed all intellectual property rights for Apo E mimetic molecules it owned and assigned its Exclusive License Agreement between The University of Alabama at Birmingham Research Foundation (&#8220;UABRF&#8221;) and LipimetiX, LLC, for the UABRF intellectual property related to Apo E mimetic molecules AEM-28 and its analogs to the JV, in return for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">400,000</font> voting common ownership units (now common stock) representing <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">40</font>% ownership in JV, and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">378,000</font> in cash (for certain initial patent-related costs and legal expenses).</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt">LipimetiX, LLC was formed by the principals of Benu BioPharma, Inc. (&#8220;Benu&#8221;) and UABRF to commercialize UABRF&#8217;s intellectual property related to Apo E mimetic molecules, including AEM-28 and analogs. Benu is composed of Dennis I. Goldberg, Ph.D., Phillip M. Friden, Ph.D. and Eric M. Morrel, Ph.D. The Exclusive License Agreement, as amended, calls for payment of patent filing, maintenance and other related patent fees, as well as a royalty of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3</font>% on Net Sales of Licensed Products during the Term of the Agreement. The Agreement terminates upon the expiration of all Valid Patent Claims within the Licensed Patents, which are currently estimated to expire between 2019 and 2035. The Agreement, as amended, also calls for annual maintenance payments of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25,000</font>, various milestone payments of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000</font> to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">500,000</font> and minimum royalty payments of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">500,000</font> to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,000,000</font> per year commencing on January 1 of the first calendar year following the year in which the First Commercial Sale occurs. UABRF will also be paid <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5</font>% of Non Royalty Income received.</font></div> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt">Concurrent with entering into the Contribution Agreement and the First Amendment and Consent to Assignment of Exclusive License Agreement between LipimetiX, LLC, UABRF and the Company, the Company and LipimetiX, LLC entered into a Limited Liability Company Agreement for JV which established a Joint Development Committee (&#8220;JDC&#8221;) to manage JV development activities. Upon conversion by the JV from a limited liability company to a corporation, the parties entered into a Stockholders Agreement for the JV, and the JDC was replaced by a Board of Directors (JV Board). The JV Board is composed of three members appointed by the non-Company ownership group and two members appointed by the Company. Non-development JV decisions, including the issuance of new equity, incurrence of debt, entry into strategic transactions, licenses or development agreements, sales of assets and liquidation, and approval of annual budgets, will be decided by a majority vote of the common stockholders.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt">The JV, on August 3, 2012, entered into a Management Agreement with Benu to manage JV development activities for a monthly fee of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">63,000</font> during the twenty-seven month development period, and an Accounting Services Agreement with the Company to manage JV accounting and administrative functions. The current accounting services fee is $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,000</font> a month. Commencing in November 2014, and ending in March 2015, Benu received a reduced monthly management fee in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">35,000</font>. Subsequent to March 2015, no management fee has been paid to Benu for their services.</font></div> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The joint venture formation was as follows ($000&#8217;s):</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;WIDTH: 100%; TEXT-INDENT: 0in"> <table style="OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; WIDTH: 60%; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: 0px solid; MARGIN: 0in 0in 0in 0.5in; BORDER-LEFT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="45%"> <div>Patent license rights</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>1,045</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="45%"> <div>Noncontrolling interests</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="12%"> <div>(667)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="45%"> <div>Cash paid at formation</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>378</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt">Patent license rights were recorded at their estimated fair value and are being amortized on a straight-line basis over the key patent life of eighty months.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt">The financial position and results of operations of the joint venture are presented on a consolidated basis with the financial position and results of operations of the Company. Intercompany transactions have been eliminated. The joint venture agreement requires profits and losses to be allocated on the basis of common ownership equity interests (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">60</font>% Company / <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">40</font>% noncontrolling interests). However, for the Company&#8217;s consolidated financial statement, joint venture losses were recorded on the basis of common ownership equity interests (60% Company / 40% noncontrolling interests) until common ownership equity was reduced to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font>. Subsequent joint venture losses have been allocated to the preferred ownership equity (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">100</font>% Company). Subsequent to March 31, 2013, all joint venture losses have been allocated to the Company. The Company has a revolving loan agreement with the joint venture to advance the joint venture funds for operations in an amount not to exceed a net (net of expected tax credits or other funds obtained) of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">700,000</font>, with the net amount due December 31, 2015. Losses incurred by the joint venture in excess of the capital accounts of the joint venture will be allocated to the Company to the extent of net outstanding advances. At September 30, 2015, outstanding advances on the revolving loan agreement totaled $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">759,000</font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt">The joint venture incurred net operating expenses, prior to the elimination of intercompany transactions, of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">503,000</font> in the nine month period ended September 30, 2015 and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6,738,000</font> for the period from August 3, 2012 (inception) to September 30, 2015, of which $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">503,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6,071,000</font>, respectively, have been recorded by the Company. The joint venture operating expenses are included in research and development expenses in the condensed consolidated statements of operations.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt">Neither the Company nor the noncontrolling interests have an obligation to contribute additional funds to the joint venture or to assume any joint venture liabilities or to provide a guarantee of either joint venture performance or any joint venture liability. Losses allocated to the noncontrolling interests represent an additional potential loss for the Company as the noncontrolling interests are not obligated to contribute assets to the joint venture to the extent they have a negative capital account, and depending on the ultimate outcome of the joint venture, the Company could potentially absorb all losses associated with the joint venture. From formation of the joint venture, August 3, 2012, through September 30, 2015, losses totaling $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">667,000</font> have been allocated to the noncontrolling interests. If the joint venture or Company is unable to obtain additional funding, the ability of the joint venture to continue development of AEM-28 and its analogs, including AEM-28-14, would be impaired as would the joint venture&#8217;s ability to continue operations. If the joint venture does not continue as a going concern, at September 30, 2015 the Company would incur an additional loss of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">667,000</font> for the joint venture losses allocated to the noncontrolling interests.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"> <font style="FONT-SIZE: 10pt">The joint venture formation was as follows ($000&#8217;s):</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;WIDTH: 100%; TEXT-INDENT: 0in"> <table style="OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; WIDTH: 60%; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: 0px solid; MARGIN: 0in 0in 0in 0.5in; BORDER-LEFT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="45%"> <div>Patent license rights</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>1,045</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="45%"> <div>Noncontrolling interests</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right" width="12%"> <div>(667)</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="45%"> <div>Cash paid at formation</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>$</div> </td> <td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: times new roman; VERTICAL-ALIGN: bottom; BACKGROUND: #cceeff; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px" width="12%"> <div>378</div> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; VERTICAL-ALIGN: middle; BACKGROUND: #cceeff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 0 1045000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">Note D. Australian Refundable Research &amp; Development Credit</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In March 2014, LipimetiX Development LLC, (see Note B) formed a wholly-owned Australian subsidiary, Lipimetix Australia Pty Ltd, to conduct Phase 1a and Phase1b/2a clinical trials in Australia. Currently Australian tax regulations provide for a refundable research and development tax credit equal to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 45</font>% of qualified expenditures. Subsequent to the end of its Australian tax years, Lipimetix Australia Pty, Ltd intends to submit claims for a refundable research and development tax credit. The transitional Australian tax periods/years granted for Lipimetix Australia Pty, Ltd end on June 30, 2014, December 31, 2014 and thereafter December 31 of each succeeding year. For the tax year ended June 30, 2014, Lipimetix Australia Pty, Ltd received a refundable research and development tax credit of AUD$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">227,000</font>. At December 31, 2014 a AUD$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">242,000</font> development tax credit was recorded by Lipimetix Australia Pty, Ltd, and at September 30, 2015, AUD$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">202,000</font> has been accrued, as it is more likely than not that the recorded refundable research and development tax credit will be approved and received. At September 30, 2015, and December 31, 2014, AUD$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">202,000</font> (US$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">142,000</font>), and AUD$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">242,000</font> (US$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">196,000</font>), respectively, have been accrued and are included in other current assets in our condensed consolidated balance sheets.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">Note C. FUNDRAISING ACTIVITIES</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">As disclosed above, management has determined that the Company will require additional capital above its current cash and working capital balances to further develop AEM-28 and its analogs and to continue operations.&#160; Accordingly, the Company has reduced its development activities.&#160; The Company&#8217;s corporate strategy is to raise funds by possibly engaging in a strategic/merger transaction, or conducting a private or public offering of debt or equity securities for capital.&#160;&#160;&#160; In connection with these efforts, we filed a Registration Statement on Form S-1 with the Securities and Exchange Commission on June 26, 2015, as amended, in connection with our contemplated public offering of shares of our Common Stock. The Registration Statement is not effective as of September 30, 2015.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">As of September 30, 2015, we have deferred recognition of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">148,000</font> of direct costs, primarily legal costs and filing fees, related to fundraising activities in connection with our contemplated public offering of shares of our Common Stock.&#160;These costs are to be offset against the equity raised upon completion of the offering. The deferred costs are included in other current assets in the Condensed Consolidated Balance Sheet at September 30, 2015.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 148000 202000 142000 242000 196000 0.6 EX-101.SCH 6 caps-20150930.xsd XBRL SCHEMA FILE 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] link:presentationLink link:definitionLink link:calculationLink 104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 106 - Disclosure - OVERVIEW OF BUSINESS link:presentationLink link:definitionLink link:calculationLink 107 - Disclosure - JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - FUNDRAISING ACTIVITIES link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - Australian Refundable Research & Development Credit link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - OVERVIEW OF BUSINESS (Policies) link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Tables) link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - OVERVIEW OF BUSINESS (Details Textual) link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Details) link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Details Textual) link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - FUNDRAISING ACTIVITIES (Details Textual) link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - Australian Refundable Research & Development Credit (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 caps-20150930_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 caps-20150930_def.xml XBRL DEFINITION FILE EX-101.LAB 9 caps-20150930_lab.xml XBRL LABEL FILE EX-101.PRE 10 caps-20150930_pre.xml XBRL PRESENTATION FILE EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0````(`!9;:4?1E;O\=P$``.D,```3````6T-O;G1E;G1?5'EP97-= M+GAM;,U776_"(!3]*Z:OBT7NZ]Y\"%DW3\OC7@>ALIE)MDI??F$2%'2Y#$Y=J`"DBAK20^3.T"&4*7 M9`%H.!B,$-7*@_)]'VMDT_%K!=9R!KVG'1!K3S)BC."4>*X5JA1K5.WKHN`4 MF*8K&5)R'ZCA*N!9;TZL?R$RE$`;@6I@]\1YQ-%E")VQ0)@K`;P4N?-;`:Z- M?X<A"HN?)MD`74G,303CRGC,C;-J,6/ MC#C_XUH:FUA),;-DS1L$56=MBF,N"5=MK5IKN_S0>GG)8P)Q50Q8W]@0:#UO M.24A>!Y0AT+I?W$?3@K5%DXBC($=7HJ26&!OWH;^MM^-[P'=Z8A]K=]_:WH- M.E0/'9K$63J&B>BX3D3'32(Z;A/1,4I$QUTB.NX3T?&0B`X\2$5(*HZ*4[%4 MG(JGXE1,%:?BJOC+5E']AS/]!%!+`P04````"``66VE'2'4%[L4````K`@`` M"P```%]R96QS+RYR96QSK9++;L)`#$5_)9I]<4HE%A%AQ88=0OR`.^,\E,QX MY#$B_?N.V(#"0ZW$TJ][CZZ\#JFL#C2B]AQ2U\=43'X,JQW8OG*\M"_V/Z'D4X$G1 MH>)%]2-F`Q+M*;V"^GH`A3&^.R6:E((C-Z."N[_8_`)02P,$%`````@`%EMI M1QK54*4@`0``+0L``!H```!X;"]?"A@(X^K-K>ORZ*B#UM=(,T&A"W- M?*M?G#6EQ1,.RO5&4]=/E+R/@Z;"GY>B"I-D2R#3S=AD6XJ5,6ZV=G>]W2VIIOPZ.B1;G)/09,YS$EHX'CB#W MG(-%,X<)DT1'^^N[@%*\,IW1A_(`F\WW[6:_3<)4Z,%DJ60)RG#0Y+@KA)Z@ M\\G:&E-.;%NG6]@Q_8`0@;.Y5#MF<*@VMLQSGH(GT_T.A+%'@\'8AJ,!D4'V MI6R#6LZTRN*69<%39K@4S@M/E=0R-X0>4RBF]D=`S<#($:1[Q-F=$B`:6K2H>CAP$^K007?Q,;6,;%9LFXTL[T M8"8'2(U4YS8=S+U=RF1:-5TG,:Y/6^2-::C,)^O`%&?"6$3S7S@<64W:QEO; M1:F-M=;`*.G=NNLS2ZV:_-'9SBN$6A=(^VV,N#2ABW")JXE)V,N9KP-OY?H8]3MQ9[&?^+%/^\.[>WRS`G<2 M64&^%QE[*P!-#4REVWY=^]9./BTEWC]X87V^O8SA\(8\'AC&"TWB._+T]_S? MG,<;)&Y7=[O6Y]/=O0JZ9_K#";:O_SS.;U!+`P04````"``66VE'IQ7FS#X! M``!I`P``$0```&1O8U!R;W!S+V-O&ULS9--3\,P#(;_"NJ]2[,-)**N M!T".%K?X:7H\6[GZP23@D`-&@P&0D>49-6KV1K;F)(,^JJ,CFL> M<&ZE6BF0=^U0]CL5.R-X'8YRD'W[]/=/#RE#LJYR'U1?U33-J)FDNC@P)>_S MIY=T-KDR`;D1$%5!,6P=S+)3Y[?)_;-#(M-WTFD(0@O'*HK+D(ES#?Q`D6=LM/$'@Y MJ!.FR[:%MK%>ABK=KR$ZO)RXLK7U[3'U(SI[5=474$L#!!0````(`!9;:4>9 M7)PC$`8``)PG```3````>&PO=&AE;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0 M>&?V;0O&-H&VM!-S:7;;M)F$[4X?A1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$ M+.G[SD5'Y^@X>?/N+F+HAHB4\GA@V2_;UKNW+][@5S(D$4$P&:>O\,`*I4Q> MM5II`,,X?+&A` MT%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8 M('_.;Z?D3EJ(X53"Q,!J9S]6:\?1TDB`@LE]E`6Z2?:CTQ4(,@T[.IU8SG9\ M]L3MGXS*VG0T;1K@X_%X.+;+THMP'`3@4;N>PIWT;+^D00FTHVG09-CVVJZ1 MIJJ-4T_3]WW?ZYMHG`J-6T_3:W?=TXZ)QJW0>`V^\4^'PZZ)QJO0=.MI)B?] MKFNDZ19H0D;CZWH2%;7E0-,@`%AP=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1 M_L;%!-9ITAF6-$9RG9`%#@`WQ-%,4'RO0;:*X,*2TER0UL\IM5`:")K(@?5' M@B'%W*_]]9>[R:0S>IU].LYKE']IJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+`GQ M^R-;88C'(CN]WV M6'WV3T=N(]>IP+,BUY1&)$6?R"VZY!$XM4D-,A,_")V&F&I0'`*D"3&6H8;X MM,:L$>`3?;>^",C?C8CWJV^:/5>A6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S< MHY=8%0&7&-\TJC4LQ=9XE<#QK9P\'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^ MG--`\)0O)/I*D8]ILR.G=";-Z#,:P4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS M1B&$:;OP'J\DCIJMPA$K0CYB&38:CFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX M"C>6QKQ0KH)[`?_1VC?"J_B"P#E_+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$D MN/R+RO`JQ`GH9%LE"0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/ M^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KTL@'37[]EUVY".E M,%.70[@:0KX#;;J=W#HXGIB1N0K34I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OG MP5&PH^\\EAW'B/*B(>ZAAIC/PT.'>7M?F&>5QE`T%&ULK"0L1K=@N-?Q+!3@ M9&`MH`>#KU$"\E)58#%;Q@,KD*)\3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB M4CG":9@39ZO*WF6QP54=SU5;\K"^:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB M\QE3ON>;G*YZ(G;ZEW?!8/+]<,E'#^4[YU_T74.N?O;=X_INDSM( M3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.; M>KC"1:S_6-8>^3+?.7#;.MX#7N83+$.D?L%]BHJ`$:MBOKJO3_DEG#NT>_&! M()O\UMND]MW@#'S4JUJE9"L1/TL'?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8 M\PRA9CC?AT6:&C/5BZPYC0IO0=5`Y3_;U`UH]@TT')$%7C&9MC:CY$X*/-S^ M[PVPPL2.X>V+OP%02P,$%`````@`%EMI1^C]UWY<`@``U@H```T```!X;"]S M='EL97,N>&ULS59M:]LP$/XK0AVCA1';V9IVJVTH'8'!5@;-8-^*;,N.0"^> M+&=.?_WTXEA)6)8V2TO]1:='I^<>G)'"N5/TI")I\ MCAEJ1J+&7*^40C*D]%1605-+C(K&;&(T&(?A)&"(<)C&O&53IAJ0BY:K!'X8 M(.#VWX@")_#^].VO5JBK-\"-)^].3L+[LZMM_-0NG$'@.+X4"8PFYS!X/.DH MU,].9KNZ13]Y(OV_R+>H+_907__XO",A?N6O*;DTQ$&?^S0N!?=7,(8.2./F M`2P0U?Z1<<\%%1(H?<=:@44X8MAYW"!*,DD,6")&Z-+!8P/8LNC]&.%"VM@N MPG:<4>@CR2I+8-@_CP^7>78[F.,12C>/IX$TKI%26/*IGH#>GBUK?3@N.'8B MK=\>[TJB930^7]M@!QTW$[+`HK..C*70H//?)S:CI^UKP:78(OG9Z#@UOHMF49EE/[67RZ MI/<7^Z_,OIUP2^;+5LT!$HZ0'-,S7ZVTR>N5]CPU=11IE_\I+>@[PUK[V6@^ M`PJREE!%^$H#,K\+MT8WW>@+OO%HSJ+S/<>N*I3IG\R-*)JLP"5JJ?I.%D+9 MQ01Z^ZN1'TT&K]E`D4!O?\,%:=E'J\#_R:9_`%!+`P04````"``66VE'WM-+ MR9H"```"!P``#P```'AL+W=O.8XN=K0B^I>LJ;#_ME)5Q-A0/3ARNV4%#6315%089SP: M>8ZBG!@FA=ZQ6N-7FOX*3=>*DE+O*#45[V$580)?7NC9EG&:4Z4M&)&ZCDE% M??S,,>)$F[!DAI8^GMA0[NF'#=745PWC;3`=3;'3P@ZMWBI4R)+VL&S']/WK M#XQ*NB4--YDM]G"OC]WQ9#SV>D9[+&=TKR&PW4"D,.R)9F3CXQ%&I#%RR;BA M*B"&7BO9U$P\6!9&6Z:T2=MVNY,5$ZQB+VW=-M([N?\M%7N1PA">%DIRWF6U M/[HD>X-^V[$U&E9\.&C(9MV^A(^]D04^,_5KKQOZ^0 MZ(9S>&(T%R4*A;$4%(G^\>QHVAKLX:CL+E8S9A?/&VT4X8P(M*;; M1I3$2LXN-26JV,&G/@>@\Z_-`_VXE9P5C.J?4'PCJ+[1-X?CNA#U0<@#2AZN M*J"&,*Y1!E%0RNZ`EC^O"FK9A6)V!]3\.6H"45#.[H">A]__K46(@H)V!Q3] MJ11<#Z*@NEWOU:'>3??M:3J6OUU,8WUMM]W!JP M]=J&\X7=2\1*DLZF>O+!N2__`5!+`P04````"``66VE'?+ABT$$"``"8!P`` M&````'AL+W=OYYC[&-G'>-OHB1$@G=: M-^+@E5*VC[XOBI)0+!Y82QKUY<(XQ5)U^=47+2?X;$RT]E$0Q#[%5>/EF1E[ MX7G&;K*N&O+"@;A1BOF_(ZE9=_"@-PR\5M=2Z@$_S_S1=ZXH:43%&L#)Y>`] MP<F?L"#/K/Y3G66IL@T\<"87?*OE*^M^D'X.D0Y8L%J8)RAN M0C(Z6#Q`\;M]5XUY=_9+&/0VMP'U!C0:4&H2MR"3YC$;I-0OU`;?K'-HR1FAE[0=-\&5E_,G)20F_F@M"@(+= M&G,?34;'2^@)F9/W0YYG+;Z27YA?JT:`$Y/J_#:'[84Q250"P8-*IU37Y-BI MR47J9J+:W%XO6]:) MFG=>SPY;_S/:E#C4DD'QLV97,3GW-/P+YZ_ZXOM^ZX>:@35L)W6)2AW>6,F: M1E=23_YMBOY[IC9.SV_5OP[M*OR72K"2-[_JO3PIVM#W]NQ071KYS*_?F.DA MT@5WO!'#I[>[",G;F\7WVNH=CG4W'*_P31H:V[(!&P,>#8A:#<08R)TA`+*A MKR^5K(J\YU>OA\DX5WK.T8:HD=MY8KBI6A*^%JB1*O*W`I,\>--UC`1/)(]& M0M*&4/J9$B!`5L80((B&ELP M3!V2KKP>F7.]9:;"LE]GH*,5%$(%:NG%:)"MX?(FPBM+#BU&V)P%TH=$-A;0 M1+9A-1H4I2LHBSDV1\%F<=M00(-22TB41H13O,*RF(FS.4:09I/`FU=PAQDR M465+,Z/!MF7S43,G<<<9@B`BMCPS&I1F%%NG>=3A>&VFW;F&()&H+=B,YI.: MZM`^VZ,P1FN+&KDS#D$^45O(&0TBD17H%I?A6D2XTPY!3%%;W!F-]>6YE\PY M%K-NS@%A1XF-(_NO4Q^X4+R\VTS M/_ZC*/X"4$L#!!0````(`!9;:4?NV_8NT0$``"L%```8````>&PO=V]R:W-H M965T&ULC939CILP%(9?Q>(!8K,E:420.E2C]J+2:"[::P<. M`8V-&=L)T[>O%Y*!*B3-1;SP_<>?69P-0KZI!D"C#\XZM0\:K?L=QJIL@%.U M$CUTYDHM)*?:#.41JUX"K5R(,QP1LL::9.&G6=O`BD3IQ3N6? M)V!BV`=A<)EX;8^-MA,XS_`U5[4<.M6*#DFH]\'7<%>DEG#`KQ8&->DCZWX0 MXLT.?E3[@%@%8%!J6X&:Y@P%,&8+F87?QYJ?2]K@M'^I_NQV:^P/5$$AV.^V MTHV1)0&JH*8GIE_%\!W&+3C#4C#E_E%Y4EKP2R1`G'[XMNU<._@KZ\T8NQV( MQD!T#83)W4`\!N)_`MB;N7U]HYKFF10#DOY9]-0^\G`7FSM7(N4FS9948`%S MI_+LG"=IAL^VSHA$$^3)(U&RC!0C\ED%&X&K173+(IE:1-YB/5]BZY#.6WB$ MK`@AZ3)6W,1F-O%#F]C;;.;+I%,;CX0I\;]ELE@B9T[)0Z?$.VWO.(T(V6[3 M)`SO*"V`,Z/TH5'JJWRY8Y3^K]$"Z(WPY+WNZ1%^4GEL.X4.0IM/Q+W/M1`: M3"&R,F4;&PO=V]R:W-H965T&ULC9=-(;#V8F&'?:0VG@AAQF=5UNW:/#%V7EE6NSN1*F^?Z9G4_)<#;:J<\;;$G$$G\+LBU[=T;(ODW2M_%PX_]VD0B!U*2 M'1,AW;BV2+3V)-# M?BG9+WK]3I0'F>&.EJW\:^PN+:/536(:5?X)UZ*6URO\$B(EFQ;82F!W@FZ> M:8&C!,Y=X&H%KA*X7YW!4P)O-(,%WN7*93G+D[BA5Z.!20#Y$Y8?/XN"7LJB<$,MI3;[OP, M&T`\6Y/$*G@""-H44B`^()1[KZC,,,K(CVN^`%(QG`UR22*D9?(`4M M5.A&14CW"2EJOD9XLE$.C4&/\S6O0JH879F6D6P9V3X@0S>3'7?H!CJA/^JG M@TZDF(?R?(1JL34[(\F*+3?%H/,6K#9X8S\011VZB[^&3 M^)P?R<^\.19U:[Q1QK?BRC)@8G;@-\W<"R!!T;/ MMU-6=]1+_@-02P,$%`````@`%EMI1^RZD(G9`@``00L``!@```!X;"]W;W)K MVC.; M.`E:P"EV-MN_K^UQ6$C!O@3;>6_FC;$?DU]Y_R9.C,G@HVTZL0E/4IZ?HDCL M3JRMQ",_LT[]<^!]6TDU[8^1./>LVAM2VT0XCK.HK>HN+'*S]M(7.;_(IN[8 M2Q^(2]M6_=\M:_AU$Z+PMO"S/IZD7HB*/!IX^[IEG:AY%_3LL`F?T5.)UAIB M$+]J=A6C<:#%OW+^IB??]YLPUAI8PW92AZC4XYV5K&ET))7YCPWZF5,3Q^-; M]*^F7"7_M1*LY,WO>B]/2FTG\SQDS$_`?YJ*I$:2`=5`.0!K6.RC"HM MBF3)@I;46TL*6M;S_,Q;2V;X-)ZJ3,>U``0ANHPI+08OO';JU4%!!W+H``A* M5PX=U'DT5M[M7(&,!?[:6\8:3J]#XA8@:)TZR@#,0Y+,Z]"NXQ&"8A.")`XE M%N/:3PM!9.&`HEG+F"H!0R".>K<6\X!B[!(#*$R6MF767:9BP#LH<8G!5DR* M74?^!B-HZ?8BOQ4A\"*Z5)'?C!"8"'5N+V`M%KDML,=XS0KUG9-:3IGJL*:U=>@"#4>:X\*5% M97CDH5,U?H=#X$VKNUN/IF,3P8Y?.JE; M@='JT!4^8]W9W*UO=;=H.I[/,$5^KH[L1]4?ZTX$KURJOLDT.0?.)5/"XD>U M9R?5SPZ3AAVD'E(U[J'#@XGDYUO#.G3-Q3]02P,$%`````@`%EMI1VPC-"6D M`0``K@,``!@```!X;"]W;W)K&,;%J,V[ M[0`<^I!"V2/NG.L/A-BJ`\GLG>Y!^3^--I(Y[YJ6V-X`JR-)"D*S[!>1C"M< M%C'V;,I"#TYP!<\&V4%*9CY/(/1XQ!M\#;SPMG,A0,J"S+R:2U"6:X4,-$=\ MOSF<\H"(@%<.HUW8*&@_:_T>G+_U$6=!`@BH7,C`_'&!!Q`B)/*%_T\Y;R4# M<6E?LS_&;KWZ,[/PH,4;KUWGQ688U="P0;@7/3[!U,(N)*RTL/&+JL$Z+:\4 MC"3[2"=7\1S3G]U^HJT3Z$2@,V&?1>&I4)3YASE6%D:/R*2K[5F8X.9`_454 MR,:@5VAQ`/C&R^)2[C<%N80\$X0N(*<$N2&(3SY7H&L5OM%II--\G;]=XV^7 M"K=)(5WGYVO\?,G/$W_[O<,EY#1!?DHDBPN58-JX-Q95>E!Q2Q?1>37O:1S( M#5X6/6OA'S,M5Q:=M?-CC3-HM';@JV=W.XPZ_WAF1T#C@OG;VR;M4W*<[J^O M8WZBY1=02P,$%`````@`%EMI1]5"&R.D`0``K@,``!@```!X;"]W;W)K35GHP0FNX-4@.TC)S+\3"#T> M\09?`V^\[5P(D+(@,Z_F$I3E6B$#S1'?;PZG/"`BX)W#:!`;+XM+N=\5Y!+R3!"Z@)P2 M9#,CB$\^5Z!K%7[0::33?)V_7>-OEPJW2>'M.C]?X^=+?I[X=S\[7$).$V3_ MJP197*@$T\:]L:C2@XI;NHC.JWE/XT"^X671LQ9>F&FYLNBLG1]KG$&CM0-? M/;O98=3YQS,[`AH7S#MOF[1/R7&ZO[Z.^8F6_P%02P,$%`````@`%EMI1U\K M+-JF`0``K@,``!@```!X;"]W;W)K,E' M-&^V!7#D0ZO.'FCK7+]GS)8M:&&OL(?._ZG1:.&\:QIF>P.BBI!6C"?)#=-" M=K3(8^S%%#D.3LD.7@RQ@];"?!Y!X7B@*;T$7F73NA!@1C\AO@7G=W6@26@!%)0N9!!^.<,C*!42^<+O<\[O MD@%X3HD+%'9^"7E8!WJ M"T*)%A_3*KNXCM.?[';&M@$^`WP![I+8^%0HMOE+.%'D!D=BIJWM13C!=,_] M1I3$QJ#OT-(@\(,7^;FXN\_9.>29)7PE.4Z2=%$PGWRIP+^V M^-VZPUWD[Y-M/MOBLS6?37SZ<\*UY#A+^'\EV&I#-9@FWAM+2ARZ>$M7T>5J M/O!X(-_R(N]%`W^$:61GR0F=/]9X!C6B`U\]N;JFI/6/9W$4U"Z8M]XVTWV: M'(?]Y74L3[3X`E!+`P04````"``66VE'57C/4J\2=<_V!$%MU M()F]T3TH_Z?11C+G7=,2VQM@=21)06B6[8ED7.&RB+%G4Q9Z<((K>#;(#E(R M\^\$0H]'O,'7P`MO.Q<"I"S(S*NY!&6Y5LA`<\2WF\,I#X@(^,-AM`L;!>UG MK5^#\U0?<18D@(#*A0S,'Q>X`R%"(E_X;N\V`RC&AHV"/>BQT>86MB%A)46-GY1-5BGY96"D63OZ>0JGF/ZL]M/M'4" MG0AT)OS,HO!4*,J\9XZ5A=$C,NEJ>Q8FN#E0?Q$5LC'H%5H<`+[QLKB4O[8% MN80\$X0N(*<$VA:A4]T&NDT7^=OU_C;I<)M4O@-/U_CYTM^GOB[ MSQTN(:<)LO]2@BPN5()IX]Y85.E!Q2U=1.?5O*5Q(!_PLNA9"[^9:;FRZ*R= M'VN<0:.U`U\]N]EAU/G',SL"&A?,']XV:9^2XW1_?1WS$RW_`U!+`P04```` M"``66VE':"Q[7P<"``!X!@``&0```'AL+W=OZQF0%R@=?;M%Q`=.Z%Z M(W#\?@Z<<$A;(=]5":#1!V>U.D2EULT>8Y67P*EZ$@W4YD\A)*?:+.4%JT8" M/3L29YC$\1IS6M51EKK8J\Q2<=6LJN%5(G7EG,I_1V"B/41)U`?>JDNI;0!G M*1YXYXI#K2I1(PG%(7I.]L?$01SB=P6M&LV13?XDQ+M=_#P?HMCF``QR;26H M&6[P`HQ9)>/\UXM^>EKB>-ZK?W?;->F?J((7P?Y49UV:;.,(G:&@5Z;?1/L# M_!Y65C`73+DORJ]*"]Y3(L3I1S=6M1O;[L\V]K0P@7@"^4+`G9%+\QO5-$NE M:)'LSK:AMH3)GIB#R)%R09.ABBS`;#Q+;]END^*;U?$0,H(<.T@R(+`1'QQ( MR.&.3AR=+,/\18B_&&>X[W`,.7K(+FRQFK58=2<4 MQQ,>/>;!.:YG3=9>@$R8])A%V&0S:[+Q`LL)DQZS"IML9TVV7F`]8=)C-F&3 MW:S)S@M,U;W'/"B\O=HS+DG<2213I1]`#VJ?!*_IO8^_A,E4]0?0U_+C46?@ M("^N`2J4BVOM^NTH.C399^(ZRR<\2QMZ@5]47JI:H9/0IC^Y9E((H<'XQT_F MII3F&1@6#`IMIQLSEUUC[!9:-'V?'QZ;[#]02P,$%`````@`%EMI1S6C'56D M`0``L0,``!D```!X;"]W;W)K&UL;9/;;IPP$(9? MQ?(#Q,"R:;1BD;*)JO:B4I2+]MH+`UBQ/=0V2_KVMN%]N\`12!D<^\-_9YT?( M`&[WB_?OL5J?_95;>$+Y1]2N\\DFE-30\$&Z5QQ_P%S",3BL4-KX)=5@':H% MH43Q]VD5.J[C].%D8'(F9KK;GH8/I*?,741$; MC3Y#2X/`%UX6MS)-\X+=@J-9DVTTEUFS*ICWOH;(]D)\PK.(9_D^?]CC#]L4 M#Y%_N-_G\ST^W_+Y7.+QJP+1Q="RI<-!Q4#?6=3H?L]B3 M#WE9]+R%7]RT0EMR1><[&]O0(#KPX9.[(R6=?S_K04+CPO:;WYMII*:#PWYY M(.LK+?\#4$L#!!0````(`!9;:4?+-0"4.P(``#4(```9````>&PO=V]R:W-H M965T*\\S=I>TK,DK#\2] MJC#_>R"4M?L0AMW&6WDKI-X`>0;ZN$M9D5J4K`XXN>[#+W!WA*F&&,2ODK1B M,`^T^!-C[WKQX[(/(ZV!4'*6F@*KX4&.A%+-I#+_<:3_<^K`X;QC_V;*5?)/ M6)`CH[_+BRR4VB@,+N2*[U2^L?8[<36L->&946&^@_-=2%9U(6%0X0\[EK49 M6_MD$[DP?P!R`:@/@*O9@-@%Q$\!P"HS=7W%$N<99VW`[6$T6)\YW,6J<^=` MF$U5D@@U0'4JSQXYA&D&'IK(8=``<[`8M)J&'#N:38\!2D*O`_ETQ$,=R!%L M_02QCV`U)(@M`8K&*E.#J6TA%I-$YC.-._IQ(T&K14$K)PCZ"=:++5G/MR19 M5)`X!6BF)1:3SE2:+N9)79[83[!9K'0S7^EV4<'6*7CZB0XQAPZS]B?1QE_( M`B-'D4Q0>.TVJA3"^5*AUREC%:.%*X;"?8^6DST](>--7399?` MSB;;N3P.%$_5XS73.(]S4SQA1^BUT_CLDH6S6W8*3#_350>*T5,>,'C!-_A& M?F)^*VL1G)A4=X5YL5\9DT211"^J)86ZP_L%)5>IIZF:&ULA53);MLP$/T50O>&LE;#D`7$*8KV4"#(H3W3\FA!N*@D M9:5_7VY6Y$)M+B8Y>MO('%6SD*^J!]#HC5&NCE&O]7C`6#4],*(>Q`C95V)2=.!P[-$:F*,R-\GH&(^1KOH M5G@9NE[;`JXKO/`N`P.N!L&1A/88/>X.I\(B'.#'`+-:[9'-?A;BU1Z^78Y1 M;",`A49;!6*6*SP!I5;(&/\*FN^6EKC>W]2_N&Y-^C-1\"3HS^&B>Q,VCM`% M6C)1_2+FKQ!:R*U@(ZAROZB9E!;L1HD0(V]^';A;9_]D'P?:-B$)A&0A)#ZX M-W(Q/Q--ZDJ*&4G_:D=B_\'=(3$OHD'*%4U"%5F`:;RNKO4N32M\M4(!DZPP MIX!9$-BH+Q;)EL4=/0D6V;9`NB60KC.F02#?%LBV!+*U0!8$BOLF2X?A/F7` MQ-D_7/(/7?+@4MZ[Y&L7C_E4%.6V2_&A2Q%<]O_IQ6/2`[D=W`%3H+;>ZINU2M$!J,??Q@6N[-UV`Y M4&BUW99F+_V`^(,6XVW&ULC5C;NN[\$$7M_J2JO/VDSZKN?SGJILJ[_K)YCMISH_+#.*@J(QK' M253E11UNUN.]'\UFK5^[LJC5CR9H7ZLJ;_YN5:DOCR$)YQL_B^=3-]R(-NOH M.NY05*IN"UT'C3H^AI_)PX[+`3(B?A7JTB[.@R'Y)ZU?AHMOA\Y9MUHR]!,ZW>.1\>$O+`^U+O@W:\V=>@ M#0=`7]K-^FU#V&H=O0V!`$,7F"U@2.K&9!.&SXXS$.9HXGQ+G'XC$,G&^ M(++S")1'``\Q>9:8+6"H8Q42E"0!$NJ9S(01OJI)E$@"$?,031CNX4E1GA1X MN*=J@&$.DA5*L@(2X2&9,8F=9/!"A(7$$$)Z)`*@A#EK1JR^8S*!J?#4QP0@ M-Y'5-4PBL`V^$3_Q5$'3RXQQ`P$,%\"S^!F'#/"#<:`DY#B2.$U4*,ED.DO^<0W!T( M2)]Z_"X#D+1T$W.MK3@S)=Q+"!B%X+Z4)I`4*R0E*\YL[;CQ4#`>ZO`N:G44 M#V0<$^F$/4U.H+YH.2(`\*OK6@\I[UF) M.UXFYAZ>^N8[]W"W7S-<@&SNNIXMS'8&^?;,#-<7`WTEKA"XOABB+X;KB\E[ MBBO_%]?!A(N'I??4-L67$6^[#$1&F3T$MXK,*"V/_:7EN'HXJ"=^>[U`/Q]7#9_6XEAA7#T?4PW'U M<&F?L;'%Y@OUW,PX6GQ*.N?/ZGO>/!=U&SSIKM/5^`GIJ'6G^D#QI[XL)Y4? MKA>E.G;#J>S/F^F#VW31Z?/\_?#Z$7/S#U!+`P04````"``66VE'1$F\M:L! M``"V`P``&0```'AL+W=O\7K=]#\KLYX2Q8``&U"PK,+U=X`B&"D&_\-VE^M0S$ M=7Q3_QFG]>XOS,*3%F^\<;TWFV'40,M&X5[T]`O2"/L@6&MAXQ?5HW5:WB@8 M2?8QKUS%=9K_%'FB;1-H(M"%0&?C M=\GC?EN@V!(HU@)%$CA\'_(^8M3L,F&*ARS+_NM#5ALKP73Q_EA4ZU'%V[JJ M+E?TD<:#^8)7Y<`Z^,-,QY5%%^W\\<:S:+5VX!UD=WN,>O^(ED1`ZT)X[V,S MWZLY<7JXO9+EJ5:?4$L#!!0````(`!9;:4<1RR0R@P(``/H(```9````>&PO M=V]R:W-H965TKJ MQ?2:&!*M5G&`)#U_/R!H:]I'LHAP.>?<`US!Z([))TT18MI7D9=TJ:>,50O# MH$F*"DA?<(5*/G+&I(",=\G%H!5!\%23BMP`IND9!5:B M-Z+1:U%`\F^%!-ZS2\I$P(@CH^6=L@*5-,.E1M!YJ;]:BT,H$#7@ M3X;NM-/6A/4H84(!\L<-K5&>"R&>^*_2_$XIB-UVH[ZK M9\O='R%%:YQ_9">6T_M>2*V6X:"BZ5L`O M^#E$4>W MV/+\R+@)(84!'6AB[N]>V$G"& M!9PA`:GBUDWF&`X23";)%`"83^).)[;]5Q)$`#^CV7OX=8*9X)IW$;A M'#"Z/^&L\5`:#R;J8*LPSHR?73CJNU=62B[TIN4.X?CTC,XQ6B!RJ>]4JB7X M6C)1/YUH>VV_`G$,/\2WUF)G#<3W_)J7M_*W?!Q5\()^0W+)2JH=,>.'?WU2 MGS%FB#LV7_C[D/(/D;:3HS,339^WB;R;98?AJOG2:#]WXO]02P,$%`````@` M%EMI1WJ8F,.'$B,C+GZZ(H595&?ZKT M45:EY6\^.WQ]^)FZ3^*T^,UGB[))'Z6???%U$WWQ=?G.CEOGI^X*EG!XI(W]9E!D:N5[HW%_J MJHR"0AUE^7)_38-'&$3NQQA'J._5;_6JUV25YS30DZ@(\-Q_:C^G6:MCO^QU MO[=W^&SO^>&:KDZB6.?J"._-L[S7SR3Q8_K^2B^SO(S2.8:=+/VT]^!U[H?T M]6253+.X-]S1Y63=5+,D@90G919\\-2$UT5=5&51^BFUN':-KE?+WE0/#_9^ MU_ULA*=#?N,D]GO-S?RXZ#7C^KC4>92%:R5K5>I?_^5?2*G6-F-6R;1V@H][ MJO>[YY]ZF]=X\-VCB_/C\?ED?*SPV^3B[/1X=(T_WHS.1N='8S5Y.QY?3]2> MNID4?E'HLC]*OU@H=*@" M^D7_J8IN_1B/]QZ\*&$F*MC8V'560B2;G[G$BN'+.`IT6FB51_-%67@JU67W MR9,J3Z.RRC6/CX:V),D//BL]KYFB&4\<^=,HCLJH#S&C(""D+-327_G3N*=2 M,GD_"/)*AYL::DM@PX,;T$>L;I'%HI7^2AV^//#P&?VO!%657Y6++(\^ZO`K]>+`>_WZI??B\-!^"]TCS6)1DQ:I MJ"AHKO1WMM[N1V$8$1YCTDL_"O?03.`O(PAA0,154L58_5"%>A8%T9I%W"29 MHB49/2B9\RP-X'#R+(X)^J*TU)C@FLZ&FY#O&JOG-'!@(1YDYM]?^J01"XW) M^/$?8?9/U%,U[._,TA:"O6Y1U0Z$&V)6?@X]A3KRV[N;W^ZM_8,>E[5_T*,; M=&.-9";7^/%N?`ZI7)RHB\OQU>CZ%`\TH+#628>'WB?P\?F#648/(,T0SK]5 MXS]2ER1V_'.HV1K>>FOI%%,C:17$%J/(>-)2!D3S06M]T M.QRP*VY*/NY;^T-L[&@T>:M.SBY^_W"Z4=O$Z.CZ]/WI]6G?*JS8!@!8V$1$ M[+PG[6.-^"*(A,:S125$8C\.!@]H:X_;8MDJJ"@I_^"C1PL_G6N:E=A);5S# MXV#F,XNSNT)5!01/+[I7_`#6/>BX3\_?CR>?D$RCZ66>W49`)#5=H8=;*/WF MYD].S^$W'M7\+$K]--CB,]*8? M*ZQYT%-OQM^>GI_3D*%KT)O3B^.?\?88GZY][^+]^.K]Z?CW],2;F\GI^;@/ M/X:[T;PO,]!*;[_'T0X4GB=Z@\U1H8;&O+G-]&P%EXI6G[C3^`QC/*%["\Q`]3;OA M)R44P=AU#HB(#2K04,N[C+0]K()2+4$C"<[A=D;_]8=#<%QZ[6B1KPJ\DZJ= MZ\N7!Z]WP:3A(K5ZQQX9KO\9#R'-`%N`BEPM_%L*+E;.(3$(Y"8H8;2W;>[# M@W`3/`EH"A`[NTOES;3VY9BSIP+MT_0"O,?R:$X04S%C)@>AX9-BA4@RSR%; M3]&L=!ZO@/\YIHOA1TMJ(*_FP%1(-02!]GBZ278KJ^OC5PCU-LK+JD4JDBS4 ML1WX"YX[!@OZPB2<)']FHK#1/->:AXK1;KKCK7",L2TDM MXK@E._[2"8]ZV-B6>49&@8YW1A^OQUBVBU2-JGF%-I][];II[HB`FB?]0X9? MU"T^18CHH9$E-+6,_@#+=M+&QV='GMI)L[MU#X#W[(-"6?O[[CU9EM>P&C5: M9FJL$GXYL,;B+$2-QN_VGKWFJ4Y.1X9`+! M9Q#!*``AD<9`@>;Q*M`Y9IY`")=P-#0,&'GA-6!C00_'$+0\%J6$!P8(2!ZP MAS+J&`2+`SBKB;A#'_*LFB_4)>2FU:'/C1].GS[S:W/":/Q8T.H.`B'(BW4I M+IR6<0;C`33]J?+SDHC`C/7?K0C8AXYN17NS.Y\0@HER\JH'XMBJX\V?1%F1FEH2]AEE#0Z`'K*O#?O2E>">EOS##0 MTVS/LGHBKF45DKP@$$T!*T"&AUKX,UVNR*)B`!-'U/@+.@CH"[(/\$3L!FEF M]L-PE4*7\2&6KHCNE:94FV`:O/<<1A=F'`$Y66)V"^W'Y6+5\4\ZQF!(-QKV ML"OX6<5E!,6!30%^F&A+J^1L%C1V8*):`,T(W.0KUA/7Z4YS%3""=L^+(2ND MCNU`;[,8A$-3L+!VJ/("QJ#>0"KP9&`NG'[>_90RI06"5/*Q,_7\53VT005J M/GSXTCV\CTXQKJZ>L'*TC*ZEFN\,"9CPNG,FF8@(()J8@+YC%@*_(7JQEVO) M"?G%$N[!2;_3*7!P:DB&K^82CL-+^D$`..;03)HC6YQ%L=Y7(ZQ6E!?E7I3N M)7YJU=,3`\VCQ(>=8]V7[$8(1Z2%K]0*<8V>S=![L`*E\0OXE\0(SX]7'YD$ M=35U%>DX9"N`\`K.\BC"UHC:(8@QV+3,,C(6N''('Q#NWV;D^:WAW4(;`.7& MO.@EIZ8,J\3V,/(/E`=:<=:]("I(O`D8#[H\BSA):!Q4TW'E>J;SW%"4PGR\1SR$@SZ5ZCN(,2OP MOTR-NB4`AKOP;#^%$1KEC"-QC'6.VJV2)V8*_U/14I.M&KBI@\R&CR'=S8K( M,LL$(3[>7=K$]$RK'7CBV+@N1?K4`/>;_0E8K3Q,+=,>BZ8U41IS=N8%W&XV%N M05R%M3:[Q:ZY\=JIA!EXN=&LHB)!1DQQS,"@#.6"A!8ENC7*QB2PCCKOLHM' MC]R--/%7'-!0X#&K>#^BBXA-1RO&=#,9-7E1@UK\4.51`824C%PT&^)_Q*EZ MB]-LKPZP#".1T1IA>DYL-5WQ1//"HB6].,+7DB(IAD(9"2_61!;J;@'+P.\@ M=:*![,.A>!%%+=*NH!ZLTI]KJ]C&)!J+819BW6J.*=B2KL\^]L5/&W MOZQ15GH1>)E!4TH-\8XE"_#LBR\4/!%B6S^("+OE6X91>),5O:^BA`1!&^+$ M1VAQFBUA)/X4;1?)ONU;FG[=;-G&061-/`5.GCSFBA[_TT MHSPI/3Q'@+`T/J3I/W;%0*9,6;)4(`ZX0HHCUG:S@J_#5WN&NM:(844N^_S/AMVC'KWB.,;;M M5B$/"N%Y''GKSSK&W*-D!3-5IS3#/P\C`".!:+_Q$N2VO$\J*^4/B#G3.YH@V M6BF22^(_I$/G`.QD"L?V[!4E?`Z><\+'>`.*-^%`*A@H32`T[@`DN&26"FV, M`%TYQ9@V$4K>F>*#\-;G4!BJL:"6*($C241R-D30Q1G@PR0S`2O%9\R;0`TK M4K>L^(#8C#;LII2]9?7D+5)/)"4NC]52)X@,$$Q1:G.6RX!=@_1BL:34*SR2 M'^6R.C:I23G9PB*)Z"3E]:E'0-Y=27L@D27(W);K8!;=RZ>0&!:3Z`/%[VT" M3AG%GW[\ZQMJ\)B?4S89OD^9Y=.TL0QV":!((;\Y^!J]8Q)U>$,RC,L*NL#I MSZ*:TA86`0PM11S;V$[*-$2=!_."Y$A-XK6`JC7RVY*O:]HL*91VNGR7Y7%X M1P9A"TQ(%5T6UR.?(:Z6@\_8%/?NXX;T]\RZ/R;=KG8*K66SZPT(`%A/.V7>8;D_ M.W=.N+@F%L@U;[?1AS896,6C2D(EV6-O*/_NEV"X\9DS9 MSOIQ&YRB0YAG0/Q]1.P5?U=Q:7R4J`&_!L<8<6S/@1S<$N=`B5O-:!78QAO! M%8&R.`-B+IS$DO%#`.2OSLB/F?W!.JL;9C33J=W'K&H[H42$2FG@!#V#FXW` MJXN@S`CCN5SPX+70K3NVE8216F(?@7UNC6E=;T2?*,O("*:`"U*5>,"F(V02 M<3ZY*'9/-"76VH&]3L_M=$I,W=\='>R_^R7_37/$9_4DR./Q"#XUCZO6,+,> MG9(-6=XV\NH6-VPVJ1VWR;=^S\HDC_S`[.=R?D?V]RGA0%E&DY-DS)YJG5*^ M;LGJSBAK.;?5X;LHCAMI$U+C.6L2/@,94AU', M#,/&5TTT-R%+RDJ%1BOB_7AFZKC#]<*JOJE3@F@IM;VD)!T$+.7;#$&7U30F M,*FWZ$_`/TG%Z"5*7R,$#!F)G9":,K*8NZ)B7[^EG!L@H,-Q>(\$T#/-JK(I>2Q)G+JL#M?[)MR]%P5.8''&<%H&069!+,+41>41;,/3Y M4G0NF\U,%G6&(6-]\944@@*L7=*(%,P(DV=``QM21)/E-*K&5,L/?X#G3>HX M,R%/;EQ,'5%#J;@^S]"@*C44RD7I3M!%%6`IBUE%6!Y1_$V-6ZK<%Z=%9D4% M(BXE;M70,]WY8-N\-Y61=4J]%*5;D^&)NAE"1YLS3#6-C0BCM,5)@,-NLM7/TZ%T69#89.STS;";\L)N6T?+RTX'!`R#4QV9O MH2@Q^``EZ.ZHKSC2G!DS0-NXC/ MW&\=R:KG[;,2#KA8@OV<:R\8V*P.8LBGGT9,5X[K`(#T;1N2^G1=MC\[F(Y:- MG4GK1*&IH'8_\.IE*L8`8UOF@W'*RT'L1XE=Z9S(B!D0$R#R<>MH;QU7DMH6 MO!=A&>+=`I`G420ZG$K9.7?!Q=;,HQ@6(]GS#YVIBV;1BVYU5F:^O$[D"S3/ MS-4EE.J'*I20V6V-81*\AR)U$C0"&9CEHHT]=79I&+!H"R5@EHR75*K8TI*5 MDWOX`+J!!J@>@]"3\NYHI.2@VZJ>J%?N`!8\[8L#=:`H)?.Y^6Q4 MPFT!@@0@S;D^KZ;HW>-X-70G\.LKD_^V0-=)Q5*"BN1RXG"C$3I-Z%B!3VKW M)L,/>]!KX`EULR1FH780X(XF-UQR?)[MLU=O1\J^ZL^I)"X;J.;T>C2TD,I[3VMH>&#VB6MUG5%YWUN2S* M;-FX)9C9%DXW1/"R89%TG!Y(:)^[/2I,I M"FUMWK!C890@I?A*PCYBL512TYB)::VH@?)OONXO3\6KT?GU_?7(W5R<65.AZ_'Y]=7-*! M&RKX'UU>T-;^Z;OQ]>F1NAQ?7I\>X^^+L_'1S=G81M1T'&)T/CJ[^+9WI,$= M4@`,30WB/NA00^/YIA4]\AS#FWWUZ\_U8=GF(PNE-)-.1MUES3A3QCD+8JT_ MHR*<$>V3E=[N#$1_B[B?L3ZMRVM?NGHZV,"M9M8G=%?J;1HGB.OS&CQK&YQS MK+LIA=AT41VOHP[A;YS?>:E>.C?4D5OS/;NC,+`7(?L*O*$[+!WR?ME=:H@( M&)5LJI)T-NTQ3W5Y1S3F^A=L,[/C&+VY.F'71-VWY^BY*(:?VK3=(LQVW137 M),',3LIW[TE#S/X,=_G"B!QN__GGKX>D3P3'U%E.5[8F54Y[<&SP1J<5;7U> MHO%-W'EY4F%)*J1P^UFF*CT[A M1;,X!,;.P1`6^\?[]`-0'2W5NWUU0F<(4O.-Q.NT481OWF6@;+']AO1B@_YP M98N?:"E'I]U^4=*EO[*;KZ:@M#+*UK&Z(\G4+,=M*V;U)=H#XSB';F$,V^VSY3!#04KHQ` M`!P^*A;,SK]CR&X`7%TO+B!]?,3*SKD6XF#4T+K4\$_E72SL?N&>)/)@((&4DJ$4?+'KFS8 MT?.6D7%?T:G;II!9 MYD%42-*L1@;.?!64APOD.*&^,\EQSX9@YAM*G7LDQWPE4G1Y^69"GG,A@:0^ MLLX.L!4SGBG\6!>=O:@X0K^A63N&JL99*L,'IXAU.>%BB2--*K2+DO@_4#$V MGHV:-QY8%;"T8-7K2"9_'0BY=JS2T94,17KS[?57S$F&[T("] MD#M;T[*<&>*,AAP8A?RBO`[\)=,O5UGP`E%V2#,SEP/@DB>2+1MJ>G("P/,K.T603 MHG5B\>C;)_"ZHO6OO,^?OS9^V'YR\+G8PKF.;(3N'%-J<'K-I12%+8-JQ)TV MU!:^W"W.=T2P5QG`E7=4\L1;?>VO6[5/N2E"-+6<\\KGTYI&OWD*[;?-,1U! MWGQ#\]"O,UG^>N$WW\K1JK%I'1.I`WC.FUF'Y]A"L;E9NUMFY&K+\&NQ"IP/ M"M.JR#V;/A?WR#)!M>:RV^8VOB63Y9F"O*6)_XVVTW&JA/=XVSNJG>"Q.:^` MMV';Z[ MY)&?=5EGMY4YV3NL[?$!^\293>.\LD;6##.C_LA,`9(MF0J'YFVO])&ZAN;- M;;)<:^80R19(G=V4;=4^$G!5XN`W+"K&R=`6@Q-#FZ?N\&.721Z^>#V$'.YX M6TH%<92`H7T8EY/Y=S]9?M4.X]!7_PJIUO58S%\]PA$4B4GR6D)K M:^"IA4!D1%43?-((T<>S9^*GGKUX)C\/VC\/[>?FY^$7KX:T]K.][&=[V<_VLI_M93_;RWZV ME_UL+_O97O:SO>QG>]G/]K*?[64_V\M^MI?];"_[V5[VL[WL9WO9C_4-V\M^ M_I]?]C/PKXDP%WC+AY%6CT_"=AO:7BJTO51H>ZG0]E*A[:5"VTN%MI<*;2\5 MVEXJI-VE0D/__%1!>^&MDYPTKT;E\B7MV3R:G@V<"=W4&R<+N$?*<6SO/]K> M?_3/6<.WO?]H>__1]OZC[?U'V_N/C&)L[S_ZE>\_ZG*U&R$08WN!C:<,)7LT M->NVN+UQ:7OCTC_RQJ6A?V`Z*FM9'S7OY?GEZG[&MSA1P_+/N;>:W][^M+W] MB?CWVG^`&X(!9J6./X;F[/I["=DY(KB4.@PZ._DKZ&NK_6;PUU2BC0FU7W!! MU>"_.B<'3]%;;[(?9T!K)UCWO@=VX@=B#M^_8ZWMC>O,G,?J/.\A MCKB/DBH!QN=YQJ731SYT`-_UF[!G`==U,I8I@_^#@WX;XN3VYNK;CMLJ;JP>N&H=.C_*(.9EG3\+6`Y)!][QT6T$M M(QN>":5"0XF[<;_'. MW,ETHGM]-ER5N!U$SN:(_ZW>]&)+9H`F5X0P=E?F,'"Y^*]A:)L78*@Q-7)7 MPEQGMLG-\B-%L#(\36E+IOO\RR$17IF=+SOU1LIL0`IG63K?HWR#:OO*GI/; M4-:X#G)-RO==XS9`R\L>T[SZLW/;ZWI\%U&!)U'Z=1U9@9IU>>PXH&.;QD$P M2@AI$A7*_CVB:B>[PR2IL;/&3O9(RJNZK6W&J@UC^"2.K'UYS5TP/?1]Z(4V M&_S25?N6C&,[U"L*#ZN^O3_RWHA/#OV56$R!T#GLK\'ALXU??U>ESFV_&-T< M;W3K`]\C[MIWFQ>?^GXM+5AS5T?S=J`-"R'Z.#)Y>WOBXL_JR7I*W+L>8SU) M=D&H0)FZ]N_5%86IM/YIP`$"F\4Y[53Q/CDMK+%3KU[ASGTFGG5-/;JX!ATW M7XOB`9Y+/WZ0;.J'GA9%^7!E&UL4$L!`A0# M%`````@`%EMI1TAU!>[%````*P(```L``````````````(`!J`$``%]R96QS M+RYR96QS4$L!`A0#%`````@`%EMI1QK54*4@`0``+0L``!H````````````` M`(`!E@(``'AL+U]R96QS+W=O&PO=&AE;64O=&AE;64Q+GAM;%!+ M`0(4`Q0````(`!9;:4?H_==^7`(``-8*```-``````````````"``>X-``!X M;"]S='EL97,N>&UL4$L!`A0#%`````@`%EMI1][32\F:`@```@<```\````` M`````````(`!=1```'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@` M%EMI1^[;]B[1`0``*P4``!@``````````````(`!SQ@``'AL+W=O&PO=V]R M:W-H965T&UL4$L!`A0#%`````@`%EMI1VPC-"6D`0``K@,` M`!@``````````````(`!4R$``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`%EMI1U5XSU*G`0``K@,``!@``````````````(`! MXR8``'AL+W=O&UL4$L!`A0#%`````@`%EMI1S6C'56D`0``L0,``!D````````` M`````(`!_BH``'AL+W=O&PO=V]R:W-H M965T&UL4$L! M`A0#%`````@`%EMI1X(@.L'9`P``T!0``!D``````````````(`!3#$``'AL M+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`%EMI M1WJ&UL4$L%!@`````9`!D`H08``*A;```````` ` end ZIP 12 0001171843-15-006138-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-15-006138-xbrl.zip M4$L#!!0````(`.M::4?K`59[>#H``)T-`@`1`!P`8V%PL\C#E)Q0C]Z[U/Q=1NV)L6/L[!/XH=ZI78E) MK5$WVN2_ZL:!T3JHM_Z;_&_O\O_(Z=T]J9''Q\<="WKP5`\[IAB16BVBWIP;7Z`_R<`VY$')AW+SUM#SQL?[.YBE_C`$P[SAD_8 MYRXBJ.\W@:N@@@SU=GTO1:AA[ M>2V"&E$#BXU=9N+P+FVSOTM=TQ4VVYU7CIJ;PG<\=YH4EF3FSD!,=L-"'(]F MK6[4FL:LF>^ZH''+VH6EV+"5;&@QGMT&"C*JLR=SF%T?2Y2B)!MP9\*DE]TD M*,O@QJ'S&T!!5G5O["ZI#R49#7Q9&U`ZGK7I4_F@QC,L MR&#]R<[1FM\N8JKL>VZ.LD#I%LQ;0CZA^A](I=BWK$_4=#CPIF/V>4ORT=A& MK57/AB[K?][":5R+YN[.DP0EVX6.`O-P+!R//7GDCID>6!UE&H!$8!S,L)"# M$M_4C>_P!W7A7M3WOS?KZN<`TJP%/0AF&?><*MAT3;/LM"K9=1;#MS0EV[R?2V+W7 MI+%[/Y'&EA?L!C6V&PJV`8*%GYOJY[BX',FJ]EKFL5.ZM"32F$O^.":9 M5@UTK6EL6C+-MR>9YD8E\^9BN(3.K#Z;<+UVPD?,4?DA_8HM:8&^'XO12#AW MGC!_OV2C!^;Z$I>L=QX8/.C4._VG#YQ!K;%PX%?9>^+RF06=-N]L@,!F],(" M"X`\C6UNU2"A!EER^;DUX99-A#WASN`8N.;>&36Y#8#C*I$L>=MZD,5+5)8KBI]1 M"V8+H>_?A(=\*R-X_>@P5P[Y^*O#/1FP:3%^P0;4/E5\O$T5`!X.%IC`I.B! MCOL7&?O-+?528W\EG$``,^/WKZO6*$;/EYY+;4YOO.F%9V5F?HYM*N5U7Z5`WJ;2+&1]%EE*JE"F M6-XU:F&_3R?*O+]KU!O2J*H;G3J;UZCY^[]WC?KY-2KQ5G!C[]C?->EU:](+ M;"YX5XDWHQ*;W57QOECZ22:[[_!@6.60NBP]5B-&I>^R+R$7JDK47506)X&] M+>G_Z]W)DL[#HQX'4*-ZW]^!X>]W"#!%Q>(34(^T.+'IE3_"$T/"3>M&86AQ M@:=[S"!XPAPQXDX^29VHTS07.XU*8YP7D&'OJVY\H$;%\1G["\.29!U(R3QZK8U!>88DV\_$U._4$O$5*5;`LD54K'TN[ MW2Z)I9I(VODP]O>32K8*@B6"Z&B49L_8+P[AC$-7[()/F'7N@&\:\`>;!2VN M6'&I[&D&IY6$E$]U58Q+Y-;5F(=.9P6,-ZX`K^9-;VSP[S!%<7J.T?25D>)^ M/L(8N#QRJT%;(CRCOA%L@3R+6WB-B3?:K4Z&[A>ENHQWC9EN-KOM(E1-=7I5 MWM`I!54J:W@,C3$VFHTDB$QR54$M$XW&*AN-5C50KL^L"TX?<#L:9Z6MM*$Q MT^U.&E8VP160+9.8QGP;[6XU:*M(2V.^C6X2TWK`+!.0QDXWNHV28&(;G4L& ME!J#W$B&/VDZY7$L"Q,UQK,H]RAUFGU'4@*)6K,?HUG)JIV:DGOP[`RP2L<0@`N&.DW&5YP$KL0V%;S)7![O;B$M5X!J.9 M,L"+M*J@628NC3=H&O5F2327W!$N/(>@E;E,EM`UC1>(H4C3*(]AF3PTQK\$ MAD5)G3NF[>,7:6Z$BS.ZYWDN?_`]C$3NQ95P$*4K;!NJE)>>QE<4T*LJ^)Z+ MZR7CU=1XI@+ZNPZN8S$`+#A6L`[-L@L,'>75D2Z3?-E%25FDP4>:;*C;LT:P M%L:7)1ZLAD^?QK@C+@ETR6<1$H`UKJS1,A)X-?37`S?Y>8P$7(TC:^XU5X%[ MRR2CKHG9O!,V8;90*^2PLMI]B%.B9\+0N)B`@$6UR:0\%NG)643R.I>WE_;' ME;%MGLV<$=/XTFYG8VQ>C_%=`M0.6\OR8Z1QOBTC:7<6*%:%E"-/C2\V&LUN M24R8DP6++J**8/O%J+I%T;C<6BH1FD]^+6"72[.E\92M%:`&A1="RC-7C/"[ M5MSQH5$X(,*11ZPO7!;4NZ=/3)X^@7T2+F@X=:?G'AO)(I%`@4%I:3QHK=5, M3L,-@G]Y.>7H@\9_UV!ZM5Y64-!%J'!'X-SZZ55@$670^/P%[A9(KH8L1_P: M]UX>&;@'>(K#4UY,&@>],&?FM$JCR!&)QG\N:N1R&%?,FZMK^15'$9D57ZV6 M!K,I;G)D7WS=NS(W49KEAKEJ$\81E=S$((C;/GZ3M?1(I-QP;'M'C(L&,+&# MVR<+PE@/ZN42;]>+HVY61OTWQ@=#>-Z;@(T>L"L?MQQ=]U73:]_#W4`89*XZ M!.VXTPUW!RW$%]W4@K`:MHURF#-.H(#L->ZT6T^_ M9'B%.8("0Z9[N=CI[+U4DJ#`(&G?1Z:24BMG"?02[>@RP'M&:X-9`KW0.KH% M::/[7%F"`M+4K`I3VOE:TP0%1D7G%AM&W?CY\P0%-$+GLYN=E)=Y=7F"`MJ@ M6P`;^]T,'M>4+2@P"!I/O\9L00%A:5PUICV;JZ8+"LA$XTH7%7-SZ8("0BN^ MM_+%TP5ZV>\5WXWYS.D"_4CL&<47WNUG2A<4D'BC..K]ETT7%!B"YMM.%Q08 MKM:K3!<4&!J])TP9]\KY@@)2U&6$%TQ\+I@3==;" MLJ,<9+`5>)`-HD(\^V@=3;]*S*#,\@,]@#$)]G5GK&'*#X!V*VV[L6#,5@#X M+.SF#)]VW6@LVN[-LWNN;CS;P.AJ_*:>SX+(GH7/G&$MOA)]%C[/N$,=1"FB>\ZCX$GGO:^*'IF$8JV->=.(JQ1P>K,HZ-UE`Z_>U6YWV%[:$ M:5&L$?ER)=_7Q`RMA1U:Z\*]>.ROO-BU;WOKC2+P%Z&LFX><`="X]8P]2M"']3`\('4.)9K2K79N3Y#@GB`&&]U+FKPST31OT^0V:28[R M8IO.IDSZPJQ(]+K\;I>4_\V^G]B6%U*#&=HW/7T1<`GM#>WK&*KC$ MO(]U80ZI.5VD@0M>UN+[DO3QA)70YKSQ""49F:XB`!*0;YGEF\P*2R^I M`[X?>:T&-#\5T8P9V1RZ2R/DA5WO:B6/V0'J3.]=ZDC$4>7-IY'W=3`U#YO9 MT7%A2&MG"H:@%0W',J;R/7UG+_SVP'-PU;-M8>+7J.Y%V$^%0A\LP-=5.?DLB#FWA5;EP3"J'U^X-=;WP M%W5"2*J$I7HC$?\:CY3^B%E&$:4J\`7_)%>:]R?IXTX5H9>4P!7#A[!"8AYU MI\%[L>@(U7,)1O?AM;UN&<&4Y&AAMW*_CQ](G\S/9-S"Q,`DMV.J-0N2$(Z% MCL?#[Q"'56Z'20IR[PLE@)-O:< M!C=>52"GSK/.+U!9VG46[3,N36K_'61_!D\JQ-3-5D`]23?5[7+*`<"JM-M; M7_[:S*(]Q4Y)C MX8YW`CQ9I!:A'`-BF&?G8,2?_L(J1,O-O>3504N[CM,.M]G,!ZFZ[G6WOM2B M.YGRNEYD_8S;L-J`HH%PJS"^O_7E#LP)=$)NV1AW]CL#$H;'<3DDZ,1AP!(' M#ZG<34/HS,0LUW`C\"XH)N\!ZI&]\"GI0B(#P_@'VSNT M^(1(;VJSSUN7O=L_G5\=D/K8@[]/A^3L^NK^@!CX^SWX(DFNV".Y%2/J;`Z.+TY[MPI?G%W\_2'5UJ,KNSO]Q&I`Z MG,'@3O!W[&T1\'\#O/J:X;I8D4-JNT!NPZ1)?:?-G4-R?_K;?>W\ZN0415)3 M#^=G=W>*(>Q@ MQMW#<_+9V&FT0Y2D""M_H*/QX7\:G?KA(O`UPTW(/AR/+"TI/QZ9=4)4Y)<4 MKE^V?Y&H[K^$Z%-]D80<8E.7B#Z!)2B)9O4S#G1IR;WE4==ASXD3R`<F3(;-7#&-:JZAW3(_>&X,(LYM9`K2=0"VIR"!70F02W!\@=^M*?;Y)'!'Y>1/L9R4!]4&\5FQ1;Q"`&Q,]?D8+/#4X8X`1X%&;L"E\=D M;%.O+]R1/""]?_QFU.NJV?'0G4IHXY`/]S?M>O?C#KGCCLG()2Y&"";X%`1' M$%LX`^!R2">,H+1X="0=&H/$73P1*U%RLSYWR+FCNE!,@!NUB"4>G:"E`SR+ MV=F*;6+B)ES@`]HI><09!%9"S$`+9`?NGD!\Y;H@VVV"7#'7GA)0`V`7X/,Q M=N#Z$%J@K[<@^-E6[([$)!A="C^"4"?<]?PY$!BID;"8'0%O*=X!K+J*#UN" MY,-W2&3VQ@@!S/%Y#$(R4_4Z#J\W4J1=YOFN@VIAVPG9J<*9\)!";E]AG0`% M$/[0^W%_^G'G[5F&MVS5KAW2\P<^#&!S>SY)5)P$(PP#AQKV/YC2)N&^G&T2 MY19^([$%/CR^.-XF'QSQN*S"N6/N?-Q>,):_?HN;M>V8R2*]L2"G9*0Z,R-+ M-3-/I'=Z66MTE=[A+C(*,U$,P.J`A2:_?H,)CA8R/OW`=#C8_]AWI<]`DP=X MY0:N6N@8]'*"$Z@?=KN-MH`Z8:\PZT"K74:]V43YLQB)'],!6#=R1D>8QK/) MGZ>@V^90X$MMYL(_(T[)AP$N&T&X'P&#P\Q:6#@'J;D[*2'4PA' M`$30,WV(]%1G'LPH>VI"Y&!!9R:YH6J[/ZP)N-R.V>PA5K9!\$$U[J`Q#JTP MR@-O=N,I:Z3$`7$_P\PC3$97^(,AN1GBV2B#JLZ-A]T&G=LR0`,+%%7R2*7R M-S;SE*:HR=P'RP5^X9\^=8%_%"8:G_O.4`S89]*=O),,)LWG[`;S#AP(N53`B)Q%#ZVI`X8#'L(\D?R),$RU!-X; M8OT!6#A+X/?I/LQD"=P-&;6]X305B3$;P*BOALR-S\<@4O!MC\,L!0,&CE:E M*8)>PW4%3'O&R!#\-KKQH$CIR8SHA_@H`((DY6&6R4/"$=")L'TP?WC&9"G4 MH`%@($<@%8C9I"0JW_51ITR.Y!([`VZ:G3FT3`6*5S;:L\H[0!1PI?5$*4?" MPB54\S(,=^_4N&.^2H7 M]!1T=&0<^T$3$SJ"L1`X62!@!?F#OZ03@3%N-/$FH`W@-\/IA8UF:JI\&*YK M`/GOX$,B[/+=BSSO>E10&%D*M;<#TN:PV MZV5F2H>XPL3E&$0OC@>ZA/H?A5[QD"S:2*M6/C)\7,/E#4Y+2AR0SW@H)/P- M]`C)HK>#0&@[HB-##?605A#RL=EIX=F4V`YL(D16/LXK-(RA;5!D!@8K!/F_<9^0`QIAT&900G;\R3?MVY@\5R4!E[QB0TPPE` MKA$."ZU/^V,4W$8AL[%W"&%8.$YJ!ZR'B0'EK;ER[3_8PC)[)M#:>VSV,K%9 MY$2B+4D47`U[&MN!D>S[CN52+E528`RA-/@!?`Z!BZU6RZH`QE@\X"V"A,ZN M:U1-5=0F5%*?.SY;-EEG6I!>0&V#(H4?^4W/L'F>XUUO7H/>6((X(K2=TD=3 MP=7R--0",'?>$,T!P$VH1$QCP%(Q-[TRK*PFL\7WB*I7@2ICU_>#@T2I`"L> MMP?NXNO_MW>E36UC6?NOZ,U,5T&5(28L67JFJQR6Q#TDIEC2]7[JDJUK6QU9 M\DARP/WKYRQWTV)CP!`;;JJ2@*WEKN>>Y3GGN6C9-JUEJ?PU2<,,%"Z&5H;] M.ML=[>'*3K"?9SR3TL!Y_$7\HA>L7*4-O1Z-6=G@PRK("LLR"N%KO!"768US ME1V>,WR=WO40#E7X.0YSEJ-D:X'X#-&/RL]E[72D\?'PO2<=)BF;B(/F!/4(UF1VI*MBM;Z+!`(MCRJK! MA8"CW;SK^*8W1/`^&QM9AHI$RGYZ>MQ`:CI../^D@&`I;*=HP,^DXY(G84_ZGK](W[.:PB_*]RR[O=_\=<;Q M6!V-R?_>\T=A#.='+T0SE+\EBW`< M^5.<-B\R^9Y.T[\.QQ4ULJE,]"N%XW;ZC49,5@TQP'2G310\!C`<&.3'0BE]([Z[TX67P`:J7 MR4"`>FL/&^DK7<$=AM.=W*K2<9Z-0.>5WD6C.Z!?3!0.U/ M&\H(2$5W"K>`ADW0,S\-0M"",Y!./@:QL^^HB\-J"DMK>R10BX!EC.WGQ"#; M)[Z8EG^2I,;92JLG\GO?O=.C4WN2%@V1;7U.3CYORJ'W*?@U+L2Y$AFNKW,V M-V:TG$P07J7P4!HQ"=OPLB2:8+^WOSK3LB9,;MPV,2ZY3*Z% M5N1W_9&/5M?'$"/M@Z$_\A0>&H8,M&"_;KA[(J7M",^PXYCS9>^R@$>%MZRL M5%_E$VD%\&+*'_`Y1"DU_;E@P.U_0S]JRC@OX)5ATD5WIL#A%`T=PE" M(4U&#")"J)T":3-F'ZGF!)B8=*0\J<:GL9QH8\$@S[!#Y_BFR"WA_@D MA$`P!@HM4HRZL,4('XX2&87$H!NY"OO>:()G09)]%W#$@.#M(GB-S@XP'2>B MP6*,[6,Z,\1H#,(/C@N44"DW6#\0;\S&B!P#L]4/4Q:="I.%D+),'?-\8(B` MWPCZR#6\)\M#Y8BG9^D7],,;_A1&#"0M.G$P*%MT]",@RH*,?,0'']'U&A>Y M;0/GVK$U+6I*0.H']*3ZVYTKZ)%V2EMCC&`J&(DVGL")2#"Y;-)%'#NJ6;CF MHTA%1GTN7TJ'>BU^#`UL"=#+X,"U<)`,-;(U%SQ6A3[1KY,T"JY1+8CDV8X' MLD;[-5!S9GN/,'G4*H5N+`!KL*B*^.\$=`($..+2$GVX(<\J2,=4:0'8GU(L MQD`7M6(Q2'SI.S)@2-K69L^1_[0/SQU6-NNVMP%C7@(^%F![19B>:;\F/2;LU;EJ5QSOZFUD0GB4>O,1 MC/DHN2YB5$L.P[N"5==O"-=Z^N'\G!',29%K**,/%?K.!)@R,>#K"3LR]2AE M+Y"XOY'0>G`!7>OG?-Q/:# MH"%(I;+6+YK:+"]_C@K6N,2O3MN.IQ[3'JQQJ?V;(@46`3GY/9MX2>E/-;48H>8FI)Z])5X@8(=!CTA[)'%>Q M/Z427H=19.'T4"L<)+*V!-CM.I9*)1M&F`LK,AD\+&3,6F8_TCUF?1GI@Z]L MLU^&3F-2&^"A$XP_PC7=)W.+OBC1L\AB8K6=]34\S#`/9HP@<[B5J]"0K7HV MZ49H=>JR'MY)F(Y08\.;,-3V,B\(-!5.+P!4 M*PO?K<0G;;LY?"@B7C9'*R)+0AAM!&[/'X<8>(+9Q]2.W"0J8"5!MEB2]#NC M%_C2KA_Y2I'K8RJI2$TR<'V4/TG-JK'@Z;0Q4G3^HVO>;BYV)^5RMO2@>G\` M`YGKEJO!C"E67^"=FF(B!=\N`K+5(=S!7?Z"]-IV/#TL&B(SF=2XJ`AI]N?P$9GFOH` M/>\CX>/>:[*M&K(54GQ M";L&!Z%J4,CT$7$FL\-*;Z80'6I*2OM)HR MBEWCAE+="G')RY#A#[U9U#,9'@8GI^C1.:V#$YQT"CW&C&`ZHKDQ6;[7. M?:OI\^QG2I#``/LRS9V#9F$#_.(EU['4#8B&8CJSC@19W%3!6I6SR>VRVD:1 M%I@N0!&@%908SUDW.)3QPS`F=Z/!="1)CJXJ+X!U&R49,:3$RB-IZY*UZU@; M1GA.TNE-(%&*XY5SH=%\,IJOK)6#F1!F>1C!!-LJD?60J/('HB!AZ]TWNP+$ M290/";AZC>^*0D&(4:D6V9U'E";VAA0C.*6EWW[D?Q=2?)@1E")/!"1`H`61 MH$J$ZORN$[FUXYA!VZ(`)0O8A#2:<,-?<$#3:S3&H/9>E6!&'D=&F>;)7+0T&>R MSNK9*D_U(AX.%O1:MYNAU%3.@'J!7W,R2*<6DFS!;^1AS92!JFP:8]Z2,`8E M<$)"AUUGD]%8AE)!'@JU9F2:!!5SEWH<"D"47"-L668<;PW;R\;ZIY`<$$J( MSI2_!6\B">)MRQ<,-C(]!!%MNF$PD$."_A)&#=^4AD+E&?X`-10A^)P$:_=. MGEV!5$21/AHL]R[5%5%''$>@S*OP+.OZ$M8VJG=1V^^`@]-/N3JNM/[%#ZNK M,J^3YX3,0_C,FVC/).<.-_#*">GHK-+BM4&(IK"V2(NM5'"G\2()D>Y4>*&G M`O%ET&(AF@]0_4B^P-8)W1&Q`JGCJ/J!R?@7"=S$BVBZ9!TRF"?>Y[W(#T=* M.*?H@Y.R@_Q_/M4DK\0U;/<>6OYP;49);\H;?3T$&X)1-_#"+L%H^!4>:/<9 MN1')S@BY3DZ@=6<^#/!&+5"G4C21:$437%#/=.&DW/MK$C#$2.>"0R5M`SP7H8N($)QYQK(J*-8;="2KF M_USFHCMH-)M-_%L8P(;E-(E5H4@.]S!(7#JE[&8I!+ZN#\;@=8:1;T.#0A+E MMDR-I6-E_DM`WB?=*!SPX2`CJOS6OH*4HYPI3!2@>5/RZD#.0RO0S MF6([F/A4Z99.6MF%XMVR$!S9=%1>=];CIV5_MRZNQLZX.I^\=*X7'XCFBO$P MX?U%'WF7,MYJG&*+OU#.T)V=UM[OQ:[#$2AD6((5$E,DG5LI$X+PK%9$TBKT M9Y;!QE)7?-F+KU;CZ^5&"_;*[YFURC<]E.S1S'&XMH*[L#:7NOV+;;2SO\J+ MF&>2+&4AZX`R[:/:`SF]U1SZ8LO0Q'$^:\U7[+T0D^SM1DI$T?IWJBR8H'>&RI8 MC'4A,-2%]';VA-$CP*V4?8A MF(B*+WQ_VSOE:=":=7=:,T(AI6,ALES5F558#-:-9@A+0G)TQ]_=W7Z[#Q_6M;["V+,":ORA@@71#\>Z)NM3>F+6516 M)*B[PKL:H[4%NJW)PVE=7!7HK+XFVZ8-^.8M%#_8]!#;=U8"A-5D4&1V4;Y/ M";-($G;8VP!E-T_&80_ZM+^UU]RT6\*-LQOSP3O2(`Y\V94&-Q)8A-#,6".* MJ!F+Q4,-EOFP@&4NM*=A54_SE<>7U&%.!*1RX)]:K3,N/Q&C_Z/\)BN":5-1 M*"\PNV]]HC#056\1*DK!MP:3(032J<)NZ\$`8W7(,$5^;H:SS@-SU[1J,2PW MZ;L8!HTE4,3OY]+=$2@^C?KP*#G.<9G]RD!@U&*3K-!)<1-F.:=H\R1*OSUF M0#042$Y=K%PWIM:;H/!NIBSO^7T<"9%3*-8X761H0:YXI5$+Q0"N9M1G"`WC M!CU)S,'#H)5^W`"P$PZD?0`#%5&U8UU%7M;3%0&)F)#-TC\$NQO0!A(1FSJ5 M6[>]S\DUEIMKX!A6/$,*QJCLH,)\YK/*R>/Z*I2.*UAH#?3/T7A@D#=,*0B^ M(/;?:_B: MK=E,Z`X!O(0'$F4F+(O0,9[ZY%QGMUJ]^:VV"Y[YMN+-"*I33<$-B7&K[W4QK.!,0MYH[ZF_&("X[T_NVTQW!Z M\Y_:YI;?_:!FSAS7@R=O9IMUI\5'\NWM3=QKOGNWO[>S,Z>%_-I[MV[F`+Y[ MRM;=CX'[_5*:.(>&^V[MG#64^\W':F?/'VUI^7R M=S31CB;:T40[FFA'$^U.D?O8NXXFVM%$K^3*7.==)74S1Q/MULTRUHVCB78T MT:N[8!U-M*.)?@YK_;YA.T<3O3+=<331SV4SWIKNX&BB'4VTHXEV--'/G"9Z M]4'!"^/0"L`U:31(PN.'(];>K!%B;3YZ;'W@:XZUVK%6RT/=L58[UNK5VBEM MQUKM6*O=MG*LU8ZUVK%6KQW\UK%6/Z?I=ZS5:S9C:[W:'&OU3Y^#=5X_;<=: M_7Q8J]?$?3S7&USP&W]$7U&G;Y<3:L6!H==`=N6'>Y-WG3?YR;W)CE-[;6`6 MBZ#"'*?V"DW(.NLCET/'J>TXM5>A[8Y3^W+&WC^RB4=KS+1Z6L*Z7OX!??6R"^XCCY`Q_*] M&FV_'#J6;\?RO6(LWZM_3M6?,W6%A4,VN.``*U!6/SQRM>].J$<]H1SC^`JV MW7)+.L9QQSB^[L?'X@=$^6AI2X1P.P:U*M9NY("8:B6_=M9)S[C8$-*6RB?> MXZ0Y6*.3YKE@)!Q1NB-*=T3ICBB]ICN.*/U!*]X1I9M6.J)T1Y3^X!EQ1.GK M973][6W'0>\XZ!T'O>.@=QST M#^"@?PXZVEW5K;*ZIBJEP71T9033R-6'*&GOUTU)P\=G.8S@8%$]Z2N5C]GV M?N^TOUYZW^"T?'WXY/.V=?X".O<^*USCI8!+O]Y?BR?>B='9]= MMH_@]\[I\>'5Z;':F:VO1_"W==KY=%%=G<66_4Q=0J`6G;D!#N:R(L MD$1P).8:E\UL%\@4H8$B/>-D]'6N%Z7NS$O_L'W-CQ?Y*RZO$1RU7'6M6&-S MJ>_CR3GD[\499G$.--$H(2C3 M&JE=__Z-58VECO[^TXS^?FU(&<-?6W(.ZD)%UC28K]5,\)HD/74LB]2PB0&Z MNY8K,M+\,\3\2SB-2G+:EDNJ8F%-K4.N6TCET>NE+ZKYG!PG(<)<=A@7P[R* M[5V17V/L^?(!1=L+5GWKX_E)P<.`S2GVN:'3>^CJ>>4=V0::U>49N=PR$H5[ M/XQE/8EAQ1\)IM/&2O(LWL?^5+EW)`*L'T;$"T>$:L*PI"DJ0!X*=;&@M!S$ M"F&B.N$KDJD?L4Q?ZG8O"Y@8;LV]"S_B*L6RQP%&&F0M_$FJZA1=BG2D<`9Z M2'C,S-FD*P=GWF2L'(,WX]!D6.&!^0V63J`H8@\9IBX=G5:]876%+GY//EI. MW+$1VPP-&8>$9.&C$6R5]S3@;YJ[^Z4V%F>1Z'_,5$IGHSUO/D$W=^KU?I!\ M[+67Q4G)70I'N1]39?$=M9V(]!Q7H<`@$-_23Y!@2FT^^D@C8SG0A/<<:EE, MN]A+>K!!0%:RL"8?,JWP+JXCV'./9U/]@IWY"KT[ES,*IPI6B4$&)4S@OD4A M>,:GYBD&^^=THS(:$Z6/TK.40XFH, M.>*/"TZNH\.":D)%%3#`AP^>5='I"L\B]EE1=0>I%L$=]W!?D4*%U"ZPBDIC M<($FPA`T$7A/J=NV:X-^/CJ4\-9QY/=85?-E?!@5&SC.>DP\!JVDCS5?NHXB M%U2A?`BO\T84$*-JUCB@1@5$'X2:$&-8&(*]_#J9?;.&@L(&W[('F<:\%V8R M;*7U-RIQD6'!C9Y@8.&U1,0V%-91?H.5K!HXCNF41U&7R2I@KAL*54^QV<(\ MJV&&:S*ER5A%$*,0WAO(N2.%4E(LTW5\WG!:0R%^"HB?/I5H8X"FY5L80_Q?/ECHP+6!B1$EM5 M'4FAA5PVXV$58Z"G!:A MVXU_XBQ;;I[-#^LWCD^W!/YH'UU^QI\1EU)JLXT&E10B_++.M^/SD]/.'Q^\ M'R&B;,2OWL?.^='Q^=9EYPP1&S<>9;KIC\_;GSY?%KZ0[SW`U\J+#CNGIZVS M"VA9#^;2'V?FL1\[EY>=+X4'5,8<_S)J4MYT>GQBO_-6A`T8H&">_/M5)/H6 MRC)/5:\_'W,O=MZ,;ZSO@QDS69P'+Z>)0/4RI8GP8`POVX>MTZW6:?L3=`3F M+D]&T/K6X7\^G7>NOAY]\/[1ZPG1[\M'_2$;L-=LJCUS^?^G\#HN8">7G'P< M]<(CU-&_7^WM_U(`Q1#\LBX'M`IM8FC1131]'5&%NY/G/@E]795I9/J7NF\_4>3_G@[YMQU`W`_43=7K&T<'+S=?,FK M>W7$VB-J7)2L2<:CGQL#YB6?9G.Z9QL4LW;A@R.V@HI;6L^ M+O=3^W;?OGO)V\26CB:K8ZDQ4N;JFUUK>I0(\7*D]3"WT"+%.8%(@0W2L M@BBC),V)7#91]"WXR"U0GG4)GQ\R&>^[F)KJ3WU9,0DNGK)3UD%S7WP8Z'G7 MOJIZDDU-(%WM>IPF_5!%9;GN#1=[-@5J7D:!K,7K8UG9IPI$4,],-9_TK5%? M_.G!QG[F(E,F8NDCR! MMB\[D^[M_OMJR'G]%)?UU;FJA[U>U+2L>&_#:E#9(%C%(^3RHK0*I>(@$>'A M+%VC\0A@X!K,BL1'Q*C6,T[%U)I`SH[*9EA^'LY!X^UN32:..O)E>PBK6,01 M>1LP](*()3:9V:IFY_8EX/+QA_(1!J;YMHJ@::@2Z>$/@22?YFC3RDP9N%A= ML]5ERD53+,:K5&7.8;]L\)+-GZ+JI'#*0D$3L^JQ%-1M)ZV>L.FN^O)4*Q\5 M_6#F`.@L1U+.3&=-^1^B)B@9)42Y,.^QIEP.C:NIEZ.&E7&[M8-9U&'@1TFF M@%KB@+%^)6VI(3?N6.+HI+H"]B_Y?LI,MJ6J"W:_>D2LISN/)8*Z69)V2=U6 MI72S+`&S"SM5KQQC(AI(<(.QJG]O&2F:#U-B/ZJ3[=J,AEYC#Y5D7\ M'#-BUJQ34:+:S6'1F4R8.@,>Q3I\>8=1/AWA&"5`OU81MJLCU5=>*F4>5Y,. MMQ!\>:V(%+D"$U,4\H>5E]Y:ULLFIZX=B2`1V>WUFOPZQ;RP2KF!LHY37"[E MM'1MJG9]*(E07VUZX24S_YA9TS)1BY5Y4L6AB`_RHC<4P202G;Y=HOA,9LM= MXCL>4!_JH+E&]:%^>KGA^0VXN]6TMF#;50-<.[2M0]LZM.WZS*1#VSJT[6J( M)H>V?4;2R:%M'=K6B36'MEV=/;WFJ%*'MG5HVZ=`VZZ9.^_.CKDJ.T^.8O2, M@SW!Q^E5)H)V+)DZXD%+%W60U!CP6<<@9N[NYMMY1?4LZ8ZKBZ-75-\$)CK[ M]ZNMW5>_->U*]@]I6J6CH`/#TYA03?[2ZOUW$C(@L1WG?CQ`WTN+XC[T52J" MG46Z^*'A&-ZB`MW=XUNF];5N%3O9F%(KGDF4;F1`>K8V/ MFZK8J>]=#\':GFYQ465KQ2`W3QB$?CHU#[TQ%WAG^=0[S8.&#-MA[4OO;.AG MPMOQ*6)(O^QT7[_QO1Z8\V'/C[P\#;&@:AB;!VU[A[H^I?5Z!"RF8C")I`!7 M47ZNV).:Y3P3<&(@CP@WQ9WLUU?SP16$_1%:<&PJA$SMF&8#*W#]4 M@@SCJJ5N8^'";.:@-W#4R34B(10P42/H8X]K@MYG?!CJ0S`R%?PL-8G15-EK M:IHW()1%0.^:VTKJH^1"D-%76*)EH.>>*O"6BA)'T2Z5>Q0^M#Z;]!1[#C9B MVSN105,U8A)Z5GK7W.85Z@'=:4%A;/SJ:+FE3=]4(\.$+*T9KN6_?.]-36&J M^KXS[-Q@QN8-L:Q550^/77HGFC6=T*62_%XOG5#Y6BHB'V;>*"'`SW>L\I4/ M8:43DGK(^4ZFBW=<&AI73"7S9*%Z7=%S%E08+ZI,]!,-T<;5Q7++=]4LIDWN MXI.LVZ7WY_U!77]FX2GE0M.9<38ZDG'WNIX:([?P\TDZ"Q`I>;^\;"C$,Z!H MO8^&7[`.3N!.9`\L&%9+8?XZV'L!9L$AG)Q77X_.6^V+]M=/7NOPLOVM?=D^ MKF'N>GX:_RJVO95I*LD`Z2]_B(9=[@_/KT!PC7C$@*GC2>/7\+B1Z8(V>DW# M.O&)I&4JJ:/9H:^3]#NAY>2E4M*04MF?I"2J-!E6/0<)*6[UL#TS)U2H,D7Q M$94J)`^M##9\[(Q:Q-:CK&RK4C:?I*57M7`)(`E-8Z)1QAN#LF+(&..!/Y"% M(GU30/?U2*0#1#Z;G`IBFI06#G.JCM/P!V%A4V\\Z49A#_3!/M>GEM5YB0R5 M<]PR`0-OJHW*P;;Z5/<3,HC!*V/18ZR3Q,9FQ/69I%1V%]-5(U)>SZ'E7+L3 MKM6,M:AYGR`WVL76CD'77ICF$*G#30\TGX'@RM$957I6&ON;`ZV=6-7_PVK+ MY.D%KQU+EH;JJ&1#/^4ZPWCU(:#GS M[Q@^'J8@D>0B%OE*WZ@<=O'@Y>\$LR(N:;/+IC%(NXN@^WZ&29,#/XPS29/, M4H;$7,`$(I@7%@D;+:]>SUM-SXQY_"(ZJJRZ+W740UM'_2AUU`O44>O-O>>A MN"ZJ?):=^N=F#W3Z1W+\S[',\T3<0U'=G^V6;[[Z#;9!P2D_[^7EAG9P\MDY M?ZCT!;MYK:P3U\43M.D/EC_8_1Q>F&3X3"W,#R-83)T^+?6:6,.!U2FP$TN= M`LNUT*EJ0U>H*V]OF9_'Z,K.FS]W:>'L+;4K[^;/RCIUY?W\67E_<,>N')/H M_2+R81*T-7=W1Q4Y.!-I#W['@NL+K;O%0G)OFU8OQB!S[&[LO/JMN7U@^K!P M"ZEK__J_K:V3),G)3KR0QQJ\9VM+]1R.Q^\?^G`)Z&3B%'[Q;NBC-$'Y/,SS M\8?7KZ^OK[=ONFFTG:2#U[`\=E_CUZ_QPE?R^GPZANLI*PT.G5>_T<-?5YX. MG__K-3XJ_(#_4BO^!U!+`P04````"`#K6FE'$L$==)0&``"U2P``%0`<`&-A M<',M,C`Q-3`Y,S!?8V%L+GAM;%54"0`#>`L``00E#@``!#D! M``#M7&UO&CD0_G[2_8<]^GEY2=JJB9*K""$G3DF#DK0ZZ72JS.X`5KWVGNTE M<*?[[S=>(`7VE0+!I/V499GQSCS/S'CL-3E[/PZ8,P*IJ.#GE4:U7G&`>\*G M?'!>^?APY;ZK..]__?FGLU]2:/(@B?=%S?6=1K51/7'P MHO[6_2!&[E&]\<;YL]XX;;P^K;_^R_FW>?.?T[Y_<%SG\?&QZN,(.AZAZHG` M<5WS'$;YEQY1X*!A7)U7AEJ'I[6:D1_W)*L*.:@=U>O'M;E@92IY.E9T2?KQ M>"[;J/UQ1A"LA+V$$3(0!WKCM-T/1OJ$!:.IU(=34 MAQM\CA"@AV/#6\W(U+;[ MV!JBL"$.+<%]X`I\O%""4=_$[05AAOS[(8!>Q[LR@^W*YGM,$C!`JMO^;6CR M#^-O8^.S1GT.+UI$#:^8>-RJ$PN#;L&'K83S82@0DWJ-?BXA`&,- M"*8_Q\`8\,P)'A)_1RV@MQJBF6/^".0BA!*CZ.CA3AR M9S@BAK65:69WLT^)!FP/<\J4GIQ`G0OL)_&F3V]%4N(L76CEDYP%2;(,[&IP MK]AK<>DS32EV/^9/&Y-O1)AI5INZ1:2OZ0C\U28)9]0$KBZ@B!RPF MK2M%"%)/NCB-:ZP+IB;$*\I\RO+5K"%?EI;5Q$ASQ^)6H.EY(L+VI4LF!$MN MB38[0\$NR@KZ@BPG["9*1DNKYU)<9>D<&EU9?EC<&"1K1H=[+#(O);M"QG!K M+6DOTB8&'X39X!!<(X9HR@#;()"@\NC=U@/LBH6UJNVV(#BH,%HK)*R@=[NI M4!P$5E?RE@@"P6.C"W=.$J)6DIFY4Y(PWV):FKY/IW9U"<55:(N$5!.VX$/> M3%M"^:"H*^.0Q47SSKRBY>"WB>18011V$%%@$`?_$OK4HWGS:AGE@R*SC$.E ME^S/3^8-Y4+&TY]JDNL'11R((L2`4X95OQR6:+>X6OCERAGQC0FO((<_5K"%]`7TB8 MRCV0,:CV6$N"/E!.Y*2#2*FUUWL[?:H%$9*,ZM7PV"D"%L?;S#\^:(]#4T/S MTCY%U@)NGR%C$B__DD`44^SNC>/IL71FCAGZ`>54:6/]"&;6YS!>J&D!_YD1 MO,I:H3,6I^D=*$!@S.F`A9.E,\O;XUG/-S\(U>%8\#Q0JB5RR_Y&HQX2]1LY M:O%B-#Z%@+5+S(&8%KGBQ"Y2M(#?ZI@6AZV`E.W_^F3#3Y:;C1 MP!;DY+>$04K*;@2#Q:WW@>Z(;2'<#W0+[1)""1Z-?<%K!C'\N.H+S);X/_'] M'"K+J;]8DLNY;W$G?#\D$BY(/.D&ICASO0G6K/# M6H6_,RJG_F()+^=^.OVOK5@Y)3U8.6BY%OD)W>^(^83OZ;2_L3CKDX5Z(^".!<``.1< M`0`5`!P`8V%P&UL550)``-YR$!6>=O_SY#__QTQ\/#SM_)0&)[(2X MG==%Y\I.[)?(=GZ-5_T[W2_=+\,._'%\=O@]G!_VCKNGG;\?=[]V^U^/^__; M^;_1_?]WKI]?.H>='S]^?'%AA"0;X8L3SCJ'A_0YOA?\^FK'I`."!?&W@VF2 MO'T].J+MWU\C_TL838YZQ\M%A6/VZP^'P*/M7:!I[7^.L_UWHV$FF*J%<'6X+^G^'JV:']*?# M;N_PI/OE/7;7@KD[GIRCTR1,9=S)9OR:+-_+M(/9F M;S[%F/TVCFVA)2.D80!2:;OE+(CVN:H>I@CD+*AG`\PO^8>^?$PODAC+R!Q?$42 MV_/C%_*>I+:O(*MX*`WR_F?H!QJ.W\/K>FY'$ MXZ0^&9%9;P`Z'`6V'TY6HH&E)=AX)(@)B[\$8>^Y]+/QH7M MT[7W>4I(HC*S90;;B',O\4C]=4UJM+74\+ZO M!%_^67S(>EL!2^61Z\V.EFV.;-\_$"+E;'!6^Q.ZLSG-%)"-UE0D^!LX@XEU MZ)*QG?J)1@$98VL4-YS97F!&VN70C87-QCFTH*@L. M\VLU]'*J*2WJXRB!03OXT!EG"-_H;_12%D4NB;P==&":;RE^=,$A@ M9E[[V=<67@6,[?LTTD<:'$]M^HPR>'A$_B5>_ M9!_J`I7+GZWU9N#2MV/8$#PGH?/KZ-UC34%A'^OD9&"0UHI544CSFK0RQ9*0 MV$SWVB*M*.15Z:/+8&N[L772/S9($V]#\,&1I-;95/'PL#DZV6..K*T]FDFN MRGM-HV1]`&.3MJ-/6?[1?R(3C[H0@N2[/>-]QEA-`7?7)#6LK6K3SQD?!YN) MTUTR<0E0(MN_A9W<^W^11245&VT!0V\_N6`"89-QMALR+M.(NFANO-BQ_;\1 M.[H.W"MX]SE\\)H#$I-[/".45&-ALW*^RU?DQO-)=`D23<*H^@4IM03Y^_O& M!1<&FX;!;FAXB6QZ9/B\F+V&/H>`4AN0^73?5,\`P%;Z<*>?AW`V"X-L*_$\ MM2,2/Z0)/>.DHE9_*RHZ`KJS?:-'%A7'/CW>K:/@!885.`=H$^NDMW=$;,O/ M47EW-RH?@3`N%>C&MWFO1*D-"'V^;TIG`.!HO:%]KCK1'TGDA6[U9HG9%D"8 M=)L8G?H,(!PV&EKBJFSD>[A13W6H/:ZA1+XE)5CA@.,SLV'/\L;N6 MYV7=&J;8<+]9V8#"X62Y9P2`1^5S#V.G(<*((:43D>W#8?J+-7*<,(7M2S!Y M#'W/\4A<=>8AZF+USFM87]*B\O`B/!94',GJ&_6@2"^=JOPISP(N M>"/G)OLY$W`MY&U-"='GH.'AC8:XF^O?TMR9^P8&69"(/@"5_:Q^Z^$W-9=\ M,2PCIS[U^=N04_@",]M;?:.^#/4X'*[VV:SQ01DY+FJ?+5R+JF[:1(METY.C M!L%4'V==0GMFJZUUVJ(?5_RJL#EBHS!SO%2?ET<8BT01S2F1H8;5W#IM,8BJ M+CM<(.V>1-V1B>WGI\.<;02CE75JTN%B8M/``]'NP5,N#/?3LMG$.C4:'27\ M]O.4N*WJ+:G;/492US..KW9MA0L_RS4\'9PSD#OO+4L6?N9+RC>UX/G\)YS>V3O?5X\?!PN&G-:.]+*8XJI_1W.J= M&XWUD+;Y."J7X:>(A$-1:W:Y)HIP?#*T>C/8;DHBRX^N:KJ M!Y!;#!01OSB\L-;-Y^LOZ(UEF+OIW:@3<-\7(8;BW&(Q?M MGB33T/V8OVO)'V';"/]O3UBQ5,IC6&;/5$'(X;BV6Y-X+PB@KD0"3 M$V1GR'VQR&O[5+"L,(IUUJ)1V81G58P.S@(N8,R=:"VFAD!_&&WM2^]V;I;.+,(K"'W3':K_!OS`_\G6& M`>6VF`_4A'IUE!RZSW8>`ZZULF+M"CI-+$F?5CB#U359O$1V$-N.J*Z.;%?K MO+7]%:WHZH*>'\8<(>.+1>E?.''KC<:SSDQ:5,S`=B5JV.]B?:AX`N#-GOZ= MF?222/F,FW,E/AX\XSM.<)Y:G;=;H8>G0\%AU;FI.CSFU(S#TUM;WP;BW?6> M#9ZW7"-G:WY*G`V>FZJ'4W\/0$T%.YX^1'3I6_[/R/DM]>),F9OAL-D_P0ZT M6[$-J#ND==ZB!T;#GJ`1;F01Y@(L#\F41'>>_4J-D-QUG,X:S0K>B-9YB^X: M\Y.B$C:RT'(!E.^$_CBCII\=+@-6@O"Q>$>,!K6TLP]D'&CTS]0$?CRZ?P#1J,H=N`?V(ZUX*'<*__` M`)]_X%QLKP[VS3\P0.P?D-(W>O_``)-_8"#G'QCH]`]PU/E+2`^>-H)`?@;5 MQ-7Z%?6S!BU79951N!0(;:8XAP'8KN=RK+-]5'B0ZVT-,(7.<]A0@*+-%.85 M:9I$)-M0<78PVXVL0>M!\;HW,!R0VC*D1;KG?CY9S:Q!NT4I.,JJTFA!<&UY MS+IUBF-;TD2Y)K*-.5J^?G?\-/;FY,YSZ'5H:V&JEW!!-VO08NU4[HQEZ%X& M![;,8K7:;8/6ZU[H7N/9&,VD%^^RPM@`1\6+LEHK5%\0VTQZ\6Z5C^.S49\% MX4>CO;#9/,)/R$>IG35$4)IB=B66U\VLK;`93D&BNVL(8+R$Y(,;,F- M+7^99BF1WU):D6:^+(LO*F?%[F$-6Z])8>J#7H486[XS0U9A1BVWCS5LM^"% M#`'2E!4@8DW*R$X+!%5Y_X76%SQ$:!+;%81PG!88O%'NJR MPP6"+1^X:5&JX:<+(!*`Q9:\JZ4DT@#'K1P2'\5.XL/UD M\6@OECEI3#[X/4!D!`[1VFR(@'&XT)?<4YR5V:2'+W90(F8.N69\,ENRC?QL*.*^A$L):]&Z/0R`^RS6G31:3AJP/C_, M*`A2V[\'Y`D)[,`ARZT5/UV/UP$$WH>B0MP/934N#A'ZO"CWGD^R6BXB`K8: M@H#[;!9S\'`4WE[R3&YY+%_8JA.C4D,`LZ>6#CGZ'!)%F^][&"QEN`V< M<,;=SE?U`;$_BPG,AL9A!'==>JTW$'2[>VI.UP;+X;S-E!Y$=Q%TNWMJMVN" MSID=K47-W+5Q*X'9PDOFYX`Z6@[M^KPX3\1-'>(NO4?W=@#SD.[;*AQM%5U` MZ#W='\DAX]#16B1-<4))OF56SVS:PF[?HAP-AY;6$HCP5`;N80B>;T)V(^"< M.F''.R_B.DJIF][W[.")C-/`I<'-3R0FH,AIX>@EG]--BK5R5_G\6:/`+3SN MRHMI)4SJ=*XHPZHV@-6M$\G+$;L8-,YZ/J^:JGQG$->D6YE9.[6.0AD?*P5\ M>.JE:DC*O/3M.'X89ZD;L@F9FWU`+2:=S_+7=2N0R%X?!1"-U%5M$&M?$%(< M:;_5&#`9=4JKIURRM(N<24+O#)[ M`0($1PN\UX#QB9.!@^RNF.OQF-``&I*[8??0X/W"R@'R0$[:Q+K4T M$WK1R=(3SU[^*]X\O0\"7;9=4*_1CLBD5I!=.\,65>(DJZH?(&W[TG8M_$N` M1'9C3&;!YE>27*:1X`1EN[%UTN8YO3[B>,BP7,-R21<-F$,N_!&'ON=2C\:% M[=/8@NR?P:VF$5Z*4&EK=$Y,'0967G?`4*+#, M"G+_;HAO;<'[)L]TU$H4,`A3-KK[_"S*O37H^D9C:W48W?VMXODB/)_-Z.YW M]\;H5B7+@-&MA[3E17*OU#9UJK9MY8:`"4'DJ]K'C(4`F>5=VCQ*D[+1'I`A M"'ME:;N*%R8(9&;K)3VX"USZ'YJZ,+=]&ATZ2B[M*%IXP>07VT^KMH%2_0$Y M`@]7!2F<=4\>VR>S7KM]!,$(RGSQ@&B[!<;`BBB[$@(2!"$#RI0P,&B[/T8/ M&S=4B^3.FQ-W\YKK[Z2*GNJ.@!5!I*PR7S*@]-U-HZM<8@CF9+)X]&T`&;AT MKPG+.UBJ]2^(SJ/=!H$P$KA0=GTX3>D%W45"=;7"E.A$X;4P0)SM%RIK` M=J-0X3H(H9][HRD`0N#?$2F,=22#]>6OF2^U`^C.3+@/E0/IS;E0H2^[?`^FWPFK/3+H) M&@72GU7L;"OA?+9`^C.CC@`=@?1G_`L7.7@^6R#]V7!O`NE5R4(;2%_P)\%. MX"'*,+N9R_"11,]3FWEOB4)O^+R@,"]5/GO2L)#%X1?DSH2,1VDR!6/WGQ_; MQFH2-WL!2A3F74WRV'"P1>=ORGL;QZD:87D/0(?`R&I(5A$*LH#[+5D?TB1. M[(`:_RIL%;H!3@1!!0TIV\*#.G%\#18^TLO;`^B%&?MH^`Y:/!&H:?B>H\H@ MYU_MRY+[=\-W:QMLM"IP(\/WO$X&.;_L[_X:O@/T&>0#I:3DP2?,(!_L3P:Y M*EEH#=_MFX/$46#Y9Y_ST,PI6T>9U'\0)*O4C-6Q_P7=NPYU+[R_#0AKH2/2'($@(\B;5"%/R5H MV-+V!<+79Q3@(C`\E;BI16^.$UM6_W\3;S*E`.>PA9Z0[RE5T\,X`U`XF)9G MN]Z`H)R]LV*;(*VN'(#IC)]6=KSQPQ][><3?:V]74O>(OW>,Z8@_4Z#4$7\F M-YXC_I@X7R;A'%XCCW+6IW]0JOH%JN`GZXY,;/\Z2&CZ"OL8G]$*U(+UX#ZC MH4P8%X"1HWI9Q>?"<(][-YN`Q.T>Q'.UN*WL;;F-'+@;U#2.X_0&*D=[;`XV M'/VB/D;AW(./]<7BYY@>+:V/,$;T"JB\TA##O2EA/^EY`.@0IW^JXH.D$SFR MTWM5[V*OB\`9I9,/H4V;):PE9',/*MT5=!C-Z,">:#^P.@`V!QZ?-&5"E%WS1#Q$! M2:](_M\"YF5=+8EODOP@5L_HU?9HOBZJ&D$8GK`I/XWL6556%=6ME^EN]88( M(H-5B9*FFX,76W3#MN0;%:>56-[H"RI#8&N:HI@)%EOH!&=F;E>H5G^;M\>` M*?Z)^:X$C3!THL$GSI@7"C3^;V%=ZM`2M@@0#J;;8$YBDPY.Q0>`\G#&CZ@[ M.&LAQQ9>T@R;L>EB]4X0?*MT$F]B:N5:PA;:PL%TXP4V6/;F5B+%!X#R$#CK MM:Q$M9!CNT2C&39CTP64A!&MA>7I:875?CQ"PR9JA:% MID_)IN+Q\.0XFXCT%XOYG+N*J%B)7M9)OX:]IR(@+_95T`,$,VEU,8-@I?55 MGM922/Y=PF)/^B;==E)AL5)\E"GD(MFK^-B3OE%_5JWXV$R+V\K>EGNOXF-! M8KSQL9(J1QL?2^,N)KD6'\979$RBB+A/9$Z"RHUS53?`VV*L4PHC*=_`M02P,$%`````@`ZUII1]B4J937(P``6M\!`!4`'`!C M87!S+3(P,34P.3,P7VQA8BYX;6Q55`D``WG(0%9YR$!6=7@+``$$)0X```0Y M`0``W5UM;^0VDOY^P/T'WNQA,0':,_9FLMB9)+MHV^ULWWELK]V3V\5@$<@2 MVV:BECJ2VN/>P_WWXXNDEL07D5(W2>=#$(_-*E45GRJ^%8O?_>5Y%8,GF.4H M3;Y_=?+F^!6`29A&*'GX_M6GQ<71GUZ!O_SYW__MN_\X.@(_P`1F00$C<+\% MYT$1++(@_"6OZ,')FY,W[P'^X?B/1U?IT]$?CD^^`9^/3SZ/N'X^.OWU8-7[&6'YYSU&K]Y>NJ[ M!$FXHR)L1'0G[]^_?TO_BIOFZ$-.Z2_3,"BHJ7KE`M(6Y%]'5;,C\JNCDS\< M?7WRYCF/7F$;`/!=EL;P%BX!%>!#L5W#[U_E:+6.B>#T=X\97(JEB+/L+:%_ MF\`'TEGD"^_)%T[^2+[PN_+7E\$]C%\!TO+3[5RJT/L6KY+H+9;2EIPW,$-I M-$N&"=REMB_Y71%DQ0C9F_0VI5^D11`/DKM):5/B*SC,SCLZJ_;%01,.LV^# M<")A&,*OD(M2*N4N8T'M,02=BF88MA3()S MFK7U#8-U3@>BX_=?'U.-R&]^.D_#S0HFQ33!P:%`Q7:>+--L18/[]#XGPU)1 M,:+B4_8_&=!6VE?ZMT3-8)YNLA`:Z1"8]YF)(,[3`Y^G3WZL\5 M&I$]W=T?%*.ZK_#OZHE M:0BP".YW_MF`F;JY-63U2"T%4PM!M+5#^.B8OD*,OMU-0;(,\GLJ^B8_>@B" M-4'*-V]A7.35;VB0:D"F_/5/>/PO(!'H+`[R_'IY5Z3A+]-GE`MPHT%C#3PZ M\G<11)N`=`EH(QQ]<#.'T-'N@@H_AO:W!Z);F$.L]"..@N?P"<;IFD@W>U[# M)(>*\]QJ4H"3U8N`;U'E=*`[HN1'3*CP#W201"9?B M[YYE,$+%`D_]3C';7V0S+&,V=B=;YEKR^*LX@!J*TPX4&1<\@&(^@#*28'&T MLE$YY-'![G!*+QXAP`U1!D&$\C!.\PW^$8^R0&2.WP>K];.3,,PW>`N3!YNTAB%".8:@X>*R/J(H=2@B]A= M8U"U]FIDZ.^.[G"@VQ=CEM8P#S.T)K'D>GFZR5$"\YQ^;=L;^/5H+2^M]?3A M5D,[,G"]!!4A^,Q(P>'#^A/,[M-ZI^@WIIS6F#54N]WHA-Y+YJ['(A/G:^^3&'O>B!!QEJ[60;+]*\HQQ58S-O00V0T*?1IP*UO6 M'I0$GD6!EZ.-EMN;JJ/C[V&I\B-CZMK/M3RHY>`&[C/"LT^#'.77RQO18W?KO9: M468_ZNO$GGMJ(OSG===$JYV)UIBMZZ@TPOM;L6JTZ]M;$7_*X?5REA=H%110 MM2??;6A]Y1-VC%1)1ZEB/Z$";6_<1(0\',N"*F`;I%[J]#^:2S3<\S1W/7 M*X="V9['SI,"8N@4\^13@I(PS=8I3>+\KQ0EQ8]8<#SWR*^SFR`K$ICECVA= M2JYPX!$\K?OS&/V[4*]X@7D"VMP`90@I@$/(,!7X_>_EBOJ1>+5_!+XQ0O2Q/\8TB7Q:6$^FYISLJZAP[0MHM@ MS`(T3W);3/Q&\="^[@)Z7$?;PW9U\(1GU?+UL3IUN@BV%-LW;[3UG,.-A]X#!4+\N MLBIRLJW7FH"#BD69G^U^FO);4U?K"&&DOKC!)@ZR9C8=.22H=,6+L%T>/O[# MS]0D3^PCKH\*AGANZXQ@N-N.B#=\^I3L"H>ZN=TH(I=:*^'-]0T.'KEJY MZ>]:1DF/GZ>K`"6^]'G;HL)>%YG37K]?H`05\!(]P6B.!_WD`>&`,\US6.2G MVX_!SVE&KP+U1`$C+M9Q8Z9C%U>,^HB2@QT]8`S`Z190%H#=`?,EX@SHURXZ M!W>J%^C="7@5K""+"L,0+.;D$XHENIHA>=+",6'D43`=V-$&D.[O90=79\DF M;K$E&9!I0D]J-:_/BNG<7:&5Z-$%*&L&=NV\":=:/2*]3=O?'?:PU9&E-S!* MVEO'DDSN/@QY%,24IN^"1\/N=I.GTH3>!N]=(PC:.DF%ZLHKROY)D^K&/FOF M`4BDIA8E\"CL;`\<-Y@7S#(8Z>%#W-PZ1"12=U%2-_,.*"JS=['2;_-#%8^Y MA`]!S`K82"8OPE962\7P,G910%M4=893\M6KA0;Q6 M&;:U^Z^TJL6Y'JW8;F)GP]MK:9 MF?T$J@"32/Y.LC0'F<' M/@VYYD<.P4GRXC1Z(F5_09&"W0#K,E')CB(EE2V@E4>W5%+>P MO&.=TP)C(5,WK=6%;%OT*8@W<`(V:_S'+X\H?*Q:TQH1&?Y^%N7MA"L04]E< MYUV-CQZMR?:^0H?MC?N/L'A,HUU`KX6[@1BC&'$/HJ2N`3P<;?#KZ2?9]&?$ M8$<]:3C\CH'[4=ZX+\6G`\8=:0^M'U&29K1J-;LQ)A#M='L39/A'!5Z-N%A' MK)F.W.T.#)4T*?"78I*V6#$10Y8\7,(XN0?O@*[MPG=POWH&X'8?LB9CX2SF MZ2>X)?J/AGJ'@#5[(1#2JS*G MV]9?)%GF(_G9SV09J+?TID>Z!&5[>I]\"YJ\)L0'VG]VGLR^%P1P&3+CN]]F M+7JAB)C^)+S)KUD\>(T M5CO('UE=A?(?TQ"O`'*Z6NUF,M(_93`Z40!R.$O[%ZF':R^:AY!B`&6-$U#] MN\%N(DCQKEBZW4'?HQUN,,R3`L0HI&]&9.CAL9!,KT9K5S0>_;*H&],)!,JN MLWHC?J03'F^P\8K,:%;!"'(ER0R?7@[@W/GX%R2]7:0*+(-NV MX])>7=_X0[Y%!'-+#0H4^#.@\9WN?`>\%L20KPZ;3E`TWF!U9SU:,FH=H`@$ MQ:X6@=?S/[M*>Q13!T85PU`[*J2,2)KX,27E`#H'D9\25.3J%,U^.KL)$!IZ M=/'(2/B3>TKE2V*G;O^T#I_-.F<$>C!DV;?J"P`F&-*EMHLD;9T$0R(H,;6[ MU>$IK,PZK@6N(;TVIK+,0P;I)4=)IK"HD>4J,AT)N=HQU=^=YP3+#=HN$R.W MYCXZ4GI[0]S,46=*;W$TNM/Y10Z58<5=NN<+';/G,-[DZ`E>LKV^^COJR-]+ M9K?3^[7@$H(J"E"2@`8L_`CQFEW3@HE1OUC,E0B>T6JSZKWZV6EG/Z>A(V<7 M->7?/4"(TK)<%H'4MFY'(ZZ):!-`6GK?.ZHV0=K@-4I`_AA@_;[RY8[0<#O<$45`MKLBU+[@@]IW*9^88;@K M1!O"W:=K0(810'K_9Y#[[RF*#;O/,XR-N^@U[%9/VWVYRST&=WNLQZP7K[!Q M=!JF<2/M7QJ>5LP.NRBUBTD^1:,!M[G&N_$AYE)]!PC&,ZI^AI[,JS0T-YIB MZ)PX>1*P?JMV&#?+&F`(L[E6DM;SK75M&2_#VZ`0H3?E,HL/^P]YHLG>65KV MF&&TZ^'E1:#KTU??MR6+IYJ9?\'MT+J32A-'E;/[O8@T-85!9!.O'AP=5A&M:#%8 MD_5.$^;HOCS9I>,C+8_6=Y`1GKOC?;V\3;=!7&S+1\!D?JNBL.NU2MD5:_SK M)2B;5R_;.719[Y70A6F`7S4HMRH?W7+MIOT.TG%37&T:XZ#E\@G&ZIJEV M88&>:(KWQS0I'N/M!92.K[UD=IVU7XLN3!H48$<"2AJ`B1RZ[0M21\N!S?7Y MD11Q:T[$HX:"P4Y![.*K4L-/&DOSV-.DV@:K5""R(._^(NP MW]TUB5T]G:G62/&0)JNIVJ3T)`*\5-VTPL%0Y;B@$+2U#=K:>A08C)Q/\EZJ MMN?M:??P&B]V`O+AV?.:).+FM(+3&:NCV:Q?H[-]:,#,W?ZAB<;J3;2:$ZA8 ML8I@H&36*H7DR0[BWK2?"-2?V-??>-]PC`$ZM6G3V@"PZG^4A!MZ]'&_;>\J M3L@A24;J\I`R0T7*[OK7!6N+QH==A[%1X4&ZH3@P-APJS$UCR@I&B[2485"` M$['Q*+0)M31V:U"S`8NT43P`D%M#1RY&H6VO0Y53<4H6V!8W&U5ZCRQF1 MWQKH+:\,5)@7S?44\5]:/I_LJP1,NU5#NW(7-0?1)B/Q@;3'?H'2R+6[][I, M>U&EYR\C7/@CBF%>I$FOZPH:VG59D:3\A;&RC0\>ZI7`6@ZI(['"$5>U,O[Z MGQ3O+;_K`;O%.K?L,*4<)4MW!9PVH^T5@OI"I'` ME<\AUN=QFD2-PSW9,P$F MQ':]6UN^6B MQO;?MQ5)S%5O)(T(JLIWZKVY1BZW-_?`;8^Q]_&P]71#3@AC%-P4V\LBTGSG M6D+EZ-EKF0[R5[!K"H!)`*;QH+R)0;^(G\G6Z)01B!%'KG.4AW&:DT<#%<]^ MF#*PBR,3S?C=<,F0M2/WY#&089W80MK`'K3X).1R"4E:%&33M47P?!L4D#QD MF83TC5]2N#9-(CP8XV9XS"W7:&+%%,/@OC]D_W')?5N**SA7?:!EDX'\2]$:?>.Q9I9!?8/6BU@>8'(B0T*XIN4E2V? MWI,Y4JB*[7KD]BMIZ6G%K:\K,K(4J@E!10D^5[0>K(Q,.HZKM67<:PX`V?OZ M8Z>A.Y!)MVMJ.#G?DU%;5XH/IWLMM12JU9*JL3M$J%9!#51XL=;I-[<4'L[7 M,.53&OWC5+>A=6APDG(I+^SYG+XAQM9Y8[^\=W>SQ9U[V(HAT(6LJO]MP_6, M)/PEA39JN?:.P,O++<;P!)0M/0-SO_R5W`%M[PNV)7@10UP)%HOG).0!I"0B M_YO]ND%/04P.0:?%69!E6Y0\T`M'JJ,3/7K[IRF:>@F?QR*K6OI#@W1"WLNJ MJ`$E/^P;:9HN,UI1^F`2!V6I(5G)%EQ,)6F=W\%TZMS0'^8_>W3_,?I MY>QJ<3O&;:)S$5T#L,:\'7"^1>H`05\!(]P:C[*OH55$&Y MC]`ZMGLUZ4*'$1Q1"K`CJ0,YIO)BJFJLV$U0$&>(R\>],O3P2/1)H`?'I'IX MZ[J*"=CL^>:D]1TUFW6]ZM.#`53:?`$I`UT(U MB3].8ZC5Q2;#"*/74K$^<*>/%TZC`[2NR^BCS/8TJ7=^Y&QBI)@1>3(1DLZ` M_)KYJ*<\KN#7?(H\B6@F[6,:1S#+B7,46XT=:WT6UB%LH!V?"UN3TOC7)`:, MVIN][C%JSJ>G\\OY8CZ[HSM!9!-H\0_W/F.*RZY7#0.E$[_3/QM2$;GTK?Y3 MED9C_XZ*C#2IA(]W1%YYB^;)D2Z4+$Z$6&VV_";8D@P4C8TC"8']B9),^&C3<5$L#,58!GVU@Q'NB&O,R&A>PE\HO0`YI"T3C M@'/P:VO!#@>"4A>O1H!>,`E\00=)+F=$1C,A+V9`FC,?#Y;.6K*W#Q*\PKL^ MT/U!.+\*F2=AO(G(0U9I1A.QBR)#]YN"C$Z+]`J;(DT*;!8LR@.MXPASG77" MOC_D(*EVSY;B$W)W'_C][[Y^_VVYI">55O_3%0?8NH\!A_$G/O/Y<,[D,O8,BB->Q80!_LTY\TW@U5:$D9)GP9I5,EO@:6FP MAIL"A>29N6S]!L@,X*/7FGN@:V]B3[51N7JS6KFF]A-8>6DY*+'W]VB;2962 M.L]SO$(XU"P5=V9_1JJ9Y.`_WQP?'W\#UD'&"OY]"TZ^.9[@WY'_RI<50;`I M'M,,_0M&WX)WQY,__>F;R;N3D^JO*`&DT^F>/_[A'4#4"O3?Z:;("_P#CNON M_4B&02[[40E`B]L=440O&P;Q38"B>8*C%\++BX9XJGT/#6+[&R`Z&G$[(341 M(%3DM>.2;@*:6':\*S)2M36F.L*N%#(Z]]ZBCSYNH\00>C9+!A0!2F`T"[($ MAZ1\&H:;U28F9;3/X1*%2#6WTR%V4#Q`0R.^@@`C`A45>-V@`R7AH1[4U:WE M.42SIAH1:^7>D_11QQ=#,(.JECTY MIS'T=MFCO]QQY18?48(GRF3#@VUB*)R";VK=)032#G8(R1Z?VS%$0\&.W$@I MMTWXRZ#4!;\:1R]MK_[@>_1>C#P#+;.W/7GK_CIP1-N3G=@HZ.^X-L91#K/Y M[L&1MC`)4>^`6T+J73*M^O!;ED3KR2&XKD;,^>*.7KXXHR[@3+-E]U8D]S2( MR0M!=X\0%FS1\0CQ]#V(%:=1NH1VB^+J:-(%3TD#*!'XW"+[Y^'/H+0>/!BO M5XO*]?,&VH!K%?(U1)N3@R$JAD_K$ M"A."ZPPP4G9^1HP1$>'83X`%TC16DIU:2O4U' MIU%]P%0<4.FATHF[43GR:7UVJ.=F/)5+]Q+HH'8K1@!V%-ZXDKXJI0MQA[]> M^8P,70I?44/+H8^PM`$3_Z@HW/M&+;N.7QPX0V*H4_3IT'8(I%#!J3.T8=3K M""(,.72"ZUVJB(DGM,C5Y'NZH(LB+?M;K)G'/1_?#R$% MC?T*>@KYN3MG5=OJ00Q_ZD4;J7$SNYTN2-7,V=]O9E=W,P_*2/?"B"NNIXX[P`TRP1/$TB:;1"B6(2$->PNE_-J:7TKI3].O2Q51)07?@VS1^O-\\3J.@ M1>/>6S2QUO49(Z!Y\MS2[+D\8YR&OVY01@JLW61I"//\+%4>ZH_BZM=33;TV M,'W(";RN68**)\E^+KD"PM9YDN;!#!+M^+EWY3V`W^BA*Q/D.YQ%FLP>?9@U M:LT679ZOZTC,#M336FZHE-OI]%![6NBTEOA5FM369.NV_ME@'Z&;&N,J3<2E M.9H4U;N:KTNBO8\M[YDJ"7P@YU6]OF"J47VOG-X\H^I5OD%.`0GQ5Y[4XM3# MG;!4N2;H;&].7:9Y?H'U/$L3+-D&"U9KDIW"99KO'1F$^>\9SVC3#`UR0 M;>G;6,;9H`?]JJ--LD/94++1]II\[RM`O@AVGP2[;P+VT2KE^R,L'E,R`WW" M;%?L79;=4[QD)[LE$WNSC91PH5=6Z"*3/CR;DXN6<]4Q#>[L.9A1`@WF"UX/^V M`RD6M0SHIS"!2^651"F%HP`FDET2?,CCW?4ZMVQ]J,6LULUY8PVP[V$WI(U\ M\4`I=L3>TP,),RO`WFSDHK[]3D+N#A$L0&M,]>@"QH#A3:WK;`$N MK^\DAQ%V7+6W,V+\)_<^R:-:4%Y?"&E[GH>MM1M)1U[0&L#+NA\/T;?7W5U? MKM+QF7TH?@GS_`-YG`/0.6G0J0R%5Z<@\?4ZY6"@=WUV),H=N;:NV[IVR4'N M=IC+^`-&3AU5A*ZC>T/?,S_2\A%7^*^*9E0I\:=!CD)RVH+B#>Y0C0P8;0[6 M?49?-ZX4957RI;[L,0&4FIU",GIO$F:&ZUFKAV/',LU6=$_@@WO_,41EU[,& M0=(;GQON:_[YV%#?\MJA%.NI";BO58E8ZXG6."88QKR]E*6)7T.O=.6-_P/) MHXTX*F!P!`_P:K.ZA]GUDHK8R&K6=]*A#*W[[F#-N^BO&(&2$V"LR`E&>=6K MP/PW[7P?,JT\^LE><+](DZ_Z"1\ MJ\DF(/2`@.YC2@N*\/N-C,V(]E1-,PBNJ*-;C?@M>$.T#)5V"7 MQK;[PD1RJN_+XNY@MMI=G9B>+>8_TK<:W3O_?IU&L.6R=X^Q6>KZYTV94T(V M4;$B]'Q^D=Y"8ET4P]:6TB+5U%4CU!S^TP[*;!_P%%6C._3(K8$1;@F93QT\UZ8J/X_D1'>/HGC$(>S6PNH97PH=;O6M@QVJ&:0:Q,.>0_;\Q M`):/=.B5EM!FXB(/55]#06(G)0*O*_*O2'[Z;@I:LO!F_CE*6Y:!3YYO8G=E M=O>`?)E:FL-5D.NC.:15A*"D M]&T8ZU>LUF"MTL"M&TG@UN]#2JPY'YNP=-D&Q\A="73S`4K$PP.'DNMG-%25 M',!EWP/P#B>*VIHRE8)2):_>M#<&J.;PU8?.EW+2>K`3UA=WLGK0$U67%4/V M;A9JDB5-G=@P6S16AD'-S;WS[\?D#'>5O.K'V=W+R4A8Z#3:`:241[S4@+*P0+)BPL@!PTNWY*[JY5N=KUFB:)!!'F'.5AG.:;#&JL#\:S=N+/(ZTA M]''"LW'_8K=VQKXO&MS!CK4W*X$#V.9NLU[']!)E$#=53I?$5D=G;6,US',$ M+M$:K6"!_OYV^J_9[?/;L],Y>XPA1W3<\R!-;E^N)0HK^_,K>Z'F=).C!.;Y M.:2#_A,.`'*RG&L\%!UFYX_&.E=5Q\)<_N^?9:N[G$,HO=+ZL!CXM!]#)QY M<:]F4OPV*%OCNG?>ZD!%%UZIAU&9*YH`U)[_76+9KI=G&8Q0<1&$)#MJ^S%X M1JO-ZC3-LO0+RZS'?RFV"B\T8V/=%PVUY.JD8G(RMV0,0,5A`DH>H&8"*B[N M43ND9[O8'=ZM.@@.@W5.<7G\_NMCBDKRFY_X48J(02\#"Q#83V(-;1K22[*> MVU,2"C=*X3#XZ79%!1FS?K"X3]$"[WFZ"I#J;JBXN?W]!+'4W!Y!.R"!SZRE M!V.FRNS-E2K0?_5&/9OCO(@<^, MQ@-,:?4-_RRC=L>,&+-N8;0)8?0Q38K'&`^12?!`MZ#'(9O'M*GMQ%$ M!`'OR`^DX]\U.A[_ZJ<9]JUB>PL?Z-/727$5K$114=[4&@`4TG*UH6DSL&L' M2$-W$.@S=`4#/2L?%@IG.`AE03Q/(OC\WU"TKZ!HZP`,O+P2-)0-`6T)<%,? M\""Q-@\(I:D/A8CR9OD%RL,@_@<,LED2G0>%+$#(FUO%A4)J;HU65@=@;0%I M#&:DH#1N[A8>?:9O(D3/[H<-&QE@Y#1E542,&@S4+7S M(5H(CL@=N^%MJR MVJ'=08="V'FYB;#`;"58:C>QBIJ.=%QUR?+/@/S=+0I$=FSVM]R(A^K9 M*?Y<1/RW)@U4L$25LG MOMR55^K49=JV'PL#I;5%CJXP]:$1P58D3(`+_#O1&7%/>R?($,DM14>Y=BQ! M0IO[@1"I]44HZ3&]':20M:L^3AJM':*D*7,?1NC^@G<(X:PNQX?$Y(=&1^-5 MR4M%NDD_B1.<2*27@J71WI-\$]V^$`&GOR-&'.U>;)(H"U#>2HY7W&+1(;)[ MO-NG`7?#>M?>Y)$.:^>@6CW2.@DUZ(Y](T4OF]F0W@/\Z"7Z2J!D-YM9*W=@ MA)+S`F15$D$.BD<(E@VU=Q>-R4DQ^2NI?Q\D6_*^*JJN:=+?LPK6;WQT+XV$ MYQ$8WK?3+235@'LI/'"LA:1`KBPJT_9>AN2%J$BN41?L&Q>JF9T6E0?X4,WO M9!CQ8H9GT"W]8!DQS]M7HFB8/B3TSNCU\APN89;!Z!8^P62CJDN@)G.0)JK4 M@D_]JYN3P:PB`"6%^P0HG5[A,T3[N@1KPC3#J/L%_QO_"_]PC\=MJNK_`U!+ M`P04````"`#K6FE'^=$4!#4:``"VF0$`%0`<`&-A<',M,C`Q-3`Y,S!?<')E M+GAM;%54"0`#>`L``00E#@``!#D!``#M75MSXSIR?D]5_H/7 M^^RQ)=_DJ3/9DF\;;VS+Y?&<))5*L6@2LK&'`G5(2K8VE?^^#5*R=0$(@(2$ M%L\\'1\-`.+KKW%K=#=^^]O9V_$D82/R/ASO-DY]+/_*?$#WY+9_5W6E]:7\YVX(^# MD[W[>+S7/F@=[_S/0>MKZ^CKP='_[OQ?]^[_=ZZ^/^WL[;R]O7T)H84L;^%+ M$`]V]O;X=R+*?GOV4[(#'6/IM]W7+!M^W=_GY=^?D^A+G+SLMP\.#O=G!7>+ MDE_?4[I0^NUP5K:U_U]WM]^#5S+P]RA+,Y\%G[5X,Z)ZK;.SL_W\7Z%H2K^F M>?W;./"S7%3*?NU(2_#_VYL5V^,_[;7:>X>M+^]IN`LRV-GY)8DC\DCZ.WD' MOF:3(?FVF]+!,.(=SW][34C_VV[@#]-\_I\OXV`T("SKLO"*932; MW+!^G`SR7N_N\'9_/-XL=)^WD<6,9*_OG(=]7F:_O)E]Z&7-?G9'*7`?49]! M_1$+_6?>4DK\)'B])&,2Q4/^_8N$A#0SZ+AANQ:0]$#]QY2\]?KGHY0RDJ8/ M<40#2E*#;IXPOKJC`Y+1X($,,QJ2._A. M,(I(EPS:'="`+O.C^"5]XK(T`67UJVMAZI)D/HW2)_*>C?RH%E_+36%A;=JO M3=/V\5EDBU?MR"5:YC=$I^"]KUT@XR.:0:S16646JU9Z/5%S$+"4A+" M'RE,<2'?3YS[$5^4O[\2DIEHJDYCFUZK*C-0ZRL;8>;!3Z`#KUS;C9`9M[PN M--]APTFX$-->OS?D>UG8SM16.%FKFT!QX:>OUU'\9A7$7*-K675KK;-X5I1- MKR'K6S7JKA-S/1LF,&6Q+!\#M]"1A2[";$5`]\)9)WF+-<\B^7D)OAO%P<*G M(GY2BQ.5./@O7MD'NL]\5@ZR64.1_TRBO'E/NZ[7_A20;E>G0LE/CBD)OKS$ MX_V04#A!MH[X'QS&T=Y!:WIN_#/\]-&7N2[DNV=!W\N*>X<+W9UGM)LL=AW6 MIEGC\.<*G8OGWFF)_6$^V>\%KS3ZT(1^$@\J2'7:EU@/U"B%[L5#_AM?9>(D M),FWW=;N#D#LDP06UMM"0E((>?]S,=9CM.^GSWFKHW3OQ?>'G-;C?1)EZ>R7 M7$WG^)W^['W,TQ>1G\)<_3V+@]^Z[S05D*RLXQT>=EQRK2)LD5Y-.&*6VUO% M\CRRRWC@4U9"[VIA[_#HP"6OFDR)Z97!$?-ZZ(#7&O,Q+(GD!F0B&JZJ*M[1 M]HQ5'2QB0H\0$UJL18_DA?(EB&7W_D"VN(J*@M:W$%*X0,HJC7(D8@*/T1-X M`?CAI'T#6]'W_R"34@:7R@+P]K92*(0BYO`$,8<7HX1+Z)JF@1_]-_&3*Q9> MPCHCH5%6'.`[W>=68[(8`(*8JS/$7$W7@'@PB%F^M_[^ M"J)*>Z.,WXAS?.7K8$E%$,G)]K&JBTMB-3A`S/5,&$_0K.*@P8MXA^TMY&\5 M@80I%P8>7::Z@"#D**XC7S8`%\H`TM/MXTH`04*6"SN-Z;!Z(`F-P_)MI[`L M(,=H;],<:`(H$A*WP2A3;*$+3-?PF\HBLU(>5@>G1K9Z9$K@2`C%;)191,3/ M1/IT?I0&=3[;=C*7P$BHK&.>`;GL+U_PK?'BS\R7S^@FT(Z9?M:9+LR)G_VY M>A_RZ_62FT.C^E[KS'P@26XZ5^6X^.E"E-RKY!R:_4UVZ6G8C-=&<1NA+^W% MD589LOW[Q@T/P!*O5`>CK1L$\0@.;>QEU@N-(2:OY+6/K8VK2Y(&"'RGI]:_2C,*^G)3YVBP6]-R>*BI17H+$THT]!D*YW9=F MN<,KZ/)%G$N',"X;]0Q@WHCGUE902Q$,45KR"L"@)#?SCO#MOVDL>_"1C)$E?Z7`JD1*=J=RFY]9YI)8*U0-MR4L)&;P9U!$8Q3(]17$ MM"G/K0M%+5VIA-6^E\6&C3(VHVH=6'%F1@#853Q35L1*:=AQRJIY2^X'=8Z( M/$]`"/+J]>?E_.!/J*4`\(4AK48U/Q#QH1QE( M:-B2=X3B4M*4YJ5M-5_8>2SPBGP%UD!1KQ&%0M78=>0.T-=^0"/Y+"G`DQ&V7M>:&C4E:^%[>L&Z_#^K)O7&_ MCYY3&E(_X?>/:1H'^:]=MNA05^J%6*-=[QBC>6^)?O&`KX];HE8;]CN33`OS MW;V-TY2DCR2(7QCEW;U(:$82ZA>VDM[;U-.R.);+9HWJ+7HG3BU)5;3$!F*) M?A@;G3#X)1:P[DCV&H>?(^<#]0-)`L[HB\B7P[@-[\1]WMF*LXH91HF&N+!? M55>-.\KB)$_,6WAV"\">3XJT[B7*8="*=^+T?%]'/4Q12AQ,7)C,UJP@]S$+ M8I9!;^'[+T61NNHB:M,[P6A=L*<\4LP25=HN#S,NIUY_Z8CFO]/!:'`>)TG\ MQ@]P_A#^1;B/J=(,,.+4N:&.QICCE&A)'0/D-CK%S]XL:HA7_,FIJP'[Z1G^ M2"(>Y\4#NR9/B<]2Z!COY/EDX5\D_L"UVO-.4-@>E11)G%$J0\;C4[S>V]$3 M%!;'ZCRIKT]/I.9'S%GR3&]/3YUG41/)77%[>NK\00*[EZ>GSA/3KXA7X_+T M5.H,LFUW,L*IH\RDKUO5.T7AMV]KFC2"W03_7'ZR\]/7(C9^^C_=X/<137-[ MY+*O*8KH\_6I5"GPNL[&9X5&,=B^9-.R2#7JGO`?!_S4[B>3Q=%E5=$, M/^2=.K4+KE__JLC#DM=T%F=^Y"Y(>QW/-C?$,'3Z!S<,X7!*4U)DTS!4XKZ& MV)10S3"$PQ6M.D]JPY#<+ZU)AJ$..L/0J=HPU&F88:B#RS#4T3,,=9P;AB0L M_!KSZ[PE[Z$?C&9I.2VJ>E['>0R*#D]:,-R:;23$P2ZZZ/Q'5)H)?7JUO0ZN M$!8)B09@W`9,RWRG7Q*21PU+]A2KA;P.BF.BK2V%!*#;V&<56=)]@ZB8UT'@ MO;$BX#(6YOKM-FI9PL/5>Q#!@65,;FF0OYHYG40Q!T(*!`PI8,$ M3V#RIM)Y=5`\,1?:.94+$M*WVO!&!T'>4Z1$W7\X[0Y&B0Y.XE9XW(N"9!X&1WT<@IJLQ M*=Z5527!$M?PSK;8YT*^*I:A;41HM`"@,NQ=6L<[0^$M44::-LUSB!R'0V-. M>G?6*".!/N9&!%K;28MWAB(CIIHR,=5R3+:"GK&FI$JA-"*RN&XBJ3,4=@O;R[`$:"-"A:UDFNJ@.'-):-+A=!Y( M(\)VUY1IRNU-MYH[B8U2#6H-4;C-"F5INW5&6=MM@Q9NB79LEXD-9SJKU@$. MJ[F6'HAUR((`)`JVX==]-1);+6"5>Q3)KJ0K-`4"0C'S5-&0>I@E2K'AUWPU ME*):DJHJS8!@4&PUK2B#-EZ)(FPX_,UT=E"YJAG/$:H&05@HMJ?V9PH]Y!(U MP9<=<0Z;:/:[B,=%.4,-*6T+1(3BBL"V&_,I<1ZL>A>S[#6:7!/IX%14`^`H[/Z5.=7")R'6PG/+5O.7\V#; M<$`9Y9&/@(6HZ=6J#$)`<1%0F60#E!*JC2V'S<])W6HUYR!?!;I$4XRMB&O7 ME-Z0<%UG+U?O0^YNG^;Y3_D=J<\6;*TZ2J+=&`BI.6=[0]02U"`]@)75`D"B#=V@VD'C8)B]OE M!3BOO)ICVFOC"*VR-68+/!(VMRMJ%D\RZ3:.&*TZ.E(+ND2=ZL3F;CAI[_6( MA8D/8-G+Y\5FG22\DF5'^)V2M+KJ2M[AT:&U55'X)5DN7$4-Z)C[AQ,U1"=8 M#56@_B@);0^/W&.5V$I))?)6BUVR@3UPHU[[8DGDBC M%L!U_R"HV9#21M6,!Y$^G!IZ_^OA&1.7N;\2*;1ZU]3?LU*_>@A M+K;C&@\QZ%3W6H<=5R/MHW_*IQ86"D*749A?]<4K'E8B5'BVE19HO8C\-.WU M\TP1NMF-ENMXK2,4!E,160I:Q5#P[$)K)$V80Z9.F;!2&`2!PA-2P9287AD< MM_M7RR.W;(LK+PR"0.'!6&&L+F%HPCYV^N"6>INP6!`$@,+O4$:-F$@1!DN; M4@R>$@6\BU'"):=-Z5)YD`H*IT,15V6L"F$TZ$7,"VYG9R'_#W>7'_L1]\SK M9A=^DDS@M/:K'Y6>/+7J@]10N"Z64"I9;_7167I$`H-.Y)6QFS+H%AZEP(#M;JL+DL!Q?VB,:$"%)9>JEA^XW/S3,*IGV;DEHY)N/Q\ M\STIH[:\(D@)A9>B,=0A\D%`+.3K4QX86\Y^6340 M$@K;EC'W:E"V7L;`P'PA'N7D[;6.41BO*L[:1?=M/8SA?KZ>=UYA10+;US@" M.&D1IJIQL-)M`D2'R\2E=8HV0V?KX0T,`WH.N?XI6UX)!(3"$F9&J%(IA"AM M/;^!00VF>0_2!W_"38<:FW1A!1`,"AN:BCK)Y%^"R=83'$C(3D;0WQ4AE?,M MK@/B06%[S5->Z&!=$HY,D# MXR0G*G,$E,WU M[C,,:0'CP:?A#;OPAQ06SSG89=M09640%PI#8C7R=?'9>JL$PTA_Y*%&C(17 M?L)@0DQA3SX:C/)PKDO2IT%IO**ZLM)&%HDYDO:T-=]$U(&:N=]/L>1HF&:WZ7JO=,A^C MDG#4^=??1-\N#=/7J@S=1;&S,)#MXL`SA?HSX&HE]J7M=($W)5"V:)?"^QF$ MQ4`0*%99!5,2XZ`$#LHD`K=T2`0V[@K:9XXT11T2=,@BE/^%H(J'X1V`R`$]]E6*L^]5;#:3QRP^8GXJM\G M/*$"*?+T/OGOCS"E\:0)+,C?0@5P]SR_0#B"8B"\Z39&+*J22=SNAX``I_>& M5=1%O!JL0RZ6XLL<9S(IV417/=B`>-SG,K&B-AHP+464.=6"NJ%DAVZ?JK#' MMPR;I=@RS,EKBGS@K[#["BQE,9QO?J%U529#946O=7+B_"1MFI'FQ/U2JBE8 MQ7EY#L]/T\C*B?0$B4/-*EG&9I`3N3?-5C%Z,LS7S&/65,N)ZK!C)"<O4.(P8P4^8GDUR>QA&::_RJUSK#92W0TKJU"Z1V-N)%G7UR/FE] M2&(Z,L]AH]A+Z]<.-`9_X727>+P?$LJ9/.)_<`*/Y@B$G[Q;V"%&5RSC:9[$#CJ" M4EZ[A8"D,37&G@C,X7AX8[;DO^/>Z-D-_SY*L_R(PJV\ M(,5\[#S%LQ0O9,%6^!1K"EKG(?4U?QJ80F&:7;]V;D:2#?(LNB30YZ#(7@1_ M1R17"19V!SSK\#_RWTLT5Z@-\IG!E%N"!ORF7*5- MX@H@%Q2V"I?Z4R892R^=8]`8D%Y"`.4E*?X[)Z_IXRQZT76:C7AM''F(U[\N MFLJD20^H"[!S/\/9@X:J1[9UJGOM,Q3V`E.:M95%@KBVLQ,N;\PEU$M/U!KI MR%)=$#<*V\"Z%$0(U]:;[H@GD=4G;GGB M'T<+%@J6V,\7532VTW6;!G&CN)HQUZ3ZJ"5*9L$`O^&0DA[T8$S)6Z]_/DI! M?JF3T)'I)4?^)'=$`TW?+FDEKWU\Z&K`SL1X2=(@H<.9-\I*7_G#R>?0C]]* M$!JW!B=\781#YYA"M4UYY15`V:=/2(EZ-?G M,F`R;,L;`(@H;/%J&LI'JP[*I@S1ZQ$+$Y^F"WL$*^^Q"5M6O<566LD[7#)! M6>^>WJ@PJN\=NCVSZHIU<4A4@&@_I%(R%'[9YUU]]E.2"_6?4$L#!!0````( M`.M::4>ZW9RQCPD``-!1```1`!P`8V%P#]D%QG&2WFYQ- M"\56=EWXAMA)"Q1%04NT3:Q$JB*5V#@X_[U#6O)5HF7GLEHWUH<*^N7G[[_[^"_+0I\( M(Q&6Q$/#&6I@B0<1=K^(5!_53FHGEP@N3M];'?YHG9W6WJ$_3FM7M8NKTXL_ MT7_M]O^0TQ\@"ST]/9UX8$%J"RGFNH/LD($S>\BAHD!&.?7E=^3O&/AU1XE40 M^,K$E5(O:$\KK,D^G9_P:`PBI[7J[^U67Z--+?N4?5F3G@XC/Y4_KZK70RQ( M*J[>>G*AL"K\KCI_N1#U#79_;X'A5:/4($R9D)BY2Q!;H!,7:Y>7EU7]-A6- MA37&.%P(C[`8:M'DA>XXZ[1FG=<6?9(B3J3O)EE=O,ORA[)$(F:TR?Y?A#1& MW">`P)46F88^9ECR:'8+]XL.X8S%0;813T95A;@*0A9(D8BZ"[W=2HD"9!*$ M/F+&.*082$WZ7CT)0\I&/+F%!RJ^KQ3@`:@C=7%_US1F!^U=@[NQRC0V\QPF MJ9PUP6H4Z+8JB$('&246[:<(/#*BC&JDM=,:Y,=4??423*&Y+;1B[&-UT\+W MWVV:CP7QNNQG?0T<"K"F=57B2/03$;/NLI%]-5WLN[&?VVBB5EVC8\7DH3S5 M.?,(@U;@0G"?>BIZ;["O,F!_0H@4<[8*R)DY.P.B^M"I)"&MWNTTG$[?::BK M?K?5;-@#N+FQ6W:G[J#^9\<9](_4/8NZ'H9I0$Z(I`"Q*(_K2F92SP\A%?VQ MUL2?1Y+W)7G1Y:([ZH9JQ0FH3`,U1\%,[D4Q3^NX04NMV_S.Z;75_.Y)J(K4+V[Q'2IZZHYM8 M4$9$0E[&=(B8D2.Q8RPC[%[(Z,@`,\ M],D=^`_;Y\G*&*Q'Q*-R3M5^*F8*+S4F>VS8J,^L8D2HT?B7GWP)SW^@J,_M6@. MB/.W&/X)E&,8O548K:6,US!L#JJ+-PRJ8XXZ>/>6%2Q%!,WDORNVLSL2^'I[ MO2QBGV/`3/C64=R!^\#_ZXA0_ZBZ#N@PI`LFKM2WZ.N*H$'HJT(+_6P2D=%U M106(E1:8_`5.GTP#/Q51+1A*-W0P;?93TG!J(OG\;B[H`",\))%*#]44?`55 M7]`Q8&1?Q]9)+*=;/A[NZQ:H$+^\'L$`V->CC3'SLG[-Q]MJF0;-^(%*] M`T!D5Y,5;#Y54.V^*]JBL1PLIV'=:*9BE?A2I$^LI:F]_#>49ID`9:@EU];2 MQ$%`LDK>BB!9U4MOGHTEJXRN$)A5Q<6=M31S$)RMBKLB4!9*^NJY8;)=C5<$ MPU)K?FDM#1R$8K/$KPB&5$==/+O]S>J_0@!2)7UU`(3M2D(]V3`R5K4`Q3*7 M'T5K6BI]7:JT67O_;!@%D^<*!/DBS9OK*8M"6K7B+(T<@-!855LD4E(==7%` MSC#7?1;JD$VMY_*47;*Z'Q+..@>#,1?['C[S:EOY.34IMM>`S/6N]E!M*E6\ MSI>END;]"IY1-FY*$JA=507A1.JZ(J-8+5JU%"P3*?<&6L^+HZ3"EE'?5SO3 M5%;$H$QEK-Y^BG@ M[7PET^=9'H^P+U[)Y;U1YQ%,A!O14#6W\<%R5C:7BT'-\;/.@Q"SV6T>KC> MPS-=:JB_=I;-_?T@Y_AMNWK?`"DWK0O0BF^>DSUY-0'-R(V'I+GN9R[$')=: M--3?/Z9M$@Q)M,&6QP-,V=O.+UN(5<=#@OEP>/DN*CHLX_QZF< M?GK@*AHV=.[!HB@-Y;LAYOC6X6RN"VEM1&`3[974PZ)`\Q+/."+ZWIY2\372 MC0=#DJD?J&ZFFW5@N^`W=->7@(\M1#G(G:GKP^+GD;2HJZKK%WJEB:R="`ND MSZ8^F-,S89/E#\:-P)M@6$N\\31^$.H"/=`FY7'D[8@?LG#[(B)XM7[]>W)O1 MY;BTE.V.[O@,^W*6K/:_OD,F;+E'!XO3AF5A2ILS.?%GMX2\P)(VWZV--:U' MAOLL:7DXV=::BF>,AVL`](#C`& M$68"/*3Z]YVE[8T#_3FD=VS?Y_I/+`QX8O-;[9H371SV#7B7@;7`5`7+F&1&:#*7!R68?:7>(N@+F?:[+Z8EGMV*),=^3;GTED?*,I##7W;'_Y M-R[6_OY$>;Z]%8!8^.BZ1-P9P>6&IA>[Q$N64LOO&.5>%!I1YWB:69->GIC< M`6\?IY:CM6R?CXK#WX:$]_`=02P$"'@,4 M````"`#K6FE'ZP%6>W@Z``"=#0(`$0`8```````!````I($`````8V%P`L``00E#@``!#D!``!02P$"'@,4```` M"`#K6FE'$L$==)0&``"U2P``%0`8```````!````I('#.@``8V%P&UL550%``-YR$!6=7@+``$$)0X```0Y`0``4$L!`AX#%``` M``@`ZUII1Y7HCX(X%P``Y%P!`!4`&````````0```*2!ID$``&-A<',M,C`Q M-3`Y,S!?9&5F+GAM;%54!0`#>`Q0` M```(`.M::4?8E*F4UR,``%K?`0`5`!@```````$```"D@2U9``!C87!S+3(P M,34P.3,P7VQA8BYX;6Q55`4``WG(0%9U>`L``00E#@``!#D!``!02P$"'@,4 M````"`#K6FE'^=$4!#4:``"VF0$`%0`8```````!````I(%3?0``8V%P&UL550%``-YR$!6=7@+``$$)0X```0Y`0``4$L!`AX# M%`````@`ZUII1[K=G+&/"0``T%$``!$`&````````0```*2!UY<``&-A<',M M,C`Q-3`Y,S`N>'-D550%``-YR$!6=7@+``$$)0X```0Y`0``4$L%!@`````& -``8`&@(``+&A```````` ` end XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 R9.htm IDEA: XBRL DOCUMENT v3.3.0.814
Australian Refundable Research & Development Credit
 9 Months Ended
Sep. 30, 2015
Research and Development Expense [Abstract]  
Refundable Research And Development Credit [Text Block]
Note D. Australian Refundable Research & Development Credit
 
In March 2014, LipimetiX Development LLC, (see Note B) formed a wholly-owned Australian subsidiary, Lipimetix Australia Pty Ltd, to conduct Phase 1a and Phase1b/2a clinical trials in Australia. Currently Australian tax regulations provide for a refundable research and development tax credit equal to 45% of qualified expenditures. Subsequent to the end of its Australian tax years, Lipimetix Australia Pty, Ltd intends to submit claims for a refundable research and development tax credit. The transitional Australian tax periods/years granted for Lipimetix Australia Pty, Ltd end on June 30, 2014, December 31, 2014 and thereafter December 31 of each succeeding year. For the tax year ended June 30, 2014, Lipimetix Australia Pty, Ltd received a refundable research and development tax credit of AUD$227,000. At December 31, 2014 a AUD$242,000 development tax credit was recorded by Lipimetix Australia Pty, Ltd, and at September 30, 2015, AUD$202,000 has been accrued, as it is more likely than not that the recorded refundable research and development tax credit will be approved and received. At September 30, 2015, and December 31, 2014, AUD$202,000 (US$142,000), and AUD$242,000 (US$196,000), respectively, have been accrued and are included in other current assets in our condensed consolidated balance sheets.
XML 15 R8.htm IDEA: XBRL DOCUMENT v3.3.0.814
FUNDRAISING ACTIVITIES
 9 Months Ended
Sep. 30, 2015
Fundraising Activities [Abstract]  
Fundraising Activities Disclosure [Text Block]
Note C. FUNDRAISING ACTIVITIES
 
As disclosed above, management has determined that the Company will require additional capital above its current cash and working capital balances to further develop AEM-28 and its analogs and to continue operations.  Accordingly, the Company has reduced its development activities.  The Company’s corporate strategy is to raise funds by possibly engaging in a strategic/merger transaction, or conducting a private or public offering of debt or equity securities for capital.    In connection with these efforts, we filed a Registration Statement on Form S-1 with the Securities and Exchange Commission on June 26, 2015, as amended, in connection with our contemplated public offering of shares of our Common Stock. The Registration Statement is not effective as of September 30, 2015.
 
As of September 30, 2015, we have deferred recognition of approximately $148,000 of direct costs, primarily legal costs and filing fees, related to fundraising activities in connection with our contemplated public offering of shares of our Common Stock. These costs are to be offset against the equity raised upon completion of the offering. The deferred costs are included in other current assets in the Condensed Consolidated Balance Sheet at September 30, 2015.
XML 16 R2.htm IDEA: XBRL DOCUMENT v3.3.0.814
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2015
Dec. 31, 2014
Current assets    
Cash and cash equivalents $ 637 $ 2,164
Other current assets 360 555
Total current assets 997 2,719
Patent license rights, net 549 666
Furniture and equipment, net 0 0
Total assets 1,546 3,385
Current liabilities    
Accounts payable 132 124
Other accrued liabilities 56 158
Total current liabilities 188 282
Capstone Therapeutics Corp. Stockholders' Equity    
Common Stock $.0005 par value; 150,000,000 shares authorized; 40,885,411 shares in 2015 and 2014 issued and outstanding 20 20
Additional paid-in capital 189,426 189,268
Accumulated deficit (188,088) (186,185)
Total Capstone Therapeutics Corp. stockholders' equity 1,358 3,103
Noncontrolling interest 0 0
Total equity 1,358 3,103
Total liabilities and equity $ 1,546 $ 3,385
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.3.0.814
OVERVIEW OF BUSINESS
 9 Months Ended
Sep. 30, 2015
Accounting Policies [Abstract]  
Business Description and Accounting Policies [Text Block]
Note A. OVERVIEW OF BUSINESS
 
Description of the Business
 
Capstone Therapeutics Corp. (the “Company”, “we”, “our” or “us”) is a biotechnology company committed to developing a pipeline of novel peptides and other molecules aimed at helping patients with under-served medical conditions. Previously, we were focused on the development and commercialization of two product platforms: AZX100 and Chrysalin (TP508). Since March 2012, we no longer have any interest in or rights to Chrysalin. In 2012 we wound down internal operations, ceased clinical development of AZX100 in dermal scarring, formerly our principal drug candidate, and moved to a more virtual operating model. In 2014, we terminated the License Agreement for AZX100 intellectual property and returned all interest in and rights to the AZX100 intellectual property to the Licensor (AzTE).
 
On August 3, 2012, we entered into a joint venture, LipimetiX Development, LLC, (now LipimetiX Development, Inc.), (the “JV”), to develop Apo E mimetic peptide molecule AEM-28 and its analogs. The JV has a development plan to pursue regulatory approval of AEM-28, or an analog, as treatment for Homozygous Familial Hypercholesterolemia (granted Orphan Drug Designation by FDA in 2012), Acute Hypertriglyceridemic Pancreatitis, and other hyperlipidemic indications. The initial development plan extended through Phase 1a and 1b/2a clinical trials and was completed in the fourth quarter of 2014.
 
The JV received allowance from regulatory authorities in Australia permitting the JV to proceed with the planned clinical trials. The Phase 1a clinical trial commenced in Australia in April 2014 and the Phase 1b/2a clinical trial commenced in Australia in June 2014. The clinical trials for AEM-28 were randomized, double-blinded, placebo-controlled studies to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of six escalating single doses (Phase 1a in healthy patients with elevated cholesterol) and multiple ascending doses of the three highest doses from Phase 1a (Phase 1b/2a in patients with hypercholesterolemia and healthy volunteers with elevated cholesterol and high Body Mass Index). The Phase 1a clinical trial consisted of 36 patients and the Phase 1b/2a consisted of 15 patients. Both clinical trials were completed in 2014 and the Medical Safety Committee, reviewing all safety-related aspects of the clinical trials, observed a generally acceptable safety profile. As first-in-man studies, the primary endpoint was safety; yet efficacy measurements analyzing pharmacodynamics yielded statistical significance in the pooled dataset favoring AEM-28 versus placebo in multiple lipid biomarker endpoints.
 
Concurrent with the clinical development activities with AEM-28, the JV has performed pre-clinical studies that have identified an analog of AEM-28, referred to as AEM-28-14, and a new phospholipid formulation, that has the potential of equivalent efficacy, higher human dose toleration and an extended composition of matter patent life (application filed with the U.S. Patent and Trademark Office in 2015). The JV’s current intent is to prioritize the development of AEM-28-14.
 
The JV and the Company are exploring fundraising, partnering or licensing, to obtain additional funding to continue development activities of AEM-28 and its analogs, including AEM-28-14, and operations.
 
The JV and the Company do not have sufficient funding at this time to continue additional material development activities of AEM-28 and its analogs, including AEM-28-14. The JV may conduct future clinical trials in Australia, the USA, and other regulatory jurisdictions if regulatory approvals, additional funding, and other conditions permit.
 
The Company, funding permitting, intends to continue limiting its internal operations to a virtual operating model while monitoring and participating in the management of JV’s AEM-28 and analogs development activities and maintaining the required level of corporate governance and reporting required to comply with Securities and Exchange Commission rules and regulations.
 
Description of Current Peptide Drug Candidates.
 
Chimeric Apo E Mimetic Peptide Molecule – AEM-28 and its analogs
 
Apolipoprotein E is a 299 amino acid protein that plays an important role in lipoprotein metabolism. AEM-28 is a 28 amino acid mimetic of Apo E and AEM-28 and its analogs, including AEM-28-14 is a 28 amino acid mimetic of Apo E (with an aminohexanoic acid group and a phospholipid), and both contain a domain that anchors into a lipoprotein surface while also providing the Apo E receptor binding domain, which allows clearance through the heparan sulfate proteoglycan (HSPG) receptors (Syndecan-1) in the liver. AEM-28 and its analogs, including AEM-28-14, as Apo E mimetics, have the potential to restore the ability of these atherogenic lipoproteins to be cleared from the plasma, completing the reverse cholesterol transport pathway, and thereby reducing cardiovascular risk. This is an important mechanism of action for AEM-28 and its analogs, including AEM-28-14. For patients that lack LDL receptors (Homozygous Familial Hypercholesterolemia-HoFH), have acute pancreatitis, or have hypercholesterolemia, AEM-28 and its analogs may provide a therapeutic solution. Our joint venture has an Exclusive License Agreement with the University of Alabama at Birmingham Research Foundation for AEM-28 and certain of its analogs.
 
Company History
 
Prior to November 26, 2003, we developed, manufactured and marketed proprietary, technologically advanced orthopedic products designed to promote the healing of musculoskeletal bone and tissue, with particular emphasis on fracture healing and spine repair. Our product lines, which included bone growth stimulation and fracture fixation devices, are referred to as our “Bone Device Business.” In November 2003, we sold our Bone Device Business.
 
In August 2004, we purchased substantially all of the assets and intellectual property of Chrysalis Biotechnology, Inc., including its exclusive worldwide license for Chrysalin, a peptide, for all medical indications. Subsequently, our efforts were focused on research and development of Chrysalin with the goal of commercializing our products in fresh fracture healing. (In March 2012, we returned all rights to the Chrysalin intellectual property and no longer have any interest in, or rights to Chrysalin.)
 
In February 2006, we purchased certain assets and assumed certain liabilities of AzERx, Inc. Under the terms of the transaction, we acquired an exclusive license for the core intellectual property relating to AZX100, an anti-fibrotic peptide. In 2014, we terminated the License Agreement with AzTE (Licensor) for the core intellectual property relating to AZX100 and returned all interest in and rights to the AZX100 intellectual property to the Licensor.
 
On August 3, 2012, we entered into a joint venture (see Note B below), to develop Chimeric Apo E mimetic peptide molecule AEM-28 and its analogs.
 
Our development activities represent a single operating segment as they shared the same product development path and utilized the same Company resources. As a result, we determined that it is appropriate to reflect our operations as one reportable segment.
 
OrthoLogic Corp. commenced doing business under the trade name of Capstone Therapeutics on October 1, 2008, and we formally changed our name from OrthoLogic Corp. to Capstone Therapeutics Corp. on May 21, 2010.
 
In these notes, references to “we”, “our”, “us”, the “Company”, “Capstone Therapeutics”, “Capstone”, and “OrthoLogic” refer to Capstone Therapeutics Corp. References to our joint venture or “JV”, refer to LipimetiX Development, Inc. (formerly LipimetiX Development, LLC).
 
Financial Statement Presentation and Management’s Plan
 
The accompanying financials statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.
 
The report from our Independent Registered Public Accounting Firm on our consolidated financial statements for the year ended December 31, 2014 included in our Annual Report on Form 10-K expressed substantial doubt about the Company’s ability to continue as a going concern.
 
Management has determined that the Company will require additional capital above its current cash and working capital balances to further develop AEM-28 and its analogs or continue operations. Accordingly, the Company has reduced its development activities. The Company’s corporate strategy is to raise funds by possibly engaging in a strategic/merger transaction, or conducting a private or public offering of debt or equity securities for capital. These financial statements do not include any adjustments that might result from the outcome of the uncertainty of the Company successfully implementing its corporate strategy.
 
In the opinion of management, the unaudited condensed interim financial statements include all adjustments necessary for the fair presentation of our financial position, results of operations, and cash flows, and all adjustments were of a normal recurring nature. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the complete fiscal year. The financial statements include the consolidated results of Capstone Therapeutics Corp. and our 60% owned subsidiary, LipimetiX Development, Inc. Intercompany transactions have been eliminated.
 
Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to Securities and Exchange Commission rules and regulations, although we believe that the disclosures herein are adequate to make the information presented not misleading. These unaudited condensed financial statements should be read in conjunction with the financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2014. Information presented as of December 31, 2014 is derived from audited financial statements.
 
Use of Estimates
 
The preparation of financial statements in accordance with accounting principles generally accepted in the United States requires that management make a number of assumptions and estimates that affect the reported amounts of assets, liabilities, and expenses in our financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management’s assumptions regarding current events and actions that may impact us in the future, actual results may differ from these estimates and assumptions.
 
Legal and Other Contingencies
 
The Company is subject to legal proceedings and claims that arise in the ordinary course of business. The Company records a liability when it is probable that a loss has been incurred and the amount is reasonably estimable. There is significant judgment required in both the probability determination and as to whether an exposure can be reasonably estimated. In the opinion of management, there was not at least a reasonable possibility the Company may have incurred a material loss with respect to loss contingencies.
 
Joint Venture Accounting
 
The Company entered into a joint venture in which it has contributed $6,000,000, and the noncontrolling interests have contributed certain patent license rights. Neither the Company nor the noncontrolling interests have an obligation to contribute additional funds to the joint venture or to assume any joint venture liabilities or to provide a guarantee of either joint venture performance or any joint venture liability. The financial position and results of operations of the joint venture are presented on a consolidated basis with the financial position and results of operations of the Company. Intercompany transactions have been eliminated. Joint venture losses were recorded on the basis of common ownership equity interests (60% Company / 40% noncontrolling interests) until common ownership equity was reduced to $0. Subsequent joint venture losses are being allocated to the preferred ownership equity (100% Company). Subsequent to March 31, 2013, all joint venture losses are being allocated to the Company. The Company has a revolving loan agreement with the joint venture to advance the joint venture funds for operations in an amount not to exceed a net (net of expected tax credits or other funds obtained) of $700,000, with the net amount due December 31, 2015. Losses incurred by the joint venture in excess of the capital accounts of the joint venture will be allocated to the Company to the extent of net outstanding advances.
 
Cash and Cash Equivalents
 
At September 30, 2015, cash and cash equivalents included money market accounts.
 
Recent Accounting Pronouncements
 
 In August 2014, the Financial Accounting Standards Board issued Accounting Standard Update (“ASU”) No. 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40)(“Update”): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, providing a requirement under U.S. GAAP for an entity’s management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date the financial statements are issued; and if those conditions exist, to disclose that fact, the conditions and the potential effects on the entity’s ability to meet its obligations. The Update will be effective for an annual period ending after December 15, 2016, with early application permitted. We have not elected early application. However, if additional funds are not obtained to continue the development of AEM-28 or its analogs, or operations, it will impair our ability to continue as a going concern. If we do not continue as a going concern, the Company may incur additional losses, up to, and possibly exceeding our net joint venture investment and revolving loan balance.
XML 18 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 19 R7.htm IDEA: XBRL DOCUMENT v3.3.0.814
JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS
 9 Months Ended
Sep. 30, 2015
Business Combinations [Abstract]  
Business Combination Disclosure [Text Block]
Note B. JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS
 
On August 3, 2012, we entered into a Contribution Agreement with LipimetiX, LLC to form a joint venture, LipimetiX Development, LLC (“JV”), to develop Apo E mimetic molecules, including AEM-28 and its analogs. In June 2015, the JV converted from a limited liability company to a corporation, LipimetiX Development, Inc. The Company contributed $6 million, which included $1 million for 600,000 voting common ownership units (now common stock), representing 60% ownership in the JV, and $5 million for 5,000,000 non-voting preferred ownership units (now preferred stock), which have preferential distribution rights.
 
LipimetiX, LLC contributed all intellectual property rights for Apo E mimetic molecules it owned and assigned its Exclusive License Agreement between The University of Alabama at Birmingham Research Foundation (“UABRF”) and LipimetiX, LLC, for the UABRF intellectual property related to Apo E mimetic molecules AEM-28 and its analogs to the JV, in return for 400,000 voting common ownership units (now common stock) representing 40% ownership in JV, and $378,000 in cash (for certain initial patent-related costs and legal expenses).
 
LipimetiX, LLC was formed by the principals of Benu BioPharma, Inc. (“Benu”) and UABRF to commercialize UABRF’s intellectual property related to Apo E mimetic molecules, including AEM-28 and analogs. Benu is composed of Dennis I. Goldberg, Ph.D., Phillip M. Friden, Ph.D. and Eric M. Morrel, Ph.D. The Exclusive License Agreement, as amended, calls for payment of patent filing, maintenance and other related patent fees, as well as a royalty of 3% on Net Sales of Licensed Products during the Term of the Agreement. The Agreement terminates upon the expiration of all Valid Patent Claims within the Licensed Patents, which are currently estimated to expire between 2019 and 2035. The Agreement, as amended, also calls for annual maintenance payments of $25,000, various milestone payments of $50,000 to $500,000 and minimum royalty payments of $500,000 to $1,000,000 per year commencing on January 1 of the first calendar year following the year in which the First Commercial Sale occurs. UABRF will also be paid 5% of Non Royalty Income received.
 
Concurrent with entering into the Contribution Agreement and the First Amendment and Consent to Assignment of Exclusive License Agreement between LipimetiX, LLC, UABRF and the Company, the Company and LipimetiX, LLC entered into a Limited Liability Company Agreement for JV which established a Joint Development Committee (“JDC”) to manage JV development activities. Upon conversion by the JV from a limited liability company to a corporation, the parties entered into a Stockholders Agreement for the JV, and the JDC was replaced by a Board of Directors (JV Board). The JV Board is composed of three members appointed by the non-Company ownership group and two members appointed by the Company. Non-development JV decisions, including the issuance of new equity, incurrence of debt, entry into strategic transactions, licenses or development agreements, sales of assets and liquidation, and approval of annual budgets, will be decided by a majority vote of the common stockholders.
 
The JV, on August 3, 2012, entered into a Management Agreement with Benu to manage JV development activities for a monthly fee of approximately $63,000 during the twenty-seven month development period, and an Accounting Services Agreement with the Company to manage JV accounting and administrative functions. The current accounting services fee is $1,000 a month. Commencing in November 2014, and ending in March 2015, Benu received a reduced monthly management fee in the amount of $35,000. Subsequent to March 2015, no management fee has been paid to Benu for their services.
 
The joint venture formation was as follows ($000’s):
 
Patent license rights
 
$
1,045
 
Noncontrolling interests
 
 
(667)
 
Cash paid at formation
 
$
378
 
 
Patent license rights were recorded at their estimated fair value and are being amortized on a straight-line basis over the key patent life of eighty months.
 
The financial position and results of operations of the joint venture are presented on a consolidated basis with the financial position and results of operations of the Company. Intercompany transactions have been eliminated. The joint venture agreement requires profits and losses to be allocated on the basis of common ownership equity interests (60% Company / 40% noncontrolling interests). However, for the Company’s consolidated financial statement, joint venture losses were recorded on the basis of common ownership equity interests (60% Company / 40% noncontrolling interests) until common ownership equity was reduced to $0. Subsequent joint venture losses have been allocated to the preferred ownership equity (100% Company). Subsequent to March 31, 2013, all joint venture losses have been allocated to the Company. The Company has a revolving loan agreement with the joint venture to advance the joint venture funds for operations in an amount not to exceed a net (net of expected tax credits or other funds obtained) of $700,000, with the net amount due December 31, 2015. Losses incurred by the joint venture in excess of the capital accounts of the joint venture will be allocated to the Company to the extent of net outstanding advances. At September 30, 2015, outstanding advances on the revolving loan agreement totaled $759,000.
 
The joint venture incurred net operating expenses, prior to the elimination of intercompany transactions, of $503,000 in the nine month period ended September 30, 2015 and $6,738,000 for the period from August 3, 2012 (inception) to September 30, 2015, of which $503,000 and $6,071,000, respectively, have been recorded by the Company. The joint venture operating expenses are included in research and development expenses in the condensed consolidated statements of operations.
 
Neither the Company nor the noncontrolling interests have an obligation to contribute additional funds to the joint venture or to assume any joint venture liabilities or to provide a guarantee of either joint venture performance or any joint venture liability. Losses allocated to the noncontrolling interests represent an additional potential loss for the Company as the noncontrolling interests are not obligated to contribute assets to the joint venture to the extent they have a negative capital account, and depending on the ultimate outcome of the joint venture, the Company could potentially absorb all losses associated with the joint venture. From formation of the joint venture, August 3, 2012, through September 30, 2015, losses totaling $667,000 have been allocated to the noncontrolling interests. If the joint venture or Company is unable to obtain additional funding, the ability of the joint venture to continue development of AEM-28 and its analogs, including AEM-28-14, would be impaired as would the joint venture’s ability to continue operations. If the joint venture does not continue as a going concern, at September 30, 2015 the Company would incur an additional loss of $667,000 for the joint venture losses allocated to the noncontrolling interests.
XML 20 R3.htm IDEA: XBRL DOCUMENT v3.3.0.814
CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] - $ / shares
Sep. 30, 2015
Dec. 31, 2014
Common stock, par value (in dollars per share) $ 0.0005 $ 0.0005
Common stock, shares authorized 150,000,000 150,000,000
Common stock, shares issued 40,885,411 40,885,411
Common stock, shares outstanding 40,885,411 40,885,411
XML 21 R1.htm IDEA: XBRL DOCUMENT v3.3.0.814
Document And Entity Information
 9 Months Ended
Sep. 30, 2015
shares
Document Information [Line Items]  
Entity Registrant Name Capstone Therapeutics Corp.
Entity Central Index Key 0000887151
Current Fiscal Year End Date --12-31
Entity Filer Category Smaller Reporting Company
Trading Symbol CAPS
Entity Common Stock, Shares Outstanding 0
Document Type 10-Q
Amendment Flag false
Document Period End Date Sep. 30, 2015
Document Fiscal Period Focus Q3
Document Fiscal Year Focus 2015
XML 22 R4.htm IDEA: XBRL DOCUMENT v3.3.0.814
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
OPERATING EXPENSES        
General and administrative $ 241 $ 373 $ 1,265 $ 1,047
Research and development 175 865 808 2,667
Total operating expenses 416 1,238 2,073 3,714
Interest and other expenses (income), net 19 (4) 28 (67)
Loss from operations before taxes 435 1,234 2,101 3,647
Income tax benefit 0 0 (198) 0
NET LOSS 435 1,234 1,903 3,647
Less: Net Loss attributable to the noncontrolling interest 0 0 0 0
Net Loss attributable to Capstone Therapeutics Corp. stockholders $ 435 $ 1,234 $ 1,903 $ 3,647
Per Share Information:        
Net loss, basic and diluted, attributable to Capstone Therapeutic Corp. stockholders (in dollars per share) $ 0.01 $ 0.03 $ 0.05 $ 0.09
Basic and diluted shares outstanding (in shares) 40,885 40,885 40,885 40,885
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.3.0.814
OVERVIEW OF BUSINESS (Details Textual) - USD ($)
Sep. 30, 2015
Aug. 03, 2012
Accounting Policies [Line Items]    
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures $ 6,000,000 $ 6,000,000
Revolving Credit Facility [Member]    
Accounting Policies [Line Items]    
Line of Credit Facility, Maximum Borrowing Capacity $ 700,000  
Lipimetix [Member]    
Accounting Policies [Line Items]    
Equity Method Investment, Ownership Percentage 60.00%  
Common Stock [Member]    
Accounting Policies [Line Items]    
Joint Venture Losses Recognition Criteria, Common Ownership Equity $ 0  
Noncontrolling Interest, Ownership Percentage by Parent 60.00%  
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners 40.00%  
Preferred Stock [Member]    
Accounting Policies [Line Items]    
Noncontrolling Interest, Ownership Percentage by Parent 100.00%  
XML 24 R11.htm IDEA: XBRL DOCUMENT v3.3.0.814
JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Tables)
 9 Months Ended
Sep. 30, 2015
Business Combinations [Abstract]  
Schedule Of Joint Venture Payments [Table Text Block]
The joint venture formation was as follows ($000’s):
 
Patent license rights
 
$
1,045
 
Noncontrolling interests
 
 
(667)
 
Cash paid at formation
 
$
378
 
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.3.0.814
FUNDRAISING ACTIVITIES (Details Textual)
 9 Months Ended
Sep. 30, 2015
USD ($)
Fundraising Activities [Line Items]  
Recognition of Deferred Revenue $ 148,000
XML 26 R13.htm IDEA: XBRL DOCUMENT v3.3.0.814
JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Details) - Lipimetix [Member]
$ in Thousands
 9 Months Ended
Sep. 30, 2015
USD ($)
Related Party Transaction [Line Items]  
Patent license rights $ 1,045
Noncontrolling interests (667)
Cash paid at formation $ 378
XML 27 R14.htm IDEA: XBRL DOCUMENT v3.3.0.814
JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Details Textual) - USD ($)
 9 Months Ended 38 Months Ended
Aug. 03, 2012
Sep. 30, 2015
Sep. 30, 2015
Related Party Transaction [Line Items]      
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures $ 6,000,000 $ 6,000,000 $ 6,000,000
Joint Venture Investments In Voting Common Ownership Units (in shares) 600,000    
Joint Venture Method Investment Ownership Percentage 60.00%    
Joint Venture Investments In Non Voting Preferred Ownership Units 5,000,000    
Joint Venture Investments Common Ownership Units, Co-venture (in shares) 400,000    
Ownership Percentage Co-venture 40.00%    
Percentage Of Royalty Payment 3.00%    
Development Activities Monthly Fee $ 63,000    
Accounting and Administrative Monthly Fee $ 1,000    
Joint Venture, Operating Expenses, Inter Company Transactions   503,000 6,738,000
Joint Venture, Operating Expenses Allocated To Company   503,000 6,071,000
Percentage Of Non Royalty Income 5.00%    
Reduced Monthly Management Fee $ 35,000    
Revolving Credit Facility [Member]      
Related Party Transaction [Line Items]      
Line of Credit Facility, Maximum Borrowing Capacity   700,000 700,000
Long-term Line of Credit   759,000 759,000
Common Stock [Member]      
Related Party Transaction [Line Items]      
Joint Venture Losses Recognition Criteria, Common Ownership Equity   $ 0 $ 0
Noncontrolling Interest, Ownership Percentage by Parent   60.00% 60.00%
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners   40.00% 40.00%
Preferred Stock [Member]      
Related Party Transaction [Line Items]      
Noncontrolling Interest, Ownership Percentage by Parent   100.00% 100.00%
Exclusive License Agreement [Member]      
Related Party Transaction [Line Items]      
Annual Maintenance Payments 25,000    
Exclusive License Agreement [Member] | Maximum [Member]      
Related Party Transaction [Line Items]      
Milestone Payments 500,000    
Royalty Expense 1,000,000    
Exclusive License Agreement [Member] | Minimum [Member]      
Related Party Transaction [Line Items]      
Milestone Payments 50,000    
Royalty Expense 500,000    
Lipimetix [Member]      
Related Party Transaction [Line Items]      
Noncash or Part Noncash Acquisition, Other Liabilities Assumed   $ 667,000  
Voting Common Ownership Units [Member]      
Related Party Transaction [Line Items]      
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures 1,000,000    
Non Voting Preferred Ownership Units [Member]      
Related Party Transaction [Line Items]      
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures $ 5,000,000    
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.3.0.814
Australian Refundable Research & Development Credit (Details Textual)
 6 Months Ended 9 Months Ended 12 Months Ended
Jun. 30, 2014
AUD
Sep. 30, 2015
AUD
Dec. 31, 2014
AUD
Sep. 30, 2015
USD ($)
Sep. 30, 2015
AUD
Dec. 31, 2014
USD ($)
Dec. 31, 2014
AUD
Research And Development Disclosure [Line Items]              
Other Assets, Current | $       $ 360,000   $ 555,000  
Lipimetix Australia Pty Ltd [Member]              
Research And Development Disclosure [Line Items]              
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent   45.00%          
Research and Development Expense, Total AUD 227,000 AUD 202,000 AUD 242,000        
Other Assets, Current       $ 142,000 AUD 202,000 $ 196,000 AUD 242,000
XML 29 R5.htm IDEA: XBRL DOCUMENT v3.3.0.814
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
OPERATING ACTIVITIES    
Net loss $ (1,903) $ (3,647)
Non cash items:    
Depreciation and amortization 117 121
Non-cash stock compensation 158 52
Change in other operating items:    
Other current assets 195 (44)
Accounts payable 8 137
Other accrued liabilities (102) 234
Cash flows used in operating activities (1,527) (3,147)
INVESTING ACTIVITIES    
Cash flows provided by investing activities 0 0
FINANCING ACTIVITIES    
Cash flows provided by financing activities 0 0
NET DECREASE IN CASH AND CASH EQUIVALENTS (1,527) (3,147)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 2,164 6,258
CASH AND CASH EQUIVALENTS, END OF PERIOD $ 637 $ 3,111
XML 30 R10.htm IDEA: XBRL DOCUMENT v3.3.0.814
OVERVIEW OF BUSINESS (Policies)
 9 Months Ended
Sep. 30, 2015
Accounting Policies [Abstract]  
Description Of Business [Policy Text Block]
Description of the Business
 
Capstone Therapeutics Corp. (the “Company”, “we”, “our” or “us”) is a biotechnology company committed to developing a pipeline of novel peptides and other molecules aimed at helping patients with under-served medical conditions. Previously, we were focused on the development and commercialization of two product platforms: AZX100 and Chrysalin (TP508). Since March 2012, we no longer have any interest in or rights to Chrysalin. In 2012 we wound down internal operations, ceased clinical development of AZX100 in dermal scarring, formerly our principal drug candidate, and moved to a more virtual operating model. In 2014, we terminated the License Agreement for AZX100 intellectual property and returned all interest in and rights to the AZX100 intellectual property to the Licensor (AzTE).
 
On August 3, 2012, we entered into a joint venture, LipimetiX Development, LLC, (now LipimetiX Development, Inc.), (the “JV”), to develop Apo E mimetic peptide molecule AEM-28 and its analogs. The JV has a development plan to pursue regulatory approval of AEM-28, or an analog, as treatment for Homozygous Familial Hypercholesterolemia (granted Orphan Drug Designation by FDA in 2012), Acute Hypertriglyceridemic Pancreatitis, and other hyperlipidemic indications. The initial development plan extended through Phase 1a and 1b/2a clinical trials and was completed in the fourth quarter of 2014.
 
The JV received allowance from regulatory authorities in Australia permitting the JV to proceed with the planned clinical trials. The Phase 1a clinical trial commenced in Australia in April 2014 and the Phase 1b/2a clinical trial commenced in Australia in June 2014. The clinical trials for AEM-28 were randomized, double-blinded, placebo-controlled studies to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of six escalating single doses (Phase 1a in healthy patients with elevated cholesterol) and multiple ascending doses of the three highest doses from Phase 1a (Phase 1b/2a in patients with hypercholesterolemia and healthy volunteers with elevated cholesterol and high Body Mass Index). The Phase 1a clinical trial consisted of 36 patients and the Phase 1b/2a consisted of 15 patients. Both clinical trials were completed in 2014 and the Medical Safety Committee, reviewing all safety-related aspects of the clinical trials, observed a generally acceptable safety profile. As first-in-man studies, the primary endpoint was safety; yet efficacy measurements analyzing pharmacodynamics yielded statistical significance in the pooled dataset favoring AEM-28 versus placebo in multiple lipid biomarker endpoints.
 
Concurrent with the clinical development activities with AEM-28, the JV has performed pre-clinical studies that have identified an analog of AEM-28, referred to as AEM-28-14, and a new phospholipid formulation, that has the potential of equivalent efficacy, higher human dose toleration and an extended composition of matter patent life (application filed with the U.S. Patent and Trademark Office in 2015). The JV’s current intent is to prioritize the development of AEM-28-14.
 
The JV and the Company are exploring fundraising, partnering or licensing, to obtain additional funding to continue development activities of AEM-28 and its analogs, including AEM-28-14, and operations.
 
The JV and the Company do not have sufficient funding at this time to continue additional material development activities of AEM-28 and its analogs, including AEM-28-14. The JV may conduct future clinical trials in Australia, the USA, and other regulatory jurisdictions if regulatory approvals, additional funding, and other conditions permit.
 
The Company, funding permitting, intends to continue limiting its internal operations to a virtual operating model while monitoring and participating in the management of JV’s AEM-28 and analogs development activities and maintaining the required level of corporate governance and reporting required to comply with Securities and Exchange Commission rules and regulations.
 
Description of Current Peptide Drug Candidates.
 
Chimeric Apo E Mimetic Peptide Molecule – AEM-28 and its analogs
 
Apolipoprotein E is a 299 amino acid protein that plays an important role in lipoprotein metabolism. AEM-28 is a 28 amino acid mimetic of Apo E and AEM-28 and its analogs, including AEM-28-14 is a 28 amino acid mimetic of Apo E (with an aminohexanoic acid group and a phospholipid), and both contain a domain that anchors into a lipoprotein surface while also providing the Apo E receptor binding domain, which allows clearance through the heparan sulfate proteoglycan (HSPG) receptors (Syndecan-1) in the liver. AEM-28 and its analogs, including AEM-28-14, as Apo E mimetics, have the potential to restore the ability of these atherogenic lipoproteins to be cleared from the plasma, completing the reverse cholesterol transport pathway, and thereby reducing cardiovascular risk. This is an important mechanism of action for AEM-28 and its analogs, including AEM-28-14. For patients that lack LDL receptors (Homozygous Familial Hypercholesterolemia-HoFH), have acute pancreatitis, or have hypercholesterolemia, AEM-28 and its analogs may provide a therapeutic solution. Our joint venture has an Exclusive License Agreement with the University of Alabama at Birmingham Research Foundation for AEM-28 and certain of its analogs.
Company History [Policy Text Block]
Company History
 
Prior to November 26, 2003, we developed, manufactured and marketed proprietary, technologically advanced orthopedic products designed to promote the healing of musculoskeletal bone and tissue, with particular emphasis on fracture healing and spine repair. Our product lines, which included bone growth stimulation and fracture fixation devices, are referred to as our “Bone Device Business.” In November 2003, we sold our Bone Device Business.
 
In August 2004, we purchased substantially all of the assets and intellectual property of Chrysalis Biotechnology, Inc., including its exclusive worldwide license for Chrysalin, a peptide, for all medical indications. Subsequently, our efforts were focused on research and development of Chrysalin with the goal of commercializing our products in fresh fracture healing. (In March 2012, we returned all rights to the Chrysalin intellectual property and no longer have any interest in, or rights to Chrysalin.)
 
In February 2006, we purchased certain assets and assumed certain liabilities of AzERx, Inc. Under the terms of the transaction, we acquired an exclusive license for the core intellectual property relating to AZX100, an anti-fibrotic peptide. In 2014, we terminated the License Agreement with AzTE (Licensor) for the core intellectual property relating to AZX100 and returned all interest in and rights to the AZX100 intellectual property to the Licensor.
 
On August 3, 2012, we entered into a joint venture (see Note B below), to develop Chimeric Apo E mimetic peptide molecule AEM-28 and its analogs.
 
Our development activities represent a single operating segment as they shared the same product development path and utilized the same Company resources. As a result, we determined that it is appropriate to reflect our operations as one reportable segment.
 
OrthoLogic Corp. commenced doing business under the trade name of Capstone Therapeutics on October 1, 2008, and we formally changed our name from OrthoLogic Corp. to Capstone Therapeutics Corp. on May 21, 2010.
 
In these notes, references to “we”, “our”, “us”, the “Company”, “Capstone Therapeutics”, “Capstone”, and “OrthoLogic” refer to Capstone Therapeutics Corp. References to our joint venture or “JV”, refer to LipimetiX Development, Inc. (formerly LipimetiX Development, LLC).
Basis Of Presentation and Management Plan [Policy Text Block]
Financial Statement Presentation and Management’s Plan
 
The accompanying financials statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.
 
The report from our Independent Registered Public Accounting Firm on our consolidated financial statements for the year ended December 31, 2014 included in our Annual Report on Form 10-K expressed substantial doubt about the Company’s ability to continue as a going concern.
 
Management has determined that the Company will require additional capital above its current cash and working capital balances to further develop AEM-28 and its analogs or continue operations. Accordingly, the Company has reduced its development activities. The Company’s corporate strategy is to raise funds by possibly engaging in a strategic/merger transaction, or conducting a private or public offering of debt or equity securities for capital. These financial statements do not include any adjustments that might result from the outcome of the uncertainty of the Company successfully implementing its corporate strategy.
 
In the opinion of management, the unaudited condensed interim financial statements include all adjustments necessary for the fair presentation of our financial position, results of operations, and cash flows, and all adjustments were of a normal recurring nature. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the complete fiscal year. The financial statements include the consolidated results of Capstone Therapeutics Corp. and our 60% owned subsidiary, LipimetiX Development, Inc. Intercompany transactions have been eliminated.
 
Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to Securities and Exchange Commission rules and regulations, although we believe that the disclosures herein are adequate to make the information presented not misleading. These unaudited condensed financial statements should be read in conjunction with the financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2014. Information presented as of December 31, 2014 is derived from audited financial statements.
Use of Estimates, Policy [Policy Text Block]
Use of Estimates
 
The preparation of financial statements in accordance with accounting principles generally accepted in the United States requires that management make a number of assumptions and estimates that affect the reported amounts of assets, liabilities, and expenses in our financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management’s assumptions regarding current events and actions that may impact us in the future, actual results may differ from these estimates and assumptions.
Commitments and Contingencies, Policy [Policy Text Block]
Legal and Other Contingencies
 
The Company is subject to legal proceedings and claims that arise in the ordinary course of business. The Company records a liability when it is probable that a loss has been incurred and the amount is reasonably estimable. There is significant judgment required in both the probability determination and as to whether an exposure can be reasonably estimated. In the opinion of management, there was not at least a reasonable possibility the Company may have incurred a material loss with respect to loss contingencies.
Interest in Unincorporated Joint Ventures or Partnerships, Policy [Policy Text Block]
Joint Venture Accounting
 
The Company entered into a joint venture in which it has contributed $6,000,000, and the noncontrolling interests have contributed certain patent license rights. Neither the Company nor the noncontrolling interests have an obligation to contribute additional funds to the joint venture or to assume any joint venture liabilities or to provide a guarantee of either joint venture performance or any joint venture liability. The financial position and results of operations of the joint venture are presented on a consolidated basis with the financial position and results of operations of the Company. Intercompany transactions have been eliminated. Joint venture losses were recorded on the basis of common ownership equity interests (60% Company / 40% noncontrolling interests) until common ownership equity was reduced to $0. Subsequent joint venture losses are being allocated to the preferred ownership equity (100% Company). Subsequent to March 31, 2013, all joint venture losses are being allocated to the Company. The Company has a revolving loan agreement with the joint venture to advance the joint venture funds for operations in an amount not to exceed a net (net of expected tax credits or other funds obtained) of $700,000, with the net amount due December 31, 2015. Losses incurred by the joint venture in excess of the capital accounts of the joint venture will be allocated to the Company to the extent of net outstanding advances.
Cash and Cash Equivalents, Policy [Policy Text Block]
Cash and Cash Equivalents
 
At September 30, 2015, cash and cash equivalents included money market accounts.
New Accounting Pronouncements, Policy [Policy Text Block]
Recent Accounting Pronouncements
 
 In August 2014, the Financial Accounting Standards Board issued Accounting Standard Update (“ASU”) No. 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40)(“Update”): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, providing a requirement under U.S. GAAP for an entity’s management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date the financial statements are issued; and if those conditions exist, to disclose that fact, the conditions and the potential effects on the entity’s ability to meet its obligations. The Update will be effective for an annual period ending after December 15, 2016, with early application permitted. We have not elected early application. However, if additional funds are not obtained to continue the development of AEM-28 or its analogs, or operations, it will impair our ability to continue as a going concern. If we do not continue as a going concern, the Company may incur additional losses, up to, and possibly exceeding our net joint venture investment and revolving loan balance.
XML 31 FilingSummary.xml IDEA: XBRL DOCUMENT 3.3.0.814 html 26 92 1 false 10 0 false 5 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.capstonethx.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.capstonethx.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] Sheet http://www.capstonethx.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] Statements 3 false false R4.htm 104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.capstonethx.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.capstonethx.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 5 false false R6.htm 106 - Disclosure - OVERVIEW OF BUSINESS Sheet http://www.capstonethx.com/role/OverviewOfBusiness OVERVIEW OF BUSINESS Notes 6 false false R7.htm 107 - Disclosure - JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS Sheet http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogs JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS Notes 7 false false R8.htm 108 - Disclosure - FUNDRAISING ACTIVITIES Sheet http://www.capstonethx.com/role/FundraisingActivities FUNDRAISING ACTIVITIES Notes 8 false false R9.htm 109 - Disclosure - Australian Refundable Research & Development Credit Sheet http://www.capstonethx.com/role/AustralianRefundableResearchDevelopmentCredit Australian Refundable Research & Development Credit Notes 9 false false R10.htm 110 - Disclosure - OVERVIEW OF BUSINESS (Policies) Sheet http://www.capstonethx.com/role/OverviewOfBusinessPolicies OVERVIEW OF BUSINESS (Policies) Policies 10 false false R11.htm 111 - Disclosure - JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Tables) Sheet http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsTables JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Tables) Tables http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogs 11 false false R12.htm 112 - Disclosure - OVERVIEW OF BUSINESS (Details Textual) Sheet http://www.capstonethx.com/role/OverviewOfBusinessDetailsTextual OVERVIEW OF BUSINESS (Details Textual) Details http://www.capstonethx.com/role/OverviewOfBusinessPolicies 12 false false R13.htm 113 - Disclosure - JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Details) Sheet http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsDetails JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Details) Details http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsTables 13 false false R14.htm 114 - Disclosure - JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Details Textual) Sheet http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsDetailsTextual JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Details Textual) Details http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsTables 14 false false R15.htm 115 - Disclosure - FUNDRAISING ACTIVITIES (Details Textual) Sheet http://www.capstonethx.com/role/FundraisingActivitiesDetailsTextual FUNDRAISING ACTIVITIES (Details Textual) Details http://www.capstonethx.com/role/FundraisingActivities 15 false false R16.htm 116 - Disclosure - Australian Refundable Research & Development Credit (Details Textual) Sheet http://www.capstonethx.com/role/AustralianRefundableResearchDevelopmentCreditDetailsTextual Australian Refundable Research & Development Credit (Details Textual) Details http://www.capstonethx.com/role/AustralianRefundableResearchDevelopmentCredit 16 false false All Reports Book All Reports In ''CONDENSED CONSOLIDATED BALANCE SHEETS'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression. In ''CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS'', column(s) 1, 2 are contained in other reports, so were removed by flow through suppression. caps-20150930.xml caps-20150930_cal.xml caps-20150930_def.xml caps-20150930_lab.xml caps-20150930_pre.xml caps-20150930.xsd true true